<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004137.pub3" GROUP_ID="RENAL" ID="443302071513475977" MERGED_FROM="" MODIFIED="2008-10-14 05:19:38 +0200" MODIFIED_BY="Narelle Willis" REVIEW_NO="076" REVMAN_SUB_VERSION="5.0.16" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.0">
<COVER_SHEET MODIFIED="2008-10-14 05:19:38 +0200" MODIFIED_BY="Narelle Willis">
<TITLE>Nonsteroidal anti-inflammatory drugs (NSAIDS) versus opioids for acute renal colic</TITLE>
<CONTACT MODIFIED="2008-10-14 05:19:38 +0200" MODIFIED_BY="Narelle Willis"><PERSON ID="16111" ROLE="AUTHOR"><PREFIX>A/Prof</PREFIX><FIRST_NAME>Anna</FIRST_NAME><LAST_NAME>Holdgate</LAST_NAME><POSITION>Director</POSITION><EMAIL_1>Anna.holdgate@sswahs.nsw.gov.au</EMAIL_1><ADDRESS><DEPARTMENT>Emergency Medicine Research Unit</DEPARTMENT><ORGANISATION>Liverpool Hospital</ORGANISATION><ADDRESS_1>Sydney South West Area Health Service</ADDRESS_1><CITY>Liverpool</CITY><ZIP>2170</ZIP><REGION>NSW</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 2 98283990</PHONE_1><FAX_1>+61 2 98283984</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-10-14 05:19:38 +0200" MODIFIED_BY="Narelle Willis"><PERSON ID="16111" ROLE="AUTHOR"><PREFIX>A/Prof</PREFIX><FIRST_NAME>Anna</FIRST_NAME><LAST_NAME>Holdgate</LAST_NAME><POSITION>Director</POSITION><EMAIL_1>Anna.holdgate@sswahs.nsw.gov.au</EMAIL_1><ADDRESS><DEPARTMENT>Emergency Medicine Research Unit</DEPARTMENT><ORGANISATION>Liverpool Hospital</ORGANISATION><ADDRESS_1>Sydney South West Area Health Service</ADDRESS_1><CITY>Liverpool</CITY><ZIP>2170</ZIP><REGION>NSW</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 2 98283990</PHONE_1><FAX_1>+61 2 98283984</FAX_1></ADDRESS></PERSON><PERSON ID="16137" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Tamara</FIRST_NAME><LAST_NAME>Pollock</LAST_NAME><POSITION>Registrar in Emergency Medicine</POSITION><ADDRESS><DEPARTMENT>Department of Emergency Medicine</DEPARTMENT><ORGANISATION>St George Hospital</ORGANISATION><CITY>Kogarah</CITY><ZIP>2217</ZIP><REGION>NSW</REGION><COUNTRY CODE="AU">Australia</COUNTRY></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-10-14 13:05:28 +1100" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="30" MONTH="4" YEAR="2006"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="30" MONTH="4" YEAR="2006"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="27" MONTH="2" YEAR="2009"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2003"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2004"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2004"/>
</DATES>
<WHATS_NEW MODIFIED="2008-10-14 13:05:35 +1100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="14" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-10-14 13:05:16 +1100" MODIFIED_BY="[Empty name]"/>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-10-14 14:03:53 +1100" MODIFIED_BY="[Empty name]">
<SUMMARY>
<TITLE>Nonsteroidal anti-inflammatory drugs and opioids can significantly relieve the pain in acute renal colic, but opioids (especially pethidine) cause more adverse effects</TITLE>
<SUMMARY_BODY>
<P>Acute renal colic occurs when mineral or organic solids pass though the urinary tract and obstruct the urinary flow. It causes a sudden onset of severe pain, which radiates from the flank to the groin and requires immediate treatment with pain-killers. It can also cause nausea, vomiting, hypertension and blood in the urine. Opioids and non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used to reduce the pain. The review found that both NSAIDs and opioids significantly reduce the pain. People experienced more adverse effects, such as vomiting, when using opioids (particularly pethidine) than when using NSAIDs.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-10-14 13:05:58 +1100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND>
<P>Renal colic is a common cause of acute severe pain. Both opioids and nonsteroidal anti-inflammatory drugs (NSAIDs) are recommended for treatment, but the relative efficacy of these drugs is uncertain.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To examine the benefits and disadvantages of NSAIDs and opioids for the management of pain in acute renal colic.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2008-10-14 13:05:42 +1100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Renal Group's specialised register, the Cochrane Central Register of Randomised Controlled Trials (CENTRAL - <I>The Cochrane Library</I>, MEDLINE, EMBASE and handsearched reference lists of retrieved articles.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised controlled trials (RCTs) comparing any opioid with any NSAID, regardless of dose or route of administration were included.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2008-10-14 13:05:58 +1100" MODIFIED_BY="[Empty name]">
<P>Data was extracted and quality assessed independently by two reviewers, with differences resolved by discussion. Dichotomous outcomes are reported as risk ratio (RR) and measurements on continuous scales are reported as mean differences (MD) with 95% confidence intervals. Subgroup analysis by study quality, drug type and drug route have been performed where possible to explore reasons for heterogeneity.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Twenty trials from nine countries with a total of 1613 participants were identified. Both NSAIDs and opioids lead to clinically significant falls in patient-reported pain scores. Due to unexplained heterogeneity these results could not be pooled although 10/13 studies reported lower pain scores in patients receiving NSAIDs. Patients treated with NSAIDs were significantly less likely to require rescue medication (RR 0.75, 95% CI 0.61 to 0.93, P = 0.007), though most of these trials used pethidine. The majority of trials showed a higher incidence of adverse events in patients treated with opioids, but there was significant heterogeneity between studies so the results could not be pooled. There was significantly less vomiting in patients treated with NSAIDs (RR 0.35, 95% CI 0.23 to 0.53, P &lt; 0.00001). In particular, patients receiving pethidine had a much higher rate of vomiting compared with patients receiving NSAIDs. Gastrointestinal bleeding and renal impairment were not reported.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Both NSAIDs and opioids can provide effective analgesia in acute renal colic. Opioids are associated with a higher incidence of adverse events, particularly vomiting. Given the high rate of vomiting associated with the use of opioids, particularly pethidine, and the greater likelihood of requiring further analgesia, we recommend that if an opioid is to be used it should not be pethidine.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-10-14 14:03:53 +1100" MODIFIED_BY="[Empty name]">
<BACKGROUND>
<P>Renal colic is most commonly caused by the passage of urinary tract calculi. It has an annual incidence of approximately 16/10,000 people and a life time incidence of 2-5% (<LINK REF="REF-Drach-1992" TYPE="REFERENCE">Drach 1992</LINK>; <LINK REF="REF-Stewart-1988" TYPE="REFERENCE">Stewart 1988</LINK>). Classically, renal colic is characterised by the sudden onset of severe pain radiating from the flank to the groin. The pain is often described as the worst pain the patient has ever experienced and may be associated with nausea, vomiting, hypertension and haematuria. </P>
<P>The pain of renal colic is due to obstruction of urinary flow with subsequent increasing wall tension in the urinary tract. Rising renal pelvic pressure stimulates local synthesis and release of prostaglandins, and subsequent vasodilatation induces a diuresis, which further increases intrarenal pressure. Prostaglandins also act directly on the ureter to induce smooth muscle spasm. </P>
<P>As the majority of renal calculi will pass spontaneously, the focus of acute management should be rapid pain relief, confirmation of the diagnosis and recognition of complications requiring immediate intervention (<LINK REF="REF-Holdgate-1999" TYPE="REFERENCE">Holdgate 1999</LINK>). Both nonsteroidal anti-inflammatory drugs (NSAIDs) and opioids have been shown to provide pain relief in acute renal colic (<LINK REF="STD-Curry-1995" TYPE="STUDY">Curry 1995</LINK>; <LINK REF="REF-Smally-1997" TYPE="REFERENCE">Smally 1997</LINK>). Opioids have the advantages of low cost, titratability, potency and familiarity; however there are concerns regarding opiate dependency, drug seeking behaviour presenting as renal colic. Opioids do not directly act on the cause of pain and require parenteral administration, which may limit their usefulness (<LINK REF="REF-Reich-1997" TYPE="REFERENCE">Reich 1997</LINK>). NSAIDs have the theoretical benefit of acting directly on the main cause of pain (prostaglandin release) and have been shown to be effective. However they are generally not titratable, have a well recognised side effect profile (including renal failure and gastrointestinal (GI) bleeding), and may be less immediate and potent in their action compared with opioids. NSAIDs can be given by a variety of routes but there is some evidence that in renal colic the intravenous (IV) route provides more rapid pain relief than oral or rectal administration (<LINK REF="REF-Tramer-1998" TYPE="REFERENCE">Tramer 1998</LINK>). A meta-analysis of NSAIDs in renal colic in 1994 suggested that NSAIDs were at least as effective as opioids in acute renal colic (<LINK REF="REF-Labreque-1994" TYPE="REFERENCE">Labreque 1994</LINK>). However this study did not specifically examine the difference in efficacy between NSAIDs and opioids, and did not clearly define pain relief, although it was the major outcome measured. For both opioids and NSAIDs, the 'optimal' dose for adequate analgesia is unknown.</P>
<P>Currently, standard Emergency Medicine texts recommend opioids and NSAIDs in the treatment of acute renal colic, both alone and in combination with each other (<LINK REF="REF-Cameron-2000" TYPE="REFERENCE">Cameron 2000</LINK>; <LINK REF="REF-Tintinalli-1999" TYPE="REFERENCE">Tintinalli 1999</LINK>). The choice of agent is generally based on clinician preference, personal experience and institutional culture.Two studies have examining the combined effect of opioids and and NSAIDs have given conflicting results and there is currently no evidence that NSIADs reduce the amount of opioid required for pain control (<LINK REF="STD-al_x002d_Sahlawi-1996" TYPE="STUDY">al-Sahlawi 1996</LINK>; <LINK REF="STD-Cordell-1996" TYPE="STUDY">Cordell 1996</LINK>).</P>
</BACKGROUND>
<OBJECTIVES>
<P>The aim of this review was to examine the benefits and disadvantages of NSAIDs and opioids, and if possible to determine which of these drug types is most appropriate for the management of pain in acute renal colic. All clinically important outcomes including degree of pain relief, efficacy of pain relief, rate of pain recurrence and treatment side effects were explored.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-10-14 14:03:53 +1100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2008-10-14 14:03:53 +1100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES>
<P>All randomised controlled trials (RCTs) or quasi-RCTs comparing any NSAID versus any opioid.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2008-10-14 13:51:03 +1100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Inclusion criteria</HEADING>
<P>All adult patients (&gt;16 years) with a clinical diagnosis of acute renal colic (pain less than 12 hours duration) and moderate to severe pain.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Exclusion criteria</HEADING>
<P>Patients with contraindications to either NSAIDs or narcotics will be excluded.</P>
</SUBSECTION>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2008-10-14 14:03:53 +1100" MODIFIED_BY="[Empty name]">
<P>All interventions that directly compare NSAIDs versus opioids in any dose, by any route (oral, intramuscular (IM), IV, rectal, subcutaneous (SC)) and in any setting were be eligible for inclusion. Combination therapies which include an opioid or NSAID were included. NSAIDs included aspirin and COX-2 inhibitors but not paracetamol or dipyrone. Dipyrone was excluded as it is banned in several countries (USA, UK, Australia) due to the associated risk of blood dyscrasias such as agranulocytosis. The efficacy of dipyrone in renal colic has been reviewed in an earlier Cochrane review (<LINK REF="REF-Edwards-2002" TYPE="REFERENCE">Edwards 2002</LINK>).</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-10-14 13:51:11 +1100" MODIFIED_BY="[Empty name]">
<P>Studies which reported any one of the following were eligible for inclusion:<BR/>
</P>
<UL>
<LI>Patient-rated pain as measured by a validated pain scale including visual analogue scales, simple descriptive scales, pain relief scales and verbal rating scales AND/OR time to pain relief AND/OR need for rescue medication AND/OR rate of pain recurrence AND/OR Adverse event rates (number of patients with one or more adverse events)</LI>
<LI>Major adverse events were defined as GI haemorrhage, renal failure, hypotension, and respiratory depression.</LI>
<LI>Minor adverse events were defined as GI disturbance without bleeding (vomiting, diarrhoea, pain), dizziness, sleepiness.</LI>
</UL>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-10-14 13:52:16 +1100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Initial search</HEADING>
<P>Relevant trials were obtained from the following sources (see Additional <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>- <I>Electronic search strategies</I>)</P>
<OL>
<LI>1. Cochrane Renal Group specialised register of randomised controlled trials</LI>
<LI>2. Cochrane Central Register of Controlled Trials (CENTRAL - issue 2, 2003 in <I>The Cochrane Library</I>) for any "New" records not yet incorporated in the specialised register</LI>
<LI>3. MEDLINE and Pre MEDLINE (1966 to 31 January 2003) were searched using the above terms, combined with the optimally sensitive strategy for the identification of RCTs (<LINK REF="REF-Dickersin-1994" TYPE="REFERENCE">Dickersin 1994</LINK>) (see Cochrane Renal Group Module).</LI>
<LI>4. EMBASE (1980 to 31 January 2003) was searched using terms similar to those used for MEDLINE and combined with a search strategy for the identification of RCTs (<LINK REF="REF-Lefebvre-1996" TYPE="REFERENCE">Lefebvre 1996</LINK>).</LI>
<LI>5. Reference lists of nephrology textbooks, review articles and relevant trials.</LI>
<LI>6. Conference proceeding's abstracts from nephrology scientific meetings.</LI>
<LI>7. Letters seeking information about unpublished or incomplete trials to investigators known to be involved in previous trials.</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Review update</HEADING>
<P>The Cochrane Renal Group's specialised register (April 2006) and CENTRAL<I> </I>(Issue 2, 2006) were searched. CENTRAL and the Renal Group's specialised register contain the handsearched results of conference proceedings from general and speciality meetings. This is an ongoing activity across the Cochrane Collaboration and is both retrospective and prospective (<A HREF="http://www.cochrane.us/masterlist.asp">http://www.cochrane.us/masterlist.asp</A>). Please refer to The Cochrane Renal Review Group's Module in T<I>he Cochrane Library</I> for the complete list of nephrology conference proceedings searched.</P>
</SUBSECTION>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-10-14 13:54:24 +1100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Included and excluded studies</HEADING>
<P>This review was undertaken by two reviewers (AH and TP). Titles and abstracts identified by the search strategy described were screened independently by AH and TP. All potentially relevant reviews were retained and the full text of these studies examined to determine which studies satisfied the inclusion criteria. Data extraction was carried out independently by the same reviewers using standard data extraction forms. Studies reported in languages other than those familiar to the authors were translated and evaluated in the presence of a native speaker of the language. Where more than one publication of one trial existed, only the publication with the most complete data was included. Where important data was not reported, we attempted to contact the original authors to get the necessary information. Discrepancies between the reviewers were resolved by discussion.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Study quality</HEADING>
<P>The quality of studies to be included was assessed independently by AH and TP without blinding to authorship or journal, using the checklist developed for the Cochrane Renal Group (<LINK REF="REF-Renal-Group-2003" TYPE="REFERENCE">Renal Group 2003</LINK>). Discrepancies were resolved by discussion. The quality items assessed were allocation concealment, intention-to-treat analysis, completeness to follow-up and blinding of investigators, participants, outcome assessors and data analysis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Quality checklist</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Allocation concealment </HEADING>
<UL>
<LI>
<I>Adequate</I> (A): Randomisation method described that would not allow investigator/participant to know or influence intervention group before eligible participant entered in the study</LI>
<LI>
<I>Unclear</I> (B): Randomisation stated but no information on method used is available</LI>
<LI>
<I>Inadequate</I> (C): Method of randomisation used such as alternate medical record numbers or unsealed envelopes; any information in the study that indicated that investigators or participants could influence intervention group</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Blinding</HEADING>
<UL>
<LI>Investigators: Yes/no/not stated</LI>
<LI>Participants: Yes/no/not stated</LI>
<LI>Outcome assessor/s: Yes/no/not stated</LI>
<LI>Data analysis: Yes/no/not stated</LI>
</UL>
<P>The above are considered not blinded if the treatment group can be identified in &gt;20% of participants because of the side effects of treatment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Intention-to-treat analysis</HEADING>
<UL>
<LI>Yes: Specifically reported by authors that intention-to-treat analysis was undertaken and this was confirmed on study assessment.</LI>
<LI>Yes: Not stated but confirmed upon study assessment.</LI>
<LI>No: Not reported and lack of intention-to-treat analysis confirmed on study assessment. (Patients who were randomised were not included in the analysis because they did not receive the study intervention, they withdrew from the study or were not included because of protocol violation).</LI>
<LI>No: Stated but not confirmed upon study assessment.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Completeness of follow-up</HEADING>
<P>Per cent of participants excluded or lost to follow-up.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Statistical assessment</HEADING>
<P>Dichotomous outcomes (need for rescue medication, rate of pain recurrence, adverse event rate) results are expressed as risk ratio (RR) with 95% confidence intervals (CI). Data was be pooled using the random effects model but the fixed effects model was also analysed to ensure robustness of the model chosen and susceptibility to outliers. Where continuous scales of measurement were used to assess the effects of treatment (patient-rated pain scores, time to pain relief), the mean difference (MD) was used, or the standardised mean difference (SMD) if different scales were used. Heterogeneity was analysed using a Chi squared test on N-1 degrees of freedom, with a p of 0.05 used for statistical significance.</P>
<P>Analysis was used to explore possible sources of heterogeneity (e.g. participants, treatments and study quality). Heterogeneity among participants could be related to age, stone size/site, and drug route/dose and where possible these subgroups were explored. Heterogeneity in treatments could be related to prior agent(s) used and the agent, dose and duration of therapy. Where possible, the risk difference (RD) with 95% CI will be calculated for adverse effects.</P>
<P>Where sufficient RCTs were identified, an attempt was made to examine for publication bias using a funnel plot (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>).</P>
</SUBSECTION>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-10-14 13:57:23 +1100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION>
<P>The initial literature search identified 74 potentially relevant studies. Of these, 49 trials were excluded on abstract review because they were not RCTs or did not compare NSAIDS and opioids. Twenty-five articles were retrieved for more detailed evaluation, of which a further five were excluded because they did not meet our inclusion criteria. Of these five studies, two did not have either an opioid or NSAID treatment arm ( <LINK REF="STD-Broggini-1985" TYPE="STUDY">Broggini 1985</LINK>; <LINK REF="STD-Slade-1967" TYPE="STUDY">Slade 1967</LINK>), one was an uncontrolled trial (<LINK REF="STD-Flannigan-1983" TYPE="STUDY">Flannigan 1983</LINK>), one was not restricted to patients with renal colic (<LINK REF="STD-Khalifa-1986" TYPE="STUDY">Khalifa 1986</LINK>) and one gave no relevant outcome measures (<LINK REF="STD-Daljord-1983" TYPE="STUDY">Daljord 1983</LINK>).Thus 20 trials were available for inclusion in the review (<LINK REF="STD-al_x002d_Sahlawi-1996" TYPE="STUDY">al-Sahlawi 1996</LINK>; <LINK REF="STD-Arnau-1991" TYPE="STUDY">Arnau 1991</LINK>; <LINK REF="STD-Cordell-1994" TYPE="STUDY">Cordell 1994</LINK>; <LINK REF="STD-Cordell-1996" TYPE="STUDY">Cordell 1996</LINK>; <LINK REF="STD-Curry-1995" TYPE="STUDY">Curry 1995</LINK>; <LINK REF="STD-Hetherington-1986" TYPE="STUDY">Hetherington 1986</LINK>; <LINK REF="STD-Indudhara-1990" TYPE="STUDY">Indudhara 1990</LINK>; <LINK REF="STD-Jonsson-1987" TYPE="STUDY">Jonsson 1987</LINK>; <LINK REF="STD-Larkin-1999" TYPE="STUDY">Larkin 1999</LINK>; <LINK REF="STD-Lehtonen-1983" TYPE="STUDY">Lehtonen 1983</LINK>; <LINK REF="STD-Lundstam-1982" TYPE="STUDY">Lundstam 1982</LINK>; <LINK REF="STD-Marthak-1991" TYPE="STUDY">Marthak 1991</LINK>; <LINK REF="STD-Oosterlinck-1990" TYPE="STUDY">Oosterlinck 1990</LINK>; <LINK REF="STD-Persson-1985" TYPE="STUDY">Persson 1985</LINK>; <LINK REF="STD-Quilez-1984" TYPE="STUDY">Quilez 1984</LINK>; <LINK REF="STD-Sandhu-1994" TYPE="STUDY">Sandhu 1994</LINK>; <LINK REF="STD-Sommer-1989" TYPE="STUDY">Sommer 1989</LINK>; <LINK REF="STD-Thompson-1989" TYPE="STUDY">Thompson 1989</LINK>; <LINK REF="STD-Torralba-1999" TYPE="STUDY">Torralba 1999</LINK>; <LINK REF="STD-Uden-1983" TYPE="STUDY">Uden 1983</LINK>). Many of the included trials did not report variance data or outcomes in a form suitable for meta-analysis. We attempted to contact the authors of all these trials but were unable to gain any further information. Six studies had treatment arms in addition to NSAIDs and opioids, mostly antispasmodics or dipyrone (<LINK REF="STD-al_x002d_Sahlawi-1996" TYPE="STUDY">al-Sahlawi 1996</LINK>; <LINK REF="STD-Arnau-1991" TYPE="STUDY">Arnau 1991</LINK>; <LINK REF="STD-Indudhara-1990" TYPE="STUDY">Indudhara 1990</LINK>; <LINK REF="STD-Lehtonen-1983" TYPE="STUDY">Lehtonen 1983</LINK>; <LINK REF="STD-Quilez-1984" TYPE="STUDY">Quilez 1984</LINK>; <LINK REF="STD-Marthak-1991" TYPE="STUDY">Marthak 1991</LINK>). Only data for the opioid and NSAIDs groups were analysed for these six trials. Two studies used a crossover design where the alternative study drug was administered if inadequate analgesia was achieved with the first drug. As the time between drugs was short and did not allow drug washout, we included only data from the pre-crossover phase of the trial (<LINK REF="STD-Cordell-1994" TYPE="STUDY">Cordell 1994</LINK>; <LINK REF="STD-Jonsson-1987" TYPE="STUDY">Jonsson 1987</LINK>). One study included a third treatment arm with combination opioids and NSAIDS, data from this treatment arm was not included (<LINK REF="STD-Cordell-1996" TYPE="STUDY">Cordell 1996</LINK>).</P>
<P>The 20 trials were conducted in nine countries, included 1613 participants and published between 1982 and 1999. The majority of studies included only those participants with renal calculi confirmed on subsequent testing using a variety of techniques, and specifically excluded patients with a clinical diagnosis which was not subsequently confirmed. Amongst the trials, five different nonsteroidal agents and seven different opioids were used, though each trial used only one type of NSAID and opioid. All but two trials (<LINK REF="STD-Larkin-1999" TYPE="STUDY">Larkin 1999</LINK>; <LINK REF="STD-Torralba-1999" TYPE="STUDY">Torralba 1999</LINK>) used fixed doses of both NSAIDs and opioids, regardless of patient weight. NSAIDs and opioids were administered by the parenteral route (IV or IM) in all but three trials (<LINK REF="STD-Cordell-1994" TYPE="STUDY">Cordell 1994</LINK>; <LINK REF="STD-Indudhara-1990" TYPE="STUDY">Indudhara 1990</LINK>; <LINK REF="STD-Thompson-1989" TYPE="STUDY">Thompson 1989</LINK>). In these three trials, NSAIDs were administered orally or rectally, while opioids were given parenterally.</P>
<P>No trial reported time to pain relief though a number reported the proportion of patients with complete pain relief within a fixed time period. We therefore used this proportion as an alternative outcome measure. No trials reported rates of pain recurrence or specifically reported serious adverse events such as renal dysfunction or gastrointestinal bleeding.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-10-14 13:54:46 +1100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Allocation concealment</HEADING>
<P>Five trials described a randomisation method which gave adequate allocation concealment (<LINK REF="STD-Cordell-1994" TYPE="STUDY">Cordell 1994</LINK>; <LINK REF="STD-Cordell-1996" TYPE="STUDY">Cordell 1996</LINK>; <LINK REF="STD-Curry-1995" TYPE="STUDY">Curry 1995</LINK>; <LINK REF="STD-Jonsson-1987" TYPE="STUDY">Jonsson 1987</LINK>; <LINK REF="STD-Larkin-1999" TYPE="STUDY">Larkin 1999</LINK>), the remaining trials did not give enough information to determine whether allocation concealment was adequate.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Blinding</HEADING>
<P>In five studies investigators, participants and outcome assessors were all blinded (<LINK REF="STD-Cordell-1994" TYPE="STUDY">Cordell 1994</LINK>; <LINK REF="STD-Cordell-1996" TYPE="STUDY">Cordell 1996</LINK>; <LINK REF="STD-Curry-1995" TYPE="STUDY">Curry 1995</LINK>; <LINK REF="STD-Jonsson-1987" TYPE="STUDY">Jonsson 1987</LINK>; <LINK REF="STD-Larkin-1999" TYPE="STUDY">Larkin 1999</LINK>). Participants were blinded in a further three studies ( <LINK REF="STD-Hetherington-1986" TYPE="STUDY">Hetherington 1986</LINK>; <LINK REF="STD-Sandhu-1994" TYPE="STUDY">Sandhu 1994</LINK>; <LINK REF="STD-Sommer-1989" TYPE="STUDY">Sommer 1989</LINK>), not blinded in three (<LINK REF="STD-Indudhara-1990" TYPE="STUDY">Indudhara 1990</LINK>; <LINK REF="STD-Thompson-1989" TYPE="STUDY">Thompson 1989</LINK>; <LINK REF="STD-Uden-1983" TYPE="STUDY">Uden 1983</LINK>) and in the remaining nine it was not stated. Outcome assessors were blinded in 11 studies (<LINK REF="STD-al_x002d_Sahlawi-1996" TYPE="STUDY">al-Sahlawi 1996</LINK>; <LINK REF="STD-Arnau-1991" TYPE="STUDY">Arnau 1991</LINK>; <LINK REF="STD-Cordell-1994" TYPE="STUDY">Cordell 1994</LINK>; <LINK REF="STD-Cordell-1996" TYPE="STUDY">Cordell 1996</LINK>; <LINK REF="STD-Curry-1995" TYPE="STUDY">Curry 1995</LINK>; <LINK REF="STD-Hetherington-1986" TYPE="STUDY">Hetherington 1986</LINK>; <LINK REF="STD-Jonsson-1987" TYPE="STUDY">Jonsson 1987</LINK>; <LINK REF="STD-Larkin-1999" TYPE="STUDY">Larkin 1999</LINK>; <LINK REF="STD-Lehtonen-1983" TYPE="STUDY">Lehtonen 1983</LINK>; <LINK REF="STD-Oosterlinck-1990" TYPE="STUDY">Oosterlinck 1990</LINK>; <LINK REF="STD-Uden-1983" TYPE="STUDY">Uden 1983</LINK>) and it was unclear in the remaining nine whether they were blinded.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Intention-to-treat analysis</HEADING>
<P>Only three studies performed analysis on an intention-to-treat basis in participants with a clinical diagnosis of renal colic (<LINK REF="STD-Persson-1985" TYPE="STUDY">Persson 1985</LINK>; <LINK REF="STD-Sandhu-1994" TYPE="STUDY">Sandhu 1994</LINK>; <LINK REF="STD-Cordell-1996" TYPE="STUDY">Cordell 1996</LINK>). Nine trials included only those patients with renal calculus subsequently confirmed on further testing, regardless of the initial clinical diagnosis (<LINK REF="STD-Lundstam-1982" TYPE="STUDY">Lundstam 1982</LINK>; <LINK REF="STD-Hetherington-1986" TYPE="STUDY">Hetherington 1986</LINK>; <LINK REF="STD-Jonsson-1987" TYPE="STUDY">Jonsson 1987</LINK>; <LINK REF="STD-Sommer-1989" TYPE="STUDY">Sommer 1989</LINK>; <LINK REF="STD-Thompson-1989" TYPE="STUDY">Thompson 1989</LINK>; <LINK REF="STD-Oosterlinck-1990" TYPE="STUDY">Oosterlinck 1990</LINK>; <LINK REF="STD-Cordell-1994" TYPE="STUDY">Cordell 1994</LINK>; <LINK REF="STD-Curry-1995" TYPE="STUDY">Curry 1995</LINK>; <LINK REF="STD-Larkin-1999" TYPE="STUDY">Larkin 1999</LINK>). The remaining trials did not clearly state whether intention-to-treat analysis was performed. No trials reported results for both patients with a clinical and a confirmed diagnosis of renal calculus.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Completeness of follow-up</HEADING>
<P>Four studies reported completeness to follow-up, though all four studies did not perform intention-to-treat analysis and the patients excluded predominantly comprised of those in whom the diagnosis was not confirmed (<LINK REF="STD-Curry-1995" TYPE="STUDY">Curry 1995</LINK>; <LINK REF="STD-Larkin-1999" TYPE="STUDY">Larkin 1999</LINK>; <LINK REF="STD-Oosterlinck-1990" TYPE="STUDY">Oosterlinck 1990</LINK>; <LINK REF="STD-Sommer-1989" TYPE="STUDY">Sommer 1989</LINK>). The majority of remaining trials implied that there was complete follow-up of all included patients, though this was not overtly stated.</P>
</SUBSECTION>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-10-14 13:57:23 +1100" MODIFIED_BY="[Empty name]">
<P>As the results from random and fixed effects models did not differ, only results from the random effects model are reported.</P>
<SUBSECTION>
<HEADING LEVEL="3">Patient rated pain scores</HEADING>
<P>Pain scores at enrolment and at a fixed period after study drug administration was measured in 15 trials. In two trials, this outcome was measured but not reported in their results (<LINK REF="STD-Hetherington-1986" TYPE="STUDY">Hetherington 1986</LINK>; <LINK REF="STD-Indudhara-1990" TYPE="STUDY">Indudhara 1990</LINK>). Four trials reported data which could not be included in our meta-analysis either because no variance was given (<LINK REF="STD-Torralba-1999" TYPE="STUDY">Torralba 1999</LINK>), or change in pain score rather than final pain score was reported (<LINK REF="STD-Sandhu-1994" TYPE="STUDY">Sandhu 1994</LINK>; <LINK REF="STD-Sommer-1989" TYPE="STUDY">Sommer 1989</LINK>; <LINK REF="STD-Thompson-1989" TYPE="STUDY">Thompson 1989</LINK>). All but one of these four trials (<LINK REF="STD-Sommer-1989" TYPE="STUDY">Sommer 1989</LINK>) demonstrated a greater reduction in pain scores in the NSAID group than in the opioid group. Nine trials reported pain on a 100 mm Visual Analogue Scale (VAS) at various time intervals after study drug administration. Most of these trials recorded VAS at 30 minutes (<LINK REF="STD-Arnau-1991" TYPE="STUDY">Arnau 1991</LINK>; <LINK REF="STD-Cordell-1996" TYPE="STUDY">Cordell 1996</LINK>; <LINK REF="STD-Curry-1995" TYPE="STUDY">Curry 1995</LINK>; <LINK REF="STD-Marthak-1991" TYPE="STUDY">Marthak 1991</LINK>; <LINK REF="STD-Persson-1985" TYPE="STUDY">Persson 1985</LINK>; <LINK REF="STD-Uden-1983" TYPE="STUDY">Uden 1983</LINK>), though two trials gave VAS scores at 20 minutes (<LINK REF="STD-Jonsson-1987" TYPE="STUDY">Jonsson 1987</LINK>; <LINK REF="STD-Larkin-1999" TYPE="STUDY">Larkin 1999</LINK>) and one at 60 minutes (<LINK REF="STD-Oosterlinck-1990" TYPE="STUDY">Oosterlinck 1990</LINK>). Five of these trials (<LINK REF="STD-Cordell-1996" TYPE="STUDY">Cordell 1996</LINK>; <LINK REF="STD-Curry-1995" TYPE="STUDY">Curry 1995</LINK>; <LINK REF="STD-Jonsson-1987" TYPE="STUDY">Jonsson 1987</LINK>; <LINK REF="STD-Persson-1985" TYPE="STUDY">Persson 1985</LINK>; <LINK REF="STD-Uden-1983" TYPE="STUDY">Uden 1983</LINK>) reported VAS with variance, in the other four trials variance was imputed from variance measures at time zero or variance for the difference in VAS between time zero and the next measured time. However the imputed variance for these four trials was substantially smaller than the actual variance in the other five trials making the reliability of these estimates uncertain. There was significant heterogeneity between these nine studies (P &lt; 0.001), and within the two subgroups of actual and imputed variance. Seven of the nine trials favoured treatment with NSAIDS (<LINK REF="STD-Arnau-1991" TYPE="STUDY">Arnau 1991</LINK>; <LINK REF="STD-Cordell-1996" TYPE="STUDY">Cordell 1996</LINK>; <LINK REF="STD-Jonsson-1987" TYPE="STUDY">Jonsson 1987</LINK>; <LINK REF="STD-Marthak-1991" TYPE="STUDY">Marthak 1991</LINK>; <LINK REF="STD-Oosterlinck-1990" TYPE="STUDY">Oosterlinck 1990</LINK>; <LINK REF="STD-Persson-1985" TYPE="STUDY">Persson 1985</LINK>; <LINK REF="STD-Uden-1983" TYPE="STUDY">Uden 1983</LINK>), one showed no difference (<LINK REF="STD-Curry-1995" TYPE="STUDY">Curry 1995</LINK>) and one showed lower pain scores in patients treated with opioids (<LINK REF="STD-Larkin-1999" TYPE="STUDY">Larkin 1999</LINK>). Subgroup analysis by NSAID type demonstrated heterogeneity for studies using ketorolac (P &lt; 0.001), but homogeneity amongst all other trials using any other type of NSAID. There is no obvious biological or clinical explanation for this heterogeneity amongst the ketorolac trials. Combined analysis of the six trials not using ketorolac (<I>analysis 19)</I> showed the VAS was, on average, 4.6 mm (95% CI 1.7 to 7.5) lower in patients receiving NSAIDs compared with those receiving opioids (P = 0.002). Subgroup analysis by type of opioid did not explain heterogeneity. Route of drug administration (IV versus IM) resulted in the same subgroups as for actual and estimated variance, with the four studies reporting variance using the IV route while the five trials with imputed variance used the IM route.</P>
<P>Overall, of the 13 trials with reported results, 10 found lower pain scores in patients treated with NSAIDs, two demonstrated no difference and only one study found lower pain scores in patients treated with opioids.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Failure to achieve complete pain relief</HEADING>
<P>Nine trials (647 participants) reported the proportion of patients who failed to achieve complete pain relief within a fixed time period after study drug administration. Eight reported this outcome at 30 minutes (<LINK REF="STD-al_x002d_Sahlawi-1996" TYPE="STUDY">al-Sahlawi 1996</LINK>; <LINK REF="STD-Lehtonen-1983" TYPE="STUDY">Lehtonen 1983</LINK>; <LINK REF="STD-Marthak-1991" TYPE="STUDY">Marthak 1991</LINK>; <LINK REF="STD-Persson-1985" TYPE="STUDY">Persson 1985</LINK>; <LINK REF="STD-Quilez-1984" TYPE="STUDY">Quilez 1984</LINK>; <LINK REF="STD-Sommer-1989" TYPE="STUDY">Sommer 1989</LINK>; <LINK REF="STD-Thompson-1989" TYPE="STUDY">Thompson 1989</LINK>; <LINK REF="STD-Uden-1983" TYPE="STUDY">Uden 1983</LINK>), while one reported at 60 minutes (<LINK REF="STD-Oosterlinck-1990" TYPE="STUDY">Oosterlinck 1990</LINK>). No study found a significant difference in the proportion of patients with complete pain relief and there was no significant heterogeneity between studies (P = 0.25). Combined analysis of all nine studies showed a trend towards a higher rate of complete pain relief in patients treated with NSAIDs, but this finding was not significant (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>
<I>:</I> RR 0.87, 95% CI 0.74 to 1.03; P = 0.11). Subgroup analysis by NSAID or opioid type did not show significant benefit for any one drug.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Need for rescue analgesia</HEADING>
<P>The need for rescue analgesia within four hours of administration of study drug was reported in nine trials with 806 participants (<LINK REF="STD-al_x002d_Sahlawi-1996" TYPE="STUDY">al-Sahlawi 1996</LINK>; <LINK REF="STD-Arnau-1991" TYPE="STUDY">Arnau 1991</LINK>; <LINK REF="STD-Cordell-1996" TYPE="STUDY">Cordell 1996</LINK>; <LINK REF="STD-Curry-1995" TYPE="STUDY">Curry 1995</LINK>; <LINK REF="STD-Hetherington-1986" TYPE="STUDY">Hetherington 1986</LINK>; <LINK REF="STD-Larkin-1999" TYPE="STUDY">Larkin 1999</LINK>; <LINK REF="STD-Lehtonen-1983" TYPE="STUDY">Lehtonen 1983</LINK>; <LINK REF="STD-Thompson-1989" TYPE="STUDY">Thompson 1989</LINK>; <LINK REF="STD-Torralba-1999" TYPE="STUDY">Torralba 1999</LINK>; <LINK REF="STD-Uden-1983" TYPE="STUDY">Uden 1983</LINK>). One study reported 'rescue' analgesia at 24 hours and was not included in analysis (<LINK REF="STD-Sandhu-1994" TYPE="STUDY">Sandhu 1994</LINK>). The decision to use rescue analgesia was generally determined by clinician preference in all trials, and the decision to give further analgesia had no objective criteria in eight of the nine studies. In four trials, pethidine was given if the physician felt the patient required further analgesia 30 minutes after study drug administration (<LINK REF="STD-al_x002d_Sahlawi-1996" TYPE="STUDY">al-Sahlawi 1996</LINK>; <LINK REF="STD-Arnau-1991" TYPE="STUDY">Arnau 1991</LINK>; <LINK REF="STD-Cordell-1996" TYPE="STUDY">Cordell 1996</LINK>; <LINK REF="STD-Curry-1995" TYPE="STUDY">Curry 1995</LINK>). In the remaining trials the additional analgesia was given 30 to 60 minutes after the study drug and the 'rescue' drug was either not specified, a second dose of the same study drug or the alternate study drug. In the pooled analysis, patients receiving NSAIDs were significantly less likely to require rescue medication than those receiving narcotics (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>: RR 0.75, 95% CI 0.61 to 0.93; P = 0.007). There was no statistical evidence of heterogeneity between these trials (P = 0.53). Subgroup analysis of only those trials with blinding of investigators and participants continued to show in favour of NSAIDs. All but one of the pooled trials (<LINK REF="STD-Uden-1983" TYPE="STUDY">Uden 1983</LINK>) used pethidine as the opiate, with dose ranges from 50-150 mg. Overall, 18.9% of patients required further analgesia after a single dose of NSAID compared with 25.4% after a single dose of opioid.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Adverse effects</HEADING>
<P>The definition of adverse effects varied between trials, and many trials included any complaint recorded on general questioning after study drug administration. No trial specifically defined or reported serious adverse events such as GI haemorrhage or renal impairment. Most trials had a short period of follow-up (maximum 24 hours, <LINK REF="STD-Sandhu-1994" TYPE="STUDY">Sandhu 1994</LINK>) and none actively sought for evidence of GI bleeding or renal impairment. All studies included reporting of adverse events, but in several studies it was not possible to distinguish whether multiple events had occurred in one patient . All but four trials (<LINK REF="STD-Arnau-1991" TYPE="STUDY">Arnau 1991</LINK>; <LINK REF="STD-Cordell-1994" TYPE="STUDY">Cordell 1994</LINK>; <LINK REF="STD-Quilez-1984" TYPE="STUDY">Quilez 1984</LINK>; <LINK REF="STD-Thompson-1989" TYPE="STUDY">Thompson 1989</LINK>) reported total number of patients reporting any adverse event, rather than total number of adverse events. The majority of these 16 trials showed a higher incidence of adverse events in patients treated with opioids, but there was significant heterogeneity between studies (P = 0.01) so the results could not be pooled. Subgroup analysis by type of opioid (pethidine versus others), route of opioid administration (IV versus IM) and type of NSAID did not explain this heterogeneity. This heterogeneity may be explained by the ad hoc nature of reporting adverse events in most trials. Subgroup analysis by study quality demonstrated no heterogeneity in the four studies with blinded assessors and participants and showed a significantly higher adverse event rate in patients treated with opioids (<LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>
<U>.1</U>: RR 0.73, 95% CI 0.57 to 0.93; P = 0.01). Studies without assessor and participant blinding continued to show significant heterogeneity.</P>
<P>Vomiting was reported as a specific adverse event in 10 trials (826 participants), with no evidence of heterogeneity (P = 0.58). In the pooled analysis, there was a significantly less vomiting in patients treated with NSAIDs (<LINK REF="CMP-001.13" TYPE="ANALYSIS">Analysis 1.13</LINK>: RR 0.35, 95% CI 0.23 to 0.53; P &lt; 0.00001). The overall rate of vomiting in patients treated with NSAIDs was 5.8%, compared to 19.5% in patients receiving opioids. Subgroup analysis by type of narcotic demonstrated that the risk of vomiting was particularly dominant in patients receiving pethidine (<LINK REF="CMP-001.18" TYPE="ANALYSIS">Analysis 1.18</LINK>
<U>.1</U>
<I>:</I> RR 0.30, 95% CI 0.18 to 0.49; P &lt; 0.00001), whereas for patients receiving non-pethidine opioids there was no significant difference between patients receiving NSAIDs and opioids (<LINK REF="CMP-001.18" TYPE="ANALYSIS">Analysis 1.18</LINK>
<U>.2</U>: RR 0.53, 95% CI 0.23 to 1.24; P = 0.15). However, there were considerably more patients in trials in which pethidine was used (509 participants) than in trials using other opioids (317 participants) which may, in part, account for the lack of statistical significance in the latter group. The dose range of pethidine was 50 to 150 mg between studies, but adverse event rates did not vary according to dosage.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Other subgroup analyses</HEADING>
<P>There was insufficient data to perform subgroup analysis by participant age, gender, stone size or stone site for all outcomes. As all opioids and all but three NSAIDs were administered parenterally it was not possible to analyse the effect of different routes of administration other than intravenous and intramuscular. Dose ranges for individual NSAIDs varied from study to study, and due to small numbers of studies for any one NSAID, subgroup analysis by NSAID dose was not undertaken. Similarly while pethidine was the most common opioid used, with dose ranges varying from 50-150 mg, subgroup analysis by pethidine dose within each outcome was limited by small study numbers.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Funnel plots</HEADING>
<P>Insufficient trials were available to perform funnel plot analysis.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>Our review aimed to assess the relative efficacy of NSAIDs and opioids in patients presenting with a clinical diagnosis of acute renal colic. The trials included in this analysis involved a number of different NSAIDs and opioids which represent common treatment patterns internationally. However, the fact that most studies only included patients who had renal calculi confirmed on subsequent testing may limit the applicability of our findings to patients who present with a clinical picture of renal colic. </P>
<P>We examined the relatively analgesic efficacy through three outcomes; pain scores at a specified time after study drug administration, proportion of patients who achieved complete pain relief within a fixed time period and the need for rescue analgesia. Both opioids and NSAIDs demonstrated a clinically important analgesic effect, with a marked reduction in pain scores over time. Significant heterogeneity between studies did not allow pooled analysis of pain scores, but qualitatively the majority of studies demonstrated a lower pain scores for patients treated with NSAIDs compared with those receiving opioids, though the differences were small. In the subgroup of patients receiving NSAIDs other than ketorolac, where pooled analysis was performed, there was a statistically significant reduction in pain scores of 4.6 mm. However, this difference in scores is unlikely to be clinically significant as previous studies have shown the minimum clinically significant difference in VAS to be in the order of 9-13 mm (<LINK REF="REF-Gallagher-2001" TYPE="REFERENCE">Gallagher 2001</LINK>; <LINK REF="REF-Todd-1996" TYPE="REFERENCE">Todd 1996</LINK>). </P>
<P>There was no significant difference between NSAIDs and opioids in the proportion of patients who achieved complete pain relief in a short time frame. The results varied widely between studies with some showing almost all patients achieving complete pain relief , while others found that less than half of patients had achieved complete pain relief. This may reflect the wide range of agents, doses and routes of administration for the study drug, though this could not be demonstrated in subgroup analysis due to the small number of studies. Given that the majority of studies did not administer the study drugs intravenously, it is not surprising that many patients had not achieved complete pain relief within 30 minutes of receiving the study drug due to slow absorption times.</P>
<P>Although both NSAIDs and opioids lead to clinically significant analgesia, a greater number of patients who received opioids required an additional dose of 'rescue' analgesia within an hour of study drug administration. As 9/10 trials pooled for this analysis used pethidine as their opioid, this finding may not be generalisable to all opioids. The lack of clear objective guidelines for the administration of a rescue drug may also limit interpretation of this finding, though subgroup analysis showed that even in blinded trials a higher proportion of patients receiving opioids required rescue pain relief.</P>
<P>Overall, both NSAIDs and opioids provided some level of analgesia though patients receiving NSAIDs achieved a slightly greater reduction in pain and were less likely to require further pain relief. However, all the included trials used fixed doses of opioids, rather than titration of opioids to an appropriate level of pain relief. Standard practice in most Emergency Departments is to titrate opioids to effect rather than give single large boluses, and this limits the applicability of our findings to every day practice (<LINK REF="REF-Cameron-2000" TYPE="REFERENCE">Cameron 2000</LINK>). The wide variety of drug types and doses used in the studies reviewed make it difficult to identify appropriate dosing regimes for clinical practice. </P>
<P>Adverse events were generally higher in patients receiving opioids, however the ad hoc nature of reporting these events makes interpretation of this finding difficult. The specific adverse event of vomiting showed a clear association with opioids, in particular pethidine. Although no studies reported serious adverse events, the short follow-up period and failure to specifically record renal dysfunction and GI bleeding means these results should be interpreted cautiously.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>Single bolus doses of both NSAIDs and opioids provide pain relief to patients with acute renal colic. However, patients receiving NSAIDs achieve greater reduction in pain scores and are less likely to require further analgesia in the short term. Opioids are associated with a higher rate of vomiting than NSAIDs and this is particularly true for pethidine. Given these findings, when a single bolus of analgesia is used we recommend an NSAID rather than an opioid If opioids are to be used either because of contraindications to NSAIDS or ease of titratibility, we recommend that it should not be pethidine given the high rate of associated vomiting.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>No studies have examined the relative efficacy of titrated opioids rather than single bolus opioids. There are few published trials examining the potential synergistic effect of NSAIDs and opioids, and further work in this area would be helpful in determining the optimal treatment regime. </P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS/>
<CONFLICT_OF_INTEREST>
<P>None known</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2008-10-14 13:57:46 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Anna Holdgate - Designing and coordinating the review, trial selection, quality assessment, data extraction, data analysis and interpretation, writing of the review.</LI>
<LI>Tamara Pollock - Trial selection, quality assessment, data extraction, data analysis and interpretation, and writing of the review.</LI>
</UL>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-10-14 14:17:17 +1100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2008-10-14 14:01:24 +1100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2008-10-14 13:58:34 +1100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-al_x002d_Sahlawi-1996" NAME="al-Sahlawi 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;al-Sahlawi KS. Tawfik OM. Comparative study of the efficacy of lysine acetylsalicylate, indomethacin and pethidine in acute renal colic. [Clinical Trial. Journal Article. Randomized Controlled Trial] European Journal of Emergency Medicine. 3(3):183-6, 1996 Sep. UI: 9023498&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>al-Sahlawi KS, Tawfik OM</AU>
<TI>Comparative study of the efficacy of lysine acetylsalicylate, indomethacin and pethidine in acute renal colic</TI>
<SO>European Journal of Emergency Medicine</SO>
<YR>1996</YR>
<VL>3</VL>
<NO>3</NO>
<PG>183-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9023498"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Arnau-1991" NAME="Arnau 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;Anonymous. Comparative study of the efficacy of dipyrone, diclofenac sodium and pethidine in acute renal colic. Collaborative Group of the Spanish Society of Clinical Pharmacology. [Clinical Trial. Journal Article. Multicenter Study. Randomized Controlled Trial] European Journal of Clinical Pharmacology. 40(6):543-6, 1991. UI: 1884733&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arnau JM, Cami J, Garcia-Alonso F, Laporte JR, Palop R</AU>
<TI>Comparative study of the efficacy of dipyrone, diclofenac sodium and pethidine in acute renal colic. Collaborative Group of the Spanish Society of Clinical Pharmacology</TI>
<SO>European Journal of Clinical Pharmacology</SO>
<YR>1991</YR>
<VL>40</VL>
<NO>6</NO>
<PG>543-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1884733"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cordell-1994" NAME="Cordell 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Cordell WH. Larson TA. Lingeman JE. Nelson DR. Woods JR. Burns LB. Klee LW. Indomethacin suppositories versus intravenously titrated morphine for the treatment of ureteral colic. [Clinical Trial. Journal Article. Randomized Controlled Trial] Annals of Emergency Medicine. 23(2):262-9, 1994 Feb. This title is held at the Children's Hospital at Westmead Medical Library. Inquire at library for years held on ext. 53615 UI: 8304606&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cordell WH, Larson TA, Lingeman JE, Nelson DR, Woods JR, Burns LB et al</AU>
<TI>Indomethacin suppositories versus intravenously titrated morphine for the treatment of ureteral colic</TI>
<SO>Annals of Emergency Medicine</SO>
<YR>1994</YR>
<VL>23</VL>
<NO>2</NO>
<PG>262-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8304606"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cordell-1996" NAME="Cordell 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Cordell WH. Wright SW. Wolfson AB. Timerding BL. Maneatis TJ. Lewis RH. Bynum L. Nelson DR. Comparison of intravenous ketorolac, meperidine, and both (balanced analgesia) for renal colic.[comment]. [Clinical Trial. Journal Article. Multicenter Study. Randomized Controlled Trial] Annals of Emergency Medicine. 28(2):151-8, 1996 Aug. This title is held at the Children's Hospital at Westmead Medical Library. Inquire at library for years held on ext. 53615 UI: 8759578&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cordell WH, Wright SW, Wolfson AB, Timerding BL, Maneatis TJ, Lewis RH et al</AU>
<TI>Comparison of intravenous ketorolac, meperidine, and both (balanced analgesia) for renal colic</TI>
<SO>Annals of Emergency Medicine</SO>
<YR>1996</YR>
<VL>28</VL>
<NO>2</NO>
<PG>151-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8759578"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Curry-1995" NAME="Curry 1995" YEAR="14-6-">
<REFERENCE NOTES="&lt;p&gt;Curry C. Kelly AM. Intravenous tenoxicam for the treatment of renal colic. [Clinical Trial. Journal Article. Randomized Controlled Trial] New Zealand Medical Journal. 108(1001):229-30, 1995 Jun 14. UI: 7603654&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Curry C, Kelly AM</AU>
<TI>Intravenous tenoxicam for the treatment of renal colic</TI>
<SO>New Zealand Medical Journal</SO>
<YR>1995</YR>
<VL>108</VL>
<NO>1001</NO>
<PG>229-30</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7603654"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hetherington-1986" NAME="Hetherington 1986" YEAR="1986">
<REFERENCE NOTES="&lt;p&gt;Hetherington JW. Philp NH. Diclofenac sodium versus pethidine in acute renal colic. [Clinical Trial. Journal Article. Randomized Controlled Trial] British Medical Journal Clinical Research Ed.. 292(6515):237-8, 1986 Jan 25. UI: 3081085&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hetherington JW, Philp NH</AU>
<TI>Diclofenac sodium versus pethidine in acute renal colic</TI>
<SO>British Medical Journal Clinical Research Ed</SO>
<YR>1986</YR>
<VL>292</VL>
<NO>6515</NO>
<PG>237-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3081085"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Indudhara-1990" MODIFIED="2008-10-14 13:58:34 +1100" MODIFIED_BY="[Empty name]" NAME="Indudhara 1990" YEAR="1990">
<REFERENCE MODIFIED="2008-10-14 13:58:34 +1100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Indudhara R. Vaidyanathan S. Sankaranarayanan A. Oral diclofenac sodium in the treatment of acute renal colic. A prospective randomized study. [Journal: Article] Clinical Trials Journal. Vol 27(5) (pp 295-300), 1990. AN: 1991125957&lt;/p&gt;" NOTES_MODIFIED="2008-10-14 13:58:34 +1100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Indudhara R, Vaidyanathan S, Sankaranarayanan A</AU>
<TI>Oral diclofenac sodium in the treatment of acute renal colic. A prospective randomized study</TI>
<SO>Clinical Trials Journal</SO>
<YR>1990</YR>
<VL>27</VL>
<NO>5</NO>
<PG>295-300</PG>
<IDENTIFIERS MODIFIED="2008-10-14 13:58:34 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-14 13:58:34 +1100" MODIFIED_BY="[Empty name]" TYPE="EMBASE" VALUE="1991125957"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jonsson-1987" NAME="Jonsson 1987" YEAR="1987">
<REFERENCE NOTES="&lt;p&gt;Jonsson PE. Olsson AM. Petersson BA. Johansson K. Intravenous indomethacin and oxycone-papaverine in the treatment of acute renal colic. A double-blind study. [Clinical Trial. Controlled Clinical Trial. Journal Article] British Journal of Urology. 59(5):396-400, 1987 May. UI: 3297230&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jonsson PE, Olsson AM, Petersson BA, Johansson K</AU>
<TI>Intravenous indomethacin and oxycone-papaverine in the treatment of acute renal colic. A double-blind study</TI>
<SO>British Journal of Urology</SO>
<YR>1987</YR>
<VL>59</VL>
<NO>5</NO>
<PG>396-400</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3297230"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Larkin-1999" NAME="Larkin 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;Larkin GL. Peacock WF 4th. Pearl SM. Blair GA. D'Amico F. Efficacy of ketorolac tromethamine versus meperidine in the ED treatment of acute renal colic. [Clinical Trial. Journal Article. Randomized Controlled Trial] American Journal of Emergency Medicine. 17(1):6-10, 1999 Jan. UI: 9928687&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Larkin GL, Peacock WF 4th, Pearl SM, Blair GA, D'Amico F</AU>
<TI>Efficacy of ketorolac tromethamine versus meperidine in the ED treatment of acute renal colic</TI>
<SO>American Journal of Emergency Medicine</SO>
<YR>1999</YR>
<VL>17</VL>
<NO>1</NO>
<PG>6-10</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9928687"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lehtonen-1983" NAME="Lehtonen 1983" YEAR="1983">
<REFERENCE NOTES="&lt;p&gt;Lehtonen T. Kellokumpu I. Permi J. Sarsila O. Intravenous indomethacin in the treatment of ureteric colic. A clinical multicentre study with pethidine and metamizol as the control preparations. [Clinical Trial. Controlled Clinical Trial. Journal Article. Randomized Controlled Trial] Annals of Clinical Research. 15(5-6):197-9, 1983. UI: 6364951 &lt;br&gt;clinical trial. controlled clinical trial. journal article. randomized controlled trial&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lehtonen T, Kellokumpu I, Permi J, Sarsila O</AU>
<TI>Intravenous indomethacin in the treatment of ureteric colic. A clinical multicentre study with pethidine and metamizol as the control preparations</TI>
<SO>Annals of Clinical Research</SO>
<YR>1983</YR>
<VL>15</VL>
<NO>5-6</NO>
<PG>197-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6364951"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lundstam-1982" NAME="Lundstam 1982" YEAR="1982">
<REFERENCE NOTES="&lt;p&gt;Lundstam SO. Leissner KH. Wahlander LA. Kral JG. Prostaglandin-synthetase inhibition with diclofenac sodium in treatment of renal colic: comparison with use of a narcotic analgesic. [Clinical Trial. Journal Article. Randomized Controlled Trial] Lancet. 1(8281):1096-7, 1982 May 15. This title is held at the Children's Hospital at Westmead Medical Library. Inquire at library for years held on ext. 53615 UI: 6122892&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lundstam SOA, Leissner KH, Wahlander LA, Kral JG</AU>
<TI>Prostaglandin-synthetase inhibition with diclofenac sodium in treatment of renal colic: comparison with use of a narcotic analgesic</TI>
<SO>Lancet</SO>
<YR>1982</YR>
<VL>1</VL>
<NO>8281</NO>
<PG>1096-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6122892"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marthak-1991" NAME="Marthak 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;Marthak KV. Gokarn AM. Rao AV. Sane SP. Mahanta RK. Sheth RD. Chavda KD. Rane BS. Vaidya AB. A multi-centre comparative study of diclofenac sodium and a dipyrone/spasmolytic combination, and a single-centre comparative study of diclofenac sodium and pethidine in renal colic patients in India. [Clinical Trial. Journal Article. Multicenter Study. Randomized Controlled Trial] Current Medical Research &amp;amp; Opinion. 12(6):366-73, 1991. UI: 2044396 &lt;br&gt;clinical trial. journal article. multicenter study. randomized controlled trial&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marthak KV, Gokarn AM, Rao AV, Sane SP, Mahanta RK, Sheth RD et al</AU>
<TI>A multi-centre comparative study of diclofenac sodium and a dipyrone/spasmolytic combination, and a single-centre comparative study of diclofenac sodium and pethidine in renal colic patients in India</TI>
<SO>Current Medical Research &amp; Opinion</SO>
<YR>1991</YR>
<VL>12</VL>
<NO>6</NO>
<PG>366-73</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2044396"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oosterlinck-1990" NAME="Oosterlinck 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Oosterlinck W. Philp NH. Charig C. Gillies G. Hetherington JW. Lloyd J. A double-blind single dose comparison of intramuscular ketorolac tromethamine and pethidine in the treatment of renal colic. [Clinical Trial. Journal Article. Randomized Controlled Trial] Journal of Clinical Pharmacology. 30(4):336-41, 1990 Apr. UI: 2341581&lt;br&gt;clinical trial. journal article. randomized controlled trial&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oosterlinck W, Philp NH, Charig C, Gillies G, Hetherington JW, Lloyd J</AU>
<TI>A double-blind single dose comparison of intramuscular ketorolac tromethamine and pethidine in the treatment of renal colic</TI>
<SO>Journal of Clinical Pharmacology</SO>
<YR>1990</YR>
<VL>30</VL>
<NO>4</NO>
<PG>336-41</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2341581"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Persson-1985" NAME="Persson 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;Persson NH. Bergqvist D. Melander A. Zederfelt B. Comparison of a narcotic (oxicone) and a non-narcotic anti-inflammatory analgesic (indoprofen) in the treatment of renal colic. [Clinical Trial. Journal Article] Acta Chirurgica Scandinavica. 151(2):105-8, 1985. UI: 3890435 &lt;br&gt;clinical trial. journal article&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Persson NH, Bergqvist D, Melander A, Zederfelt B</AU>
<TI>Comparison of a narcotic (oxicone) and a non-narcotic anti-inflammatory analgesic (indoprofen) in the treatment of renal colic</TI>
<SO>Acta Chirurgica Scandinavica</SO>
<YR>1985</YR>
<VL>151</VL>
<NO>2</NO>
<PG>105-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3890435"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Quilez-1984" NAME="Quilez 1984" YEAR="1984">
<REFERENCE NOTES="&lt;p&gt;Quilez C. Perez-Mateo M. Hernandez P. Rubio I. [Usefulness of a non-steroid anti-inflammatory, sodium diclofenac, in the treatment of renal colic. Comparative study with a spasmolytic and an opiate analgesic]. [Spanish] [Clinical Trial. Journal Article. Randomized Controlled Trial] Medicina Clinica. 82(17):754-5, 1984 May 5. UI: 6738191 &lt;br&gt;clinical trial. journal article. randomized controlled trial&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Quilez C, Perez-Mateo M, Hernandez P, Rubio I</AU>
<TI>Usefulness of a non-steroid anti-inflammatory, sodium diclofenac, in the treatment of renal colic. Comparative study with a spasmolytic and an opiate analgesic</TI>
<SO>Medicina Clinica</SO>
<YR>1984</YR>
<VL>82</VL>
<NO>17</NO>
<PG>754-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6738191"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sandhu-1994" NAME="Sandhu 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Sandhu DP. Iacovou JW. Fletcher MS. Kaisary AV. Philip NH. Arkell DG. A comparison of intramuscular ketorolac and pethidine in the alleviation of renal colic. [Clinical Trial. Journal Article. Randomized Controlled Trial] British Journal of Urology. 74(6):690-3, 1994 Dec. UI: 7827834 &lt;br&gt;clinical trial. journal article. randomized controlled trial&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sandhu DP, Iacovou JW, Fletcher MS, Kaisary AV, Philip NH, Arkell DG</AU>
<TI>A comparison of intramuscular ketorolac and pethidine in the alleviation of renal colic</TI>
<SO>British Journal of Urology</SO>
<YR>1994</YR>
<VL>74</VL>
<NO>6</NO>
<PG>690-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7827834"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sommer-1989" NAME="Sommer 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;Sommer P. Kromann-Andersen B. Lendorf A. Lyngdorf P. Moller P. Analgesic effect and tolerance of Voltaren and Ketogan in acute renal or ureteric colic. [Clinical Trial. Journal Article. Randomized Controlled Trial] British Journal of Urology. 63(1):4-6, 1989 Jan. UI: 2645969 &lt;br&gt;clinical trial. journal article. randomized controlled trial&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sommer P, Kromann-Andersen B, Lendorf A, Lyngdorf P, Moller P</AU>
<TI>Analgesic effect and tolerance of Voltaren and Ketogan in acute renal or ureteric colic</TI>
<SO>British Journal of Urology</SO>
<YR>1989</YR>
<VL>63</VL>
<NO>1</NO>
<PG>4-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2645969"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thompson-1989" NAME="Thompson 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;Thompson JF. Pike JM. Chumas PD. Rundle JS. Rectal diclofenac compared with pethidine injection in acute renal colic. [Clinical Trial. Journal Article. Randomized Controlled Trial] BMJ. 299(6708):1140-1, 1989 Nov 4. UI: 2513026 &lt;br&gt;clinical trial. journal article. randomized controlled trial&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thompson JF, Pike JM, Chumas PD, Rundle JS</AU>
<TI>Rectal diclofenac compared with pethidine injection in acute renal colic</TI>
<SO>BMJ</SO>
<YR>1989</YR>
<VL>299</VL>
<NO>6708</NO>
<PG>1140-1</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2513026"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Torralba-1999" NAME="Torralba 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;Nicolas Torralba JA. Rigabert Montiel M. Banon Perez V. Valdelvira Nadal P. Perez Albacete M. [Intramuscular ketorolac compared to subcutaneous tramadol in the initial emergency treatment of renal colic]. [Spanish] [Clinical Trial. Journal Article. Randomized Controlled Trial] Archivos Espanoles de Urologia. 52(5):435-7, 1999 Jun. UI: 10427881&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nicolas Torralba JA, Rigabert Montiel M, Banon Perez V, Valdelvira Nadal P, Perez Albacete M</AU>
<TI>Intramuscular ketorolac compared to subcutaneous tramadol in the initial emergency treatment of renal colic</TI>
<TO>Ketorolaco intramuscular frente a Tramadol subcutaneo en el tratamiento inicial de urgencia del colico renal</TO>
<SO>Archivos Espanoles de Urologia</SO>
<YR>1999</YR>
<VL>52</VL>
<NO>5</NO>
<PG>435-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10427881"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Uden-1983" NAME="Uden 1983" YEAR="1983">
<REFERENCE NOTES="&lt;p&gt;Uden P. Rentzhog L. Berger T. A comparative study on the analgesic effects of indomethacin and hydromorphinechloride-atropine in acute, ureteral-stone pain. [Clinical Trial. Journal Article. Randomized Controlled Trial] Acta Chirurgica Scandinavica. 149(5):497-9, 1983. UI: 6637313&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Uden P, Rentzhog L, Berger T</AU>
<TI>A comparative study on the analgesic effects of indomethacin and hydromorphinechloride-atropine in acute, ureteral-stone pain</TI>
<SO>Acta Chirurgica Scandinavica</SO>
<YR>1983</YR>
<VL>149</VL>
<NO>5</NO>
<PG>497-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6637313"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2008-10-14 14:01:24 +1100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Al-Walli-1998" NAME="Al Walli 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Al Waili NS, Saloom KY</AU>
<TI>Intravenous tenoxicam to treat acute renal colic: comparison with buscopan compositum</TI>
<SO>JPMA - Journal of the Pakistan Medical Association</SO>
<YR>1998</YR>
<VL>48</VL>
<NO>12</NO>
<PG>370-2</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10531771"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Altay-2003" MODIFIED="2008-10-14 13:58:48 +1100" MODIFIED_BY="[Empty name]" NAME="Altay 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-10-14 13:58:48 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Altay B, Horansali K, Kendirci M, Tanriverdi O, Boylu U, Miroglu C</AU>
<TI>Double-blind placebo controlled, randomized clinical trial of piroxicam FDDF and intramusculer piroxicam in the treatment of renal colic: A comperatives study</TI>
<SO>Turk Uroloji Dergisi</SO>
<YR>2003</YR>
<VL>29</VL>
<NO>4</NO>
<PG>460-4</PG>
<IDENTIFIERS MODIFIED="2008-10-14 13:58:48 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-14 13:58:48 +1100" MODIFIED_BY="[Empty name]" TYPE="EMBASE" VALUE="2004050146"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anonymous-2004" MODIFIED="2008-10-14 13:58:55 +1100" MODIFIED_BY="[Empty name]" NAME="Anonymous 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-10-14 13:58:55 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>NSAIDs better than opioids for kidney stone pain</TI>
<SO>Pharmaceutical Journal</SO>
<YR>2004</YR>
<VL>272</VL>
<NO>7304</NO>
<PG>759</PG>
<IDENTIFIERS MODIFIED="2008-10-14 13:58:55 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-14 13:58:55 +1100" MODIFIED_BY="[Empty name]" TYPE="EMBASE" VALUE="2004314461"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Basar-1991" NAME="Basar 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;Basar I. Bircan K. Tasar C. Ergen A. Cakmak F. Remzi D. Diclofenac sodium and spasmolytic drugs in the treatment of ureteral colic: a comparative study. [Clinical Trial. Controlled Clinical Trial. Journal Article] International Urology &amp;amp; Nephrology. 23(3):227-30, 1991. UI: 1889968&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Basar I, Bircan K, Tasar C, Ergen A, Cakmak F, Remzi D</AU>
<TI>Diclofenac sodium and spasmolytic drugs in the treatment of ureteral colic: a comparative study</TI>
<SO>International Urology &amp; Nephrology</SO>
<YR>1991</YR>
<VL>23</VL>
<NO>3</NO>
<PG>227-30</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1889968"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bertolotto-2003" NAME="Bertolotto 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bertolotto M, Quaia E, Gasparini C, Calderan L, Pozzi MR</AU>
<TI>Resistive index in patients with renal colic: differences after medical treatment with indomethacin and ketorolac</TI>
<SO>Radiologia Medica</SO>
<YR>2003</YR>
<VL>106</VL>
<NO>4</NO>
<PG>370-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="14612828"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Broggini-1985" NAME="Broggini 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;Broggini M. Corbetta E. Grossi E. Borghi C. [Sodium diclofenac in ureteral colic. Comparative double-blind study with placebo]. [Italian] [Clinical Trial. Controlled Clinical Trial. Journal Article] Minerva Urologica e Nefrologica. 37(4):493-7, 1985 Oct-Dec. UI: 3834631 &lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Broggini M, Corbetta E, Grossi E, Borghi C</AU>
<TI>Sodium diclofenac in ureteral colic. Comparative double-blind study with placebo</TI>
<SO>Minerva Urologica e Nefrologica</SO>
<YR>1985</YR>
<VL>37</VL>
<NO>4</NO>
<PG>493-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3834631"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chang-2002" MODIFIED="2008-10-14 13:59:02 +1100" MODIFIED_BY="[Empty name]" NAME="Chang 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-10-14 13:59:02 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chang C-H, Wang C-J, Yeh Y-C, Hsu S-J</AU>
<TI>Effectiveness of sublingual buprenorphine and intramuscular pethidine in acute renal colic</TI>
<SO>Formosan Journal of Surgery</SO>
<YR>2002</YR>
<VL>35</VL>
<NO>1</NO>
<PG>9-11</PG>
<IDENTIFIERS MODIFIED="2008-10-14 13:59:02 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-14 13:59:02 +1100" MODIFIED_BY="[Empty name]" TYPE="EMBASE" VALUE="2002095448"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chaudhary-1999" NAME="Chaudhary 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;Double blind, randomised, parallel, prospective, comparative, clinical evaluation of a combination of antispasmodic analgesic Diclofenac + Pitofenone + Fenpiverinium (Manyana vs Analgin + Pitofenone + Fenpiverinium (Baralgan) in biliary, ureteric and intestinal colic. [Clinical Trial. Journal Article. Randomized Controlled Trial] Journal of the Indian Medical Association. 97(6):244-5, 1999 Jun. &lt;br&gt;UI: 10645700&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chaudhary A, Gupta RL</AU>
<TI>Double blind, randomised, parallel, prospective, comparative, clinical evaluation of a combination of antispasmodic analgesic Diclofenac + Pitofenone + Fenpiverinium (Manyana vs Analgin + Pitofenone + Fenpiverinium (Baralgan) in biliary, ureteric and intestinal colic</TI>
<SO>Journal of the Indian Medical Association</SO>
<YR>1999</YR>
<VL>97</VL>
<NO>6</NO>
<PG>244-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10645700"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Clayman-2002" NAME="Clayman 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clayman RV</AU>
<TI>Effectiveness of nifedipine and deflazacort in the management of distal ureter stones</TI>
<SO>Journal of Urology</SO>
<YR>2002</YR>
<VL>167</VL>
<NO>2 Pt 1</NO>
<PG>797-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11799973"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Daljord-1983" NAME="Daljord 1983" YEAR="1983">
<REFERENCE NOTES="&lt;p&gt;Daljord OA. Barstad S. Norenberg P. [Ambulatory treatment of an acute attack in urinary calculi. A randomized study of the effects of Petidin, Fortralin, Temgesic and Confortid]. [Norwegian] [Clinical Trial. Journal Article. Randomized Controlled Trial] Tidsskrift for Den Norske Laegeforening. 103(12):1006-8, 1983 Apr 30. UI: 6192515&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Daljord OA, Barstad S, Norenberg P</AU>
<TI>Ambulatory treatment of an acute attack in urinary calculi. A randomized study of the effects of Petidin, Fortralin, Temgesic and Confortid</TI>
<SO>Tidsskrift for Den Norske Laegeforening</SO>
<YR>1983</YR>
<VL>103</VL>
<NO>12</NO>
<PG>1006-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6192515"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dellabella-2003" NAME="Dellabella 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dellabella M, Milanese G, Muzzonigro G</AU>
<TI>Efficacy of tamsulosin in the medical management of juxtavesical ureteral stones</TI>
<SO>Journal of Urology</SO>
<YR>2003</YR>
<VL>170</VL>
<NO>6 Pt 1</NO>
<PG>2202-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="14634379"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dubinsky-1997" NAME="Dubinsky 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Dubinsky I. Penciner R. Nitroglycerin and renal colic. [Clinical Trial. Letter. Randomized Controlled Trial] Annals of Emergency Medicine. 29(6):824-5, 1997 Jun. &lt;br&gt;This title is held at the Children's Hospital at Westmead Medical Library. Inquire at library for years held on ext. 53615 &lt;br&gt;UI: 9174534&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dubinsky I, Penciner R</AU>
<TI>Nitroglycerin and renal colic</TI>
<SO>Annals of Emergency Medicine</SO>
<YR>1997</YR>
<VL>29</VL>
<NO>6</NO>
<PG>824-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9174534"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-el_x002d_Sherif-1990" NAME="el-Sherif 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;el-Sherif AE. Foda R. Norlen LJ. Yahia H. Treatment of renal colic by prostaglandin synthetase inhibitors and avafortan (analgesic antispasmodic). [Clinical Trial. Journal Article. Randomized Controlled Trial] British Journal of Urology. 66(6):602-5, 1990 Dec. UI: 2265331&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>el-Sherif AE, Foda R, Norlen LJ, Yahia H</AU>
<TI>Treatment of renal colic by prostaglandin synthetase inhibitors and avafortan (analgesic antispasmodic)</TI>
<SO>British Journal of Urology</SO>
<YR>1990</YR>
<VL>66</VL>
<NO>6</NO>
<PG>602-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2265331"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Engeler-2005" NAME="Engeler 2005" YEAR="2005">
<REFERENCE NOTES="&lt;p&gt;Engeler DS. Ackermann DK. Osterwalder JJ. Keel A. Schmid HP. A double-blind, placebo controlled comparison of the morphine sparing effect of oral rofecoxib and diclofenac for acute renal colic. [Clinical Trial. Journal Article. Randomized Controlled Trial] Journal of Urology. 174(3):933-6, 2005 Sep. UI: 16093996&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Engeler DS, Ackermann DK, Osterwalder JJ, Keel A, Schmid HP</AU>
<TI>A double-blind, placebo controlled comparison of the morphine sparing effect of oral rofecoxib and diclofenac for acute renal colic</TI>
<SO>Journal of Urology</SO>
<YR>2005</YR>
<VL>174</VL>
<NO>3</NO>
<PG>933-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16093996"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eray-2002" NAME="Eray 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eray O, Cete Y, Oktay C, Karsli B, Cete N, Ersoy F</AU>
<TI>Intravenous single-dose tramadol versus meperidine for pain relief in renal colic</TI>
<SO>European Journal of Anaesthesiology</SO>
<YR>2002</YR>
<VL>19</VL>
<NO>5</NO>
<PG>368-70</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12095018"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ergene-2002" NAME="Ergene 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ergene U, Pekdemir M, Canda E, Kirkali Z, Fowler J, Coskun F</AU>
<TI>Ondansetron versus diclofenac sodium in the treatment of acute ureteral colic: A double blind controlled trial</TI>
<SO>International Urology &amp; Nephrology</SO>
<YR>2002</YR>
<VL>33</VL>
<NO>2</NO>
<PG>315-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12092646"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Finlay-1982" NAME="Finlay 1982" YEAR="1982">
<REFERENCE NOTES="&lt;p&gt;Finlay IG. Scott R. McArdle CS. Prospective double-blind comparison of buprenorphine and pethidine in ureteric colic. [Clinical Trial. Journal Article. Randomized Controlled Trial] British Medical Journal Clinical Research Ed.. 284(6332):1830-1, 1982 Jun 19. UI: 6805715&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Finlay IG, Scott R, McArdle CS</AU>
<TI>Prospective double-blind comparison of buprenorphine and pethidine in ureteric colic</TI>
<SO>British Medical Journal Clinical Research Ed</SO>
<YR>1982</YR>
<VL>284</VL>
<NO>6332</NO>
<PG>1830-1</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6805715"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Flannigan-1983" NAME="Flannigan 1983" YEAR="1983">
<REFERENCE NOTES="&lt;p&gt;Flannigan GM. Clifford RP. Carver RA. Yule AG. Madden NP. Towler JM. Indomethacin--an alternative to pethidine in ureteric colic. [Journal Article] British Journal of Urology. 55(1):6-9, 1983 Feb. UI: 6824866&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Flannigan GM, Clifford RP, Carver RA, Yule AG, Madden NP, Towler JM</AU>
<TI>Indomethacin - an alternative to pethidine in ureteric colic</TI>
<SO>British Journal of Urology</SO>
<YR>1983</YR>
<VL>55</VL>
<NO>1</NO>
<PG>6-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6824866"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fraga-2003" MODIFIED="2008-10-14 13:59:20 +1100" MODIFIED_BY="[Empty name]" NAME="Fraga 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-10-14 13:59:20 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fraga A, De Almeida M, Moreira-Da-Silva V, Sousa-Marques M, Severo L, Matos-Ferreira A et al</AU>
<TI>Intramuscular Etofenamate versus Diclofenac in the Relief of Renal Colic: A Randomised, Single-Blind, Comparative Study</TI>
<SO>Clinical Drug Investigation</SO>
<YR>2003</YR>
<VL>23</VL>
<NO>11</NO>
<PG>701-6</PG>
<IDENTIFIERS MODIFIED="2008-10-14 13:59:20 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-14 13:59:20 +1100" MODIFIED_BY="[Empty name]" TYPE="EMBASE" VALUE="2003454340"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Graiff-1985" NAME="Graiff 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;Graiff C. Bezza M. Ziller F. Stringari B. Brentari R. Bertagnolli G. Apuzzo F. Mezzena R. Caerulein in the treatment of biliary and renal colic. [Clinical Trial. Journal Article. Randomized Controlled Trial] Peptides. 6 Suppl 3:47-51, 1985.&lt;br&gt;UI: 3831972&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Graiff C, Bezza M, Ziller F, Stringari B, Brentari R, Bertagnolli G et al</AU>
<TI>Caerulein in the treatment of biliary and renal colic</TI>
<SO>Peptides</SO>
<YR>1985</YR>
<VL>6 Suppl 3</VL>
<PG>47-51</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3831972"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hedenbro-1988" NAME="Hedenbro 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Hedenbro JL. Olsson AM. Metoclopramide and ureteric colic. [Clinical Trial. Controlled Clinical Trial. Journal Article] Acta Chirurgica Scandinavica. 154(7-8):439-40, 1988 Jul-Aug. UI: 2903602&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hedenbro JL, Olsson AM</AU>
<TI>Metoclopramide and ureteric colic</TI>
<SO>Acta Chirurgica Scandinavica</SO>
<YR>1988</YR>
<VL>154</VL>
<NO>7-8</NO>
<PG>439-40</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2903602"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ho-2004" MODIFIED="2008-10-14 14:00:01 +1100" MODIFIED_BY="[Empty name]" NAME="Ho 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-10-14 14:00:01 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ho MK, Chung CH</AU>
<TI>A prospective, randomised clinical trial comparing oral diclofenac potassium and intramuscular diclofenac sodium in acute pain relief</TI>
<SO>Hong Kong Journal of Emergency Medicine</SO>
<YR>2004</YR>
<VL>11</VL>
<NO>2</NO>
<PG>69-77</PG>
<IDENTIFIERS MODIFIED="2008-10-14 14:00:01 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-14 14:00:01 +1100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="2004199659"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hofstetter-1993" NAME="Hofstetter 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Hofstetter AG. Kriegmair M. [Treatment of ureteral colic with glycerol trinitrate]. [German] [Clinical Trial. Journal Article. Randomized Controlled Trial] Fortschritte der Medizin. 111(16):286-8, 1993 Jun 10. &lt;br&gt;UI: 8330828&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hofstetter AG, Kriegmair M</AU>
<TI>Treatment of ureteral colic with glycerol trinitrate</TI>
<SO>Fortschritte der Medizin</SO>
<YR>1993</YR>
<VL>111</VL>
<NO>16</NO>
<PG>286-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8330828"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Holdgate-2005" NAME="Holdgate 2005" YEAR="2005">
<REFERENCE NOTES="&lt;p&gt;Holdgate A. Oh CM. Is there a role for antimuscarinics in renal colic? A randomized controlled trial. [Clinical Trial. Journal Article. Randomized Controlled Trial] Journal of Urology. 174(2):572-5; discussion 575, 2005 Aug. UI: 16006900&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Holdgate A, Oh CM</AU>
<TI>Is there a role for antimuscarinics in renal colic? A randomized controlled trial</TI>
<SO>Journal of Urology</SO>
<YR>2005</YR>
<VL>174</VL>
<NO>2</NO>
<PG>572-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16006900"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hussain-2001" NAME="Hussain 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hussain Z, Inman RD, Elves AW, Shipstone DP, Ghiblawi S, Coppinger SW</AU>
<TI>Use of glyceryl trinitrate patches in patients with ureteral stones: a randomized, double-blind, placebo-controlled study</TI>
<SO>Urology</SO>
<YR>2001</YR>
<VL>58</VL>
<NO>4</NO>
<PG>521-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11597530"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Iguchi-2002" NAME="Iguchi 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;Iguchi M. Katoh Y. Koike H. Hayashi T. Nakamura M. Randomized trial of trigger point injection for renal colic. [Clinical Trial. Journal Article. Randomized Controlled Trial] International Journal of Urology. 9(9):475-9, 2002 Sep. &lt;br&gt;UI: 12410926&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Iguchi M, Katoh Y, Koike H, Hayashi T, Nakamura M</AU>
<TI>Randomized trial of trigger point injection for renal colic</TI>
<SO>International Journal of Urology</SO>
<YR>2002</YR>
<VL>9</VL>
<NO>9</NO>
<PG>475-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12410926"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jones-1998" NAME="Jones 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jones JB, Dula DJ</AU>
<TI>The efficacy of sublingual hyoscyamine sulfate and intravenous ketorolac tromethamine in the relief of ureteral colic</TI>
<SO>American Journal of Emergency Medicine</SO>
<YR>1998</YR>
<VL>16</VL>
<NO>6</NO>
<PG>557-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9786536"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jones-2001" NAME="Jones 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jones JB, Giles BK, Brizendine EJ, Cordell WH</AU>
<TI>Sublingual hyoscyamine sulfate in combination with ketorolac tromethamine for ureteral colic: a randomized, double-blind, controlled trial</TI>
<SO>Annals of Emergency Medicine</SO>
<YR>2001</YR>
<VL>37</VL>
<NO>2</NO>
<PG>141-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11174230"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Khalifa-1986" NAME="Khalifa 1986" YEAR="1986">
<REFERENCE NOTES="&lt;p&gt;Khalifa MS. Sharkawi MA. Treatment of pain owing to acute ureteral obstruction with prostaglandin-synthetase inhibitor: a prospective randomized study. [Clinical Trial. Journal Article. Randomized Controlled Trial] Journal of Urology. 136(2):393-5, 1986 Aug. This title is held at the Children's Hospital at Westmead Medical Library. Inquire at library for years held on ext. 53615 UI: 3090274 &lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Khalifa MS, Sharkawi MA</AU>
<TI>Treatment of pain owing to acute ureteral obstruction with prostaglandin-synthetase inhibitor: a prospective randomized study</TI>
<SO>Journal of Urology</SO>
<YR>1986</YR>
<VL>136</VL>
<NO>2</NO>
<PG>393-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3090274"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lloret-1986" NAME="Lloret 1986" YEAR="1986">
<REFERENCE NOTES="&lt;p&gt;Lloret J. Vila A. Puig X. Monmany J. Munoz J. More J. Nifedipine in the treatment of renal colic. [Clinical Trial. Journal Article. Randomized Controlled Trial] Methods &amp;amp; Findings in Experimental &amp;amp; Clinical Pharmacology. 8(9):575-9, 1986 Sep. UI: 3773599&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lloret J, Vila A, Puig X, Monmany J, Munoz J, More J</AU>
<TI>Nifedipine in the treatment of renal colic</TI>
<SO>Methods &amp; Findings in Experimental &amp; Clinical Pharmacology</SO>
<YR>1986</YR>
<VL>8</VL>
<NO>9</NO>
<PG>575-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3773599"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lopes-2001" NAME="Lopes 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;Lopes T. Dias JS. Marcelino J. Varela J. Ribeiro S. Dias J. An assessment of the clinical efficacy of intranasal desmopressin spray in the treatment of renal colic. [Clinical Trial. Journal Article. Randomized Controlled Trial] BJU International. 87(4):322-5, 2001 Mar. UI: 11251523&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lopes T, Dias JS, Marcelino J, Varela J, Ribeiro S, Dias J</AU>
<TI>An assessment of the clinical efficacy of intranasal desmopressin spray in the treatment of renal colic</TI>
<SO>BJU International</SO>
<YR>2001</YR>
<VL>87</VL>
<NO>4</NO>
<PG>322-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11251523"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Muller-1990" MODIFIED="2008-10-14 14:00:49 +1100" MODIFIED_BY="[Empty name]" NAME="Muller 1990" YEAR="1990">
<REFERENCE MODIFIED="2008-10-14 14:00:49 +1100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Muller TF. Naesh O. Svare E. Jensen A. Glyngdal P. Metoclopramide (Primperan) in the treatment of ureterolithiasis. A prospective double-blind study of metoclopramide compared with morphatropin on ureteral colic. [Clinical Trial. Controlled Clinical Trial. Journal Article. Randomized Controlled Trial] Urologia Internationalis. 45(2):112-3, 1990. UI: 1691882&lt;/p&gt;" NOTES_MODIFIED="2008-10-14 14:00:49 +1100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Muller TF, Naesh O, Svare E, Jensen A, Glyngdal P</AU>
<TI>Metoclopramide (Primperan) in the treatment of ureterolithiasis. A prospective double-blind study of metoclopramide compared with morphatropin on ureteral colic</TI>
<SO>Urologia Internationalis</SO>
<YR>1990</YR>
<VL>45</VL>
<NO>2</NO>
<PG>112-3</PG>
<IDENTIFIERS MODIFIED="2008-10-14 14:00:49 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-14 14:00:49 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="1691882"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Muriel-1993" NAME="Muriel 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Muriel C. Ortiz P. Efficacy of two different intramuscular doses of dipyrone in acute renal colic. Cooperative Study Group. [Clinical Trial. Journal Article. Multicenter Study. Randomized Controlled Trial] Methods &amp;amp; Findings in Experimental &amp;amp; Clinical Pharmacology. 15(7):465-9, 1993 Sep. UI: 8255126&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Muriel C, Ortiz P</AU>
<TI>Efficacy of two different intramuscular doses of dipyrone in acute renal colic. Cooperative Study Group</TI>
<SO>Methods &amp; Findings in Experimental &amp; Clinical Pharmacology</SO>
<YR>1993</YR>
<VL>15</VL>
<NO>7</NO>
<PG>465-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8255126"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Muriel_x002d_Villoria-1995" NAME="Muriel-Villoria 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Muriel-Villoria C. Zungri-Telo E. Diaz-Curiel M. Fernandez-Guerrero M. Moreno J. Puerta J. Ortiz P. Comparison of the onset and duration of the analgesic effect of dipyrone, 1 or 2 g, by the intramuscular or intravenous route, in acute renal colic. [Clinical Trial. Journal Article. Randomized Controlled Trial] European Journal of Clinical Pharmacology. 48(2):103-7, 1995. UI: 7589022&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Muriel-Villoria C, Zungri-Telo E, Diaz-Curiel M, Fernandez-Guerrero M, Moreno J, Puerta J et al</AU>
<TI>Comparison of the onset and duration of the analgesic effect of dipyrone, 1 or 2 g, by the intramuscular or intravenous route, in acute renal colic</TI>
<SO>European Journal of Clinical Pharmacology</SO>
<YR>1995</YR>
<VL>48</VL>
<NO>2</NO>
<PG>103-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7589022"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nelson-1988" NAME="Nelson 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Nelson CE. Nylander C. Olsson AM. Olsson R. Pettersson BA. Wallstrom I. Rectal v. intravenous administration of indomethacin in the treatment of renal colic. [Clinical Trial. Controlled Clinical Trial. Journal Article] Acta Chirurgica Scandinavica. 154(4):253-5, 1988 Apr. UI: 3287813&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nelson CE, Nylander C, Olsson AM, Olsson R, Pettersson BA, Wallstrom I</AU>
<TI>Rectal v. intravenous administration of indomethacin in the treatment of renal colic</TI>
<SO>Acta Chirurgica Scandinavica</SO>
<YR>1988</YR>
<VL>154</VL>
<NO>4</NO>
<PG>253-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3287813"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nissen-1990" NAME="Nissen 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Nissen I. Birke H. Olsen JB. Wurtz E. Lorentzen K. Salomon H. Lynge P. Fly P. Jorgensen TH. Svane S. et al. Treatment of ureteric colic. Intravenous versus rectal administration of indomethacin. [Clinical Trial. Journal Article. Multicenter Study. Randomized Controlled Trial] British Journal of Urology. 65(6):576-9, 1990 Jun. UI: 2196971&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nissen I, Birke H, Olsen JB, Wurtz E, Lorentzen K, Salomon H et al</AU>
<TI>Treatment of ureteric colic. Intravenous versus rectal administration of indomethacin</TI>
<SO>British Journal of Urology</SO>
<YR>1990</YR>
<VL>65</VL>
<NO>6</NO>
<PG>576-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2196971"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oosterlinck-1982" NAME="Oosterlinck 1982" YEAR="1982">
<REFERENCE NOTES="&lt;p&gt;Oosterlinck W. Minnaert H. An open comparative trial of three doses of ciramadol used intravenously in renal colic. [Clinical Trial. Controlled Clinical Trial. Journal Article] Current Medical Research &amp;amp; Opinion. 8(4):290-3, 1982. &lt;br&gt;UI: c&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oosterlinck W, Minnaert H</AU>
<TI>An open comparative trial of three doses of ciramadol used intravenously in renal colic</TI>
<SO>Current Medical Research &amp; Opinion</SO>
<YR>1982</YR>
<VL>8</VL>
<NO>4</NO>
<PG>290-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6759062"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pavlik-2004" NAME="Pavlik 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pavlik I, Suchy J, Pacik D, Bokr R, Sust M, Villoria J et al</AU>
<TI>Comparison of cizolirtine citrate and metamizol sodium in the treatment of adult acute renal colic: a randomized, double-blind, clinical pilot study</TI>
<SO>Clinical Therapeutics</SO>
<YR>2004</YR>
<VL>26</VL>
<NO>7</NO>
<PG>1061-72</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15336471"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Porpiglia-2004" NAME="Porpiglia 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Porpiglia F, Ghignone G, Fiori C, Fontana D, Scarpa RM</AU>
<TI>Nifedipine versus tamsulosin for the management of lower ureteral stones</TI>
<SO>Journal of Urology</SO>
<YR>2004</YR>
<VL>172</VL>
<NO>2</NO>
<PG>568-71</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15247732"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pourrat-1984" MODIFIED="2008-10-14 14:01:06 +1100" MODIFIED_BY="[Empty name]" NAME="Pourrat 1984" YEAR="1984">
<REFERENCE MODIFIED="2008-10-14 14:01:06 +1100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Pourrat JP. Dueymes J-M. Conte JJ. Treatment of renal colic with ketoprofen. [Journal] Presse Medicale. Vol. 13(35)(pp 2125-2128), 1984. &lt;br&gt;AN: 1984212234&lt;/p&gt;" NOTES_MODIFIED="2008-10-14 14:01:06 +1100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pourrat JP, Dueymes J, Conte JJ</AU>
<TI>Treatment of renal colic with ketoprofen</TI>
<SO>Presse Medicale</SO>
<YR>1984</YR>
<VL>13</VL>
<NO>35</NO>
<PG>2125-8</PG>
<IDENTIFIERS MODIFIED="2008-10-14 14:01:06 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-14 14:01:06 +1100" MODIFIED_BY="[Empty name]" TYPE="EMBASE" VALUE="1984212234"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Primus-1989" NAME="Primus 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;Primus G. Pummer K. Vucsina F. Meindl N. [Tramadol versus metimazole in alleviating pain in ureteral colic]. [German] [Clinical Trial. Journal Article. Randomized Controlled Trial] Urologe (Ausg. A). 28(2):103-5, 1989 Mar. &lt;br&gt;UI: 2655256&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Primus G, Pummer K, Vucsina F, Meindl N</AU>
<TI>Tramadol versus metimazole in alleviating pain in ureteral colic</TI>
<SO>Urologe</SO>
<YR>1989</YR>
<VL>28</VL>
<NO>2</NO>
<PG>103-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2655256"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Resim-2005" NAME="Resim 2005" YEAR="2005">
<REFERENCE NOTES="&lt;p&gt;Resim S. Ekerbicer H. Ciftci A. Effect of tamsulosin on the number and intensity of ureteral colic in patients with lower ureteral calculus. [Journal Article. Randomized Controlled Trial] International Journal of Urology. 12(7):615-20, 2005 Jul. UI: 16045553&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Resim S, Ekerbicer H, Ciftci A</AU>
<TI>Effect of tamsulosin on the number and intensity of ureteral colic in patients with lower ureteral calculus</TI>
<SO>International Journal of Urology</SO>
<YR>2005</YR>
<VL>12</VL>
<NO>7</NO>
<PG>615-20</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16045553"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saita-2004" NAME="Saita 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saita A, Bonaccorsi A, Marchese F, Condorelli SV, Motta M</AU>
<TI>Our experience with nifedipine and prednisolone as expulsive therapy for ureteral stones</TI>
<SO>Urologia Internationalis</SO>
<YR>2004</YR>
<VL>72 Suppl</VL>
<NO>1</NO>
<PG>43-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15133333"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sanchez_x002d_Carpena-2003" MODIFIED="2008-10-14 14:01:13 +1100" MODIFIED_BY="[Empty name]" NAME="Sanchez-Carpena 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-10-14 14:01:13 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sanchez-Carpena J, Sesma-Sanchez J, Sanchez-Juan C, Tomas-Vecina S, Garcia-Alonso D, Rico-Salvado J et al</AU>
<TI>Comparison of dexketoprofen trometamol and dipyrone in the treatment of renal colic</TI>
<SO>Clinical Drug Investigation</SO>
<YR>2003</YR>
<VL>23</VL>
<NO>3</NO>
<PG>139-52</PG>
<IDENTIFIERS MODIFIED="2008-10-14 14:01:13 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-14 14:01:13 +1100" MODIFIED_BY="[Empty name]" TYPE="EMBASE" VALUE="2003132028"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Servedio-1974" NAME="Servedio 1974" YEAR="1974">
<REFERENCE NOTES="&lt;p&gt;Servedio C. The use of flavoxate in cystitis and renal colic. [Clinical Trial. Controlled Clinical Trial. Journal Article. Randomized Controlled Trial] Current Medical Research &amp;amp; Opinion. 2(8):449-54, 1974. &lt;br&gt;UI: 4614949&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Servedio C</AU>
<TI>The use of flavoxate in cystitis and renal colic</TI>
<SO>Current Medical Research &amp; Opinion</SO>
<YR>1974</YR>
<VL>2</VL>
<NO>8</NO>
<PG>449-54</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="4614949"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Slade-1967" NAME="Slade 1967" YEAR="1967">
<REFERENCE NOTES="&lt;p&gt;Slade N. Clinical blind trial of three drugs in the control of renal colic. [Clinical Trial. Controlled Clinical Trial. Journal Article] British Journal of Urology. 39(1):22-5, 1967 Feb. &lt;br&gt;UI: 5336761&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Slade N</AU>
<TI>Clinical blind trial of three drugs in the control of renal colic</TI>
<SO>British Journal of Urology</SO>
<YR>1967</YR>
<VL>39</VL>
<NO>1</NO>
<PG>22-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="5336761"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stankov-1994" NAME="Stankov 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Stankov G. Schmieder G. Zerle G. Schinzel S. Brune K. Double-blind study with dipyrone versus tramadol and butylscopolamine in acute renal colic pain. [Clinical Trial. Journal Article. Multicenter Study. Randomized Controlled Trial] World Journal of Urology. 12(3):155-61, 1994. UI: 7951343&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stankov G, Schmieder G, Zerle G, Schinzel S, Brune K</AU>
<TI>Double-blind study with dipyrone versus tramadol and butylscopolamine in acute renal colic pain</TI>
<SO>World Journal of Urology</SO>
<YR>1994</YR>
<VL>12</VL>
<NO>3</NO>
<PG>155-61</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7951343"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stein-1996" NAME="Stein 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stein A, Ben Dov D, Finkel B, Mecz Y, Kitzes R, Lurie A</AU>
<TI>Single-dose intramuscular ketorolac versus diclofenac for pain management in renal colic</TI>
<SO>American Journal of Emergency Medicine</SO>
<YR>1996</YR>
<VL>14</VL>
<NO>4</NO>
<PG>385-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8768161"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Torchi-1983" NAME="Torchi 1983" YEAR="1983">
<REFERENCE NOTES="&lt;p&gt;Torchi B. Villani U. Bruni G. Lavezzari M. Mandelli V. Intravenous indoprofen in the management of renal colic. [Clinical Trial. Journal Article. Randomized Controlled Trial] International Journal of Clinical Pharmacology Research. 3(3):167-73, 1983. UI: 6384073&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Torchi B, Villani U, Bruni G, Lavezzari M, Mandelli V</AU>
<TI>Intravenous indoprofen in the management of renal colic</TI>
<SO>International Journal of Clinical Pharmacology Research</SO>
<YR>1983</YR>
<VL>3</VL>
<NO>3</NO>
<PG>167-73</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6384073"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tura-1986" NAME="Tura 1986" YEAR="1986">
<REFERENCE NOTES="&lt;p&gt;Tura F. Iriarte JL. Bona X. Milla J. [Ceruletide as an analgesic in biliary and nephritic colic: comparative study]. [Spanish] [Clinical Trial. Journal Article. Randomized Controlled Trial] Medicina Clinica. 86(7):277-80, 1986 Feb 22. &lt;br&gt;UI: 3520181&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tura F, Iriarte JL, Bona X, Milla J</AU>
<TI>Ceruletide as an analgesic in biliary and nephritic colic: comparative study</TI>
<SO>Medicina Clinica</SO>
<YR>1986</YR>
<VL>86</VL>
<NO>7</NO>
<PG>277-80</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3520181"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xue-1996" MODIFIED="2008-10-14 14:01:24 +1100" MODIFIED_BY="[Empty name]" NAME="Xue 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-10-14 14:01:24 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xue YM, Xiong J, Gao WZ</AU>
<TI>Verapamil vs anisodamine in treating renal colic</TI>
<SO>New Drugs and Clinical Remedies</SO>
<YR>1996</YR>
<VL>15</VL>
<NO>2</NO>
<PG>77-8</PG>
<IDENTIFIERS MODIFIED="2008-10-14 14:01:24 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-14 14:01:24 +1100" MODIFIED_BY="[Empty name]" TYPE="CENTRAL" VALUE="CN-00252286"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-10-14 14:17:17 +1100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2008-10-14 14:04:25 +1100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Cameron-2000" NAME="Cameron 2000" TYPE="BOOK">
<AU>Cameron P, Jelinek G, Kelly AM, Murray L, Heyworth J</AU>
<SO>Textbook of Adult Emergency Medicine</SO>
<YR>2000</YR>
<PB>Churchill Livingston</PB>
<CY>Edinburgh</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dickersin-1994" MODIFIED="2008-10-14 14:01:31 +1100" MODIFIED_BY="[Empty name]" NAME="Dickersin 1994" TYPE="JOURNAL_ARTICLE">
<AU>Dickersin K, Scherer R, Lefebvre C</AU>
<TI>Identifying relevant studies for systematic reviews</TI>
<SO>BMJ</SO>
<YR>1994</YR>
<VL>309</VL>
<NO>6964</NO>
<PG>1286 -91</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7718048"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Drach-1992" NAME="Drach 1992" TYPE="BOOK">
<AU>Drach GW</AU>
<SO>Campbell's Urology</SO>
<YR>1992</YR>
<EN>6th</EN>
<ED>Walsh PC, Refik AB, Stamey TA, Vaughan ED</ED>
<PB>WB Saunders</PB>
<CY>Philadelphia</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Edwards-2002" MODIFIED="2008-10-14 14:03:53 +1100" MODIFIED_BY="[Empty name]" NAME="Edwards 2002" TYPE="COCHRANE_REVIEW">
<AU>Rees J, Meseguer F, Faura C, Moore RA, McQuay HJ</AU>
<TI>Single dose dipyrone for acute renal colic pain</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2008-10-14 14:03:37 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-14 14:03:37 +1100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003867"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" MODIFIED="2008-10-14 14:03:58 +1100" MODIFIED_BY="[Empty name]" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey-Smith G, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple graphical test</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<NO>7109</NO>
<PG>629-34</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9310563"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gallagher-2001" MODIFIED="2008-10-14 14:04:00 +1100" MODIFIED_BY="[Empty name]" NAME="Gallagher 2001" TYPE="JOURNAL_ARTICLE">
<AU>Gallagher EJ, Liebman M, Bijur PE</AU>
<TI>Prospective validation of clinically important changes in pain severity measured on a visual analog scale</TI>
<SO>Annals of Emergency Medicine</SO>
<YR>2001</YR>
<VL>38</VL>
<NO>6</NO>
<PG>633-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11719741"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Holdgate-1999" NAME="Holdgate 1999" TYPE="JOURNAL_ARTICLE">
<AU>Holdgate A, Harcastle J</AU>
<TI>Renal colic: a diagnostic and therapeutic review</TI>
<SO>Emergency Medicine</SO>
<YR>1999</YR>
<VL>11</VL>
<PG>9-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Labreque-1994" MODIFIED="2008-10-14 14:04:07 +1100" MODIFIED_BY="[Empty name]" NAME="Labreque 1994" TYPE="JOURNAL_ARTICLE">
<AU>Labreque M, Dostaler LP, Rouselle R, Nguyen , Poirier S</AU>
<TI>Efficacy of nonsteroidal anti-inflammatory drugs in the treatment of acute renal colic. A meta-analysis</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1994</YR>
<VL>154</VL>
<NO>12</NO>
<PG>1381-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8002690"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lefebvre-1996" MODIFIED="2008-10-14 14:04:10 +1100" MODIFIED_BY="[Empty name]" NAME="Lefebvre 1996" TYPE="CONFERENCE_PROC">
<AU>Lefebvre C, McDonald S</AU>
<TI>Development of a sensitive search strategy for reports of randomized controlled trials in EMBASE</TI>
<SO>Fourth International Cochrane Colloquium; 1996 Oct 20-24; Adelaide (Australia)</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reich-1997" MODIFIED="2008-10-14 14:04:12 +1100" MODIFIED_BY="[Empty name]" NAME="Reich 1997" TYPE="JOURNAL_ARTICLE">
<AU>Reich JD, Hanno PM</AU>
<TI>Factitious renal colic</TI>
<SO>Urology</SO>
<YR>1997</YR>
<VL>50</VL>
<NO>6</NO>
<PG>858-62</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9426714"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Renal-Group-2003" NAME="Renal Group 2003" TYPE="OTHER">
<AU>Willis NS, Mitchell R, Craig JC</AU>
<TI>Renal Group</TI>
<SO>About the Cochrane Collaboration (Collaborative Review Groups (CRGs)): in The Cochrane Library</SO>
<YR>Issue 4, 2003</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Smally-1997" NAME="Smally 1997" TYPE="JOURNAL_ARTICLE">
<AU>Smally AJ</AU>
<TI>Analgesia in renal colic</TI>
<SO>Annals of Emergency Medicine</SO>
<YR>1997</YR>
<VL>29</VL>
<NO>2</NO>
<PG>296</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9018200"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Stewart-1988" NAME="Stewart 1988" TYPE="JOURNAL_ARTICLE">
<AU>Stewart C</AU>
<TI>Nephrolithiasis</TI>
<SO>Emergency Medicine Clinics of North America</SO>
<YR>1988</YR>
<VL>6</VL>
<NO>3</NO>
<PG>617-30</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3292230"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Tintinalli-1999" NAME="Tintinalli 1999" TYPE="BOOK_SECTION">
<AU>Moll J, Peacock WF</AU>
<TI>Urologic stone disease</TI>
<SO>Emergency Medicine: a comprehensive study guide</SO>
<YR>1999</YR>
<PG>640-5</PG>
<EN>5th</EN>
<PB>McGraw-Hill</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Todd-1996" MODIFIED="2008-10-14 14:04:21 +1100" MODIFIED_BY="[Empty name]" NAME="Todd 1996" TYPE="JOURNAL_ARTICLE">
<AU>Todd KH, Funk KG, Funk JP, Bonacci R</AU>
<TI>Clinical significance of reported changes in pain severity</TI>
<SO>Annals of Emergency Medicine</SO>
<YR>1996</YR>
<VL>27</VL>
<NO>4</NO>
<PG>485-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8604867"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Tramer-1998" MODIFIED="2008-10-14 14:04:25 +1100" MODIFIED_BY="[Empty name]" NAME="Tramer 1998" TYPE="JOURNAL_ARTICLE">
<AU>Tramer MR, Williams JE, Carroll D, Wiffen PJ, Moore RA, McQuay HJ</AU>
<TI>Comparing analgesic efficacy of non-steroidal anti-inflammatory drugs given by different routes in acute and chronic pain: A qualitative systematic review</TI>
<SO>Acta Anaesthesiologica Scandinavica</SO>
<YR>1998</YR>
<VL>42</VL>
<NO>1</NO>
<PG>71-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9527748"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2008-10-14 14:17:17 +1100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Holdgate-2003" MODIFIED="2008-10-14 14:16:11 +1100" MODIFIED_BY="[Empty name]" NAME="Holdgate 2003" TYPE="COCHRANE_PROTOCOL">
<AU>Holdgate A, Pollock T</AU>
<TI>Nonsteroidal anti-inflammatory drugs (NSAIDs) versus opioids for acute renal colic</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2008-10-14 14:16:08 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-14 14:16:08 +1100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004137"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Holdgate-2004a" MODIFIED="2008-10-14 14:15:35 +1100" MODIFIED_BY="[Empty name]" NAME="Holdgate 2004a" TYPE="JOURNAL_ARTICLE">
<AU>Holdgate A, Pollock T</AU>
<TI>Systematic review of the relative efficacy of non-steroidal anti-inflammatory drugs and opioids in the treatment of acute renal colic</TI>
<SO>BMJ</SO>
<YR>2004</YR>
<VL>328</VL>
<NO>7453</NO>
<PG>1401-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15178585"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Holdgate-2004b" MODIFIED="2008-10-14 14:17:17 +1100" MODIFIED_BY="[Empty name]" NAME="Holdgate 2004b" TYPE="COCHRANE_REVIEW">
<AU>Holdgate A, Pollock T</AU>
<TI>Nonsteroidal anti-inflammatory drugs (NSAIDs) versus opioids for acute renal colic</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2008-10-14 14:17:15 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-14 14:17:15 +1100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004137.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-10-14 14:12:30 +1100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-10-14 14:12:30 +1100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-al_x002d_Sahlawi-1996">
<CHAR_METHODS>
<P>Country: Kuwait - Emergency Department<BR/>Randomisation method: Not stated<BR/>Power analysis: Not stated<BR/>BLINDING<BR/>Investigators: Not stated<BR/>Participants Not stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>20-60 years<BR/>Group 1: 50 (34M)<BR/>Group 2: 50 (37M) <BR/>Inclusion criteria: diagnosis by combined clinical and radiological <BR/>Exclusion criteria: prior treatment, allergy to trial drugs, peptic ulcer disease, asthma, pregnancy, lactation</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: Indomethacin 100 mg IV <BR/>Group 2: pethidine 100 mg lysine-acetyl salicylate 1.8 g IV</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Complete relief at 30 min<BR/>Need for rescue analgesia at 30 min<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>3rd group excluded from analysis because of drug type (acetyl salicylate)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Arnau-1991">
<CHAR_METHODS>
<P>Country: Spain - 13 Emergency Departments<BR/>Randomisation method: Not stated<BR/>Power analysis: performed<BR/>BLINDING<BR/>Investigators: Not stated<BR/>Participants: Not stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>18-65 yrs <BR/>Group 1: 116 (63M) Mean age 40.7 yrs <BR/>Group 2: 118 (61M) Mean age 41.4 yrs <BR/>Inclusion criteria: diagnosis by clinical +/- plain xray. <BR/>Exclusions: allergy to trial drug, peptic ulcer, GI bleed, mild pain, pregnancy, lactation, prior treatment</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: Diclofenac 75mg IM<BR/>Group 2: pethidine 100 mg IM</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pain score <BR/>VAS <BR/>Need for rescue analgesia<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>2 groups (217 pts) not included becasue fo drug type (dipyrone)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Cordell-1994">
<CHAR_METHODS>
<P>Country: USA - Emergency Department<BR/>Randomisation: computer generated table<BR/>Power analysis: Not stated<BR/>BLINDING<BR/>Investigators: Y<BR/>Participants: Y</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>18-75 yrs <BR/>Group 1 : 31 (18M) Mean age 39.2 yrs <BR/>Group 2: 20 (18M) Mean age 38.9 yrs <BR/>Method of diagnosis: confirmed by IVP, extraction or stone passage<BR/>Exclusions: pregnancy, peptic ulcer, bleeding disorder, anticoagulation therapy, rectal bleeding/proctitis, allergy to trial drug, recent analgesics</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: Indomethacin 100 mg PR<BR/>Group 2: 5-10mg morphine IV</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Crossover trial, at cross over patients given drug from alternate arm, post-crossover data not included<BR/>Patient relief VAS rather than pain score VAS measured, therefore not included</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Cordell-1996">
<CHAR_METHODS>
<P>Country: USA - Four emergency departments<BR/>Randomisation: computer generated block <BR/>Power analysis: performed<BR/>BLINDING:<BR/>Investigators: Y<BR/>Participants: Y</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>18 y or older<BR/>Group 1: 35 (28M), Mean age 42.0<BR/>Group 2: 36 (30M), Mean age 38.8<BR/>Inclusion criteria: diagnosis confirmed by IVP, US, stone passage or extraction<BR/>Exclusion criteria: allergy to study drug, peptic ulcer disease, bleeding disorder, anticoagulation, pregnancy, renal insufficiency, suspected drug seeking behaviour</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: 50 mg meperidine IV<BR/>Group 2: 60 mg ketorolac IV</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pain score VAS<BR/>Need for rescue analgesia<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>3rd group (35) not included because combination therapy with NSAID and opioid<BR/>ITT analysis not performed on efficacy outcomes</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Curry-1995">
<CHAR_METHODS>
<P>Country: NZ - Emergency Department<BR/>Randomisation: Not stated<BR/>Power analysis: Not stated<BR/>BLINDING:<BR/>Investigators: Y<BR/>Participants: Y</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>18-75 y<BR/>Overall 41 participants, 75% male, mean age 40 y<BR/>Inclusion criteria: diagnosis on IVP<BR/>Exclusion criteria: allergy to study drug, contraindications to either drug, suspected drug seeking behaviour</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: 40 mg tenoxicam IV<BR/>Group 2: 75 mg pethidine IV</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pain score VAS<BR/>Adverse events<BR/>Need for rescue analgesia</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Hetherington-1986">
<CHAR_METHODS>
<P>Country: UK - Emergency department<BR/>Randomisation: Not stated<BR/>Power analysis: Not stated<BR/>BLINDING:<BR/>Investigators: N<BR/>Participants: Y</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>No age limits, presumed adult<BR/>Overall 58 participants, 41 male, mean age 46 y<BR/>Group 1: 28<BR/>Group 2: 30<BR/>Inclusion criteria: diagnosis on IVP<BR/>Exclusion criteria: prior NSAIDs, allergy to trial drugs, asthma, peptic ulcer,renal insufficiency, prior analgesics</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: 100 mg pethidine IM<BR/>Group 2: 75 mg diclofenac IM</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Need for rescue analgesia<BR/>Adverse events<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Indudhara-1990">
<CHAR_METHODS>
<P>Country: India - Emergency department<BR/>Randomisation: Not stated<BR/>Power analysis: Not stated<BR/>BLINDING:<BR/>Investigators: Not stated<BR/>Participants: No</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>No age limits, presumed adult<BR/>Overall 94 participants, 68 male, age range 19-57 y<BR/>Group 1: 33<BR/>Group 2: 31<BR/>Inclusion criteria; diagnosis confirmed in plain xray (71) or ultrasound (23)<BR/>Exclusion criteria: likely alternative diagnosis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: 150 mg diclofenac PO<BR/>Group 2: 50 mg pethidine IM</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pain relief measured but not defined<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>3rd group (30) not included because of drug type ('Baralgin' )</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Jonsson-1987">
<CHAR_METHODS>
<P>Country: Sweden - Emergency admissions<BR/>Randomisation: Not stated<BR/>Power analysis: Not stated<BR/>BLINDING:<BR/>Investigators: Y<BR/>Participants: Y</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>20-75 y<BR/>Group 1: 26 (24M), Mean age 44 y<BR/>Group 2: 35 (30M), Mean age 44.5y<BR/>Inclusion criteria: diagnosis: confirmed by urinalysis or IVP<BR/>Exclusion criteria: pregnancy, peptic ulcer, severe cardiopulmonary disease, adverse reactions to study drugs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: 5 mg oxyconchloride + 50 mg papaverine IV<BR/>Group 2: 50 mg indomethacin IV</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pain score VAS<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Crossover trial, data from post-crossover period not included</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Larkin-1999">
<CHAR_METHODS>
<P>Country: USA - Emergency department<BR/>Randomisation: computer generated<BR/>Power analysis: performed<BR/>BLINDING:<BR/>Investigators: Y<BR/>Participants: Y</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Age &gt; 17 y<BR/>Group 1: 33 (26M), Mean age 45.5 y<BR/>Group 2: 37 (27M), Mean age 40.7 y<BR/>Inclusion criteria: diagnosis confirmed on IVP or stone passage<BR/>Exclusion criteria: &lt; 50 kg, pregnancy, contraindications to trial drugs or contrast, suspect drug seeking behaviour, renal dysfunction</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: 60 mg ketorolac IM<BR/>Group 2: meperidine 100-150 mg IM</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pain score VAS<BR/>Need for rescue analgesia<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Lehtonen-1983">
<CHAR_METHODS>
<P>Country: Finland - Hospital presentations<BR/>Randomisation: Not stated<BR/>Power analysis: Not stated<BR/>BLINDING:<BR/>Investigators: Not stated<BR/>Participants: Not stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>No age limits, presumed adult<BR/>Group 1: 93 (69M), Mean age 44.6 y<BR/>Group 2: 31 (26M), Mean age 39.5 y<BR/>Inclusion criteria: diagnosis by clinical, UA and IVP<BR/>Exclusion criteria: asthma, known allergy, peptic ulcer, pregnancy, prior treatment<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: 50 mg indomethacin IV<BR/>Group 2: 50 mg pethidine IV</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Complete pain relief at 30 min<BR/>Need for rescue analgesia<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>3rd study arm not included because of drug type (dipyrone)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Lundstam-1982">
<CHAR_METHODS>
<P>Country: Sweden - 2 Emergency departments<BR/>Randomisation: Not stated<BR/>Power analysis: Not stated<BR/>BLINDING:<BR/>Investigators: Not stated<BR/>Participants: Not stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>No age limit, presumed adult.<BR/>Group 1: 34 (25M), Age range 17-69<BR/>Group 2: 32 (25M), Age range 22-84<BR/>Inclusion criteria: diagnosis by urinalysis, IVP or stone passage<BR/>Exclusion criteria: none stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: 50 mg diclofenac IM<BR/>Group 2: 1 ml 'Spasmofen' (combination of multiple narcotics) IM</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Pain relief measured but not well defined and therefore not analysed</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Marthak-1991">
<CHAR_METHODS>
<P>Country: India - Presenting to 3 hospitals<BR/>Randomisation: Not stated<BR/>Power analysis: Not stated<BR/>BLINDING:<BR/>Investigators: Not stated<BR/>Participants: Not stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Adult patients.<BR/>Group 1: 25 (17M), Mean age 36.4 y<BR/>Group 2: 25 (20M), Mean age 34.0 y<BR/>Inclusion criteria: diagnosis confirmed UA, IVP or plain xray<BR/>Exclusion criteria: peptic ulcer, severe cardiac/hepatic/renal insufficiency, trial drug allergy, asthma, pregnancy, prior treatment</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: 75 mg diclofenac IM<BR/>Group 2: 75 mg pethidine IM</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pain score VAS<BR/>Adverse events<BR/>Complete relief at 30 min</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>2nd study comparing diclofenac and dipyrone not included</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Oosterlinck-1990">
<CHAR_METHODS>
<P>Country: UK and Belgium - Treatment area: not stated<BR/>Randomisation: Not stated<BR/>Power analysis: Not stated<BR/>BLINDING:<BR/>Investigators: Not stated<BR/>Participants: Not stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>18-75 y, 45-100 kg<BR/>Group 1: 45 (32M), Median age 40 y<BR/>Group 2: 37 (29M), Median age 40 y<BR/>Group 3: 39 (29M), Median age 39 y<BR/>Inclusion criteria:diagnosis by radiological evidence of stone or obstruction<BR/>Exclusion criteria: allergy to study drugs, known alcohol/narcotic abuse, temp &gt; 37.5C</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: 10 mg ketorolac IM<BR/>Group 2: 90 mg ketorolac IM<BR/>Group 3: 100 mg pethidine IM</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pain score VAS<BR/>Adverse events<BR/>Complete relief at 60 min</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Patients from group 1 included in adverse events and % with complete pain relief analysis but not VAS analysis due to inability to combine data</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Persson-1985">
<CHAR_METHODS>
<P>Country: Sweden - Emergency Department<BR/>Randomisation: computer generated<BR/>Power analysis: Not stated<BR/>BLINDING:<BR/>Investigators: Not stated<BR/>Participants: Not stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>&gt; 20 y<BR/>Group 1: 48 (35M), Mean age 47<BR/>Group 2: 46 (35M), Mean age 46<BR/>Inclusion criteria: clinical diagnosis, most confirmed on IVP<BR/>Exclusion criteria:pregnancy, peptic ulcer, bleeding disorder, adverse reactions to trial drugs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: 400 mg indoprofen IV<BR/>Group 2: 10 mg oxicone and 20 ng papaverine IM</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pain score VAS<BR/>Complete pain relief at 30 min<BR/>Adverse events<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Quilez-1984">
<CHAR_METHODS>
<P>Country: Spain - Emergency department<BR/>Randomisation: Not stated<BR/>Power analysis: Not stated<BR/>BLINDING:<BR/>Investigators: Not stated<BR/>Participants: Not stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>No age limit, presumed adult<BR/>Group 1: 24 (14M), Mean age 43.7 y<BR/>Group 2: 14 (8M), Mean age 44.9 y<BR/>Inclusion criteria: diagnosis on urinalysis, IVP or passage stone <BR/>Exclusion criteria: None</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: 75 mg diclofenac IM<BR/>Group 2: 30 mg pentazocine IM</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Complete pain relief at 30 min<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>3rd group (23 participants) given IM hyoscine, not included in analysis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Sandhu-1994">
<CHAR_METHODS>
<P>Country: UK - 6 hospitals, treatment area not stated<BR/>Randomisation: Not stated<BR/>Power analysis: Not stated<BR/>BLINDING:<BR/>Investigators: Not stated<BR/>Participants: Y</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>No age limit, presumed adult<BR/>Group 1: 76 (59M), Mean age 45.2 y<BR/>Group 2: 78 (58M), Mean age 42.1 y<BR/>Inclusion criteria: clinical diagnosis of renal colic<BR/>Exclusion criteria: prior analgesia, pregnancy, lactation, GI/renal/hepatic disease, asthma, bleeding disorder, drug abuse</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: 30 mg ketorolac IM<BR/>Group 2: 100 mg pethidine IM</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pain score changes summed over time<BR/>Rescue analgesia at 24 h<BR/>Adverse events<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Data for pain scores not used in analysis due to format of information<BR/>"Rescue analgesia" reported at 24 h and thus not included in results</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Sommer-1989">
<CHAR_METHODS>
<P>Country: Denmark - Treatment area not stated<BR/>Randomisation: Not stated<BR/>Power analysis: Not stated<BR/>BLINDING:<BR/>Investigators: Not stated<BR/>Participants: Y</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>No age limit, presumed adult<BR/>Group 1: 27 (17M), Median age 54 y<BR/>Group 2: 29 (22M), Median age 57 y<BR/>Inclusion criteria: diagnosis on IVP<BR/>Exclusion criteria: none</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: 3 ml 'Ketogan' IM<BR/>group 2: 75 mg diclofenac IM</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pain scores measured but not reported<BR/>Complete pain relief at 30 min<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-14 14:12:30 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Thompson-1989">
<CHAR_METHODS>
<P>Country: UK - Emergency department<BR/>Randomisation: coin toss<BR/>Power analysis: Not stated<BR/>BLINDING:<BR/>Investigators: Y<BR/>Participants: No</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-14 14:12:30 +1100" MODIFIED_BY="[Empty name]">
<P>No age limit, presumed adult<BR/>58 patients, baseline data not given but described as no significant difference<BR/>Inclusion criteria: diagnosis by IVP, stone passage/removal<BR/>Exclusion criteria: asthma, trial drug allergy, renal/hepatic impairment, inflammatory bowel disease, prior treatment, pregnancy, lactation</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: 100 mg pethidine 'injection', IV or IM not stated<BR/>Group 2: 100 mg diclofenac PR</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Change in pain score but not absolute scores<BR/>Complete pain relief at 30min<BR/>Rescue analgesia<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Torralba-1999">
<CHAR_METHODS>
<P>Country: Spain - Treatment area not stated<BR/>Randomisation: Not stated<BR/>Power analysis: Not stated<BR/>BLINDING:<BR/>Investigators: Not stated<BR/>Participants: Not stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>No age limit, presumed adult<BR/>48 patients, no baseline comparisons given<BR/>Inclusion criteria: method of diagnosis not described<BR/>Exclusion criteria: allergy to trial drugs, peptic ulcer, asthma, renal/hepatic/cardiac disease, bleeding disorders</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: 30 mg ketorolac IM<BR/>Group 2: 1 mg/kg tramadol SCI</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pain scores but no variance<BR/>Rescue analgesia<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Uden-1983">
<CHAR_METHODS>
<P>Country: Sweden - Treatment area not stated<BR/>Randomisation: Not stated<BR/>Power analysis: Not stated<BR/>BLINDING:<BR/>Investigators: Not stated<BR/>Participants: Not stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Age: &lt; 75 y<BR/>Group 1: 25 (20M), Mean age 41.4 y<BR/>Group 2: 25 (22M), Mean age 39.8 y<BR/>Inclusion criteria: diagnosis on clinical grounds with "xray in uncertain cases'<BR/>Exclusion criteria: peptic ulcer, cardiac insuffiency, allergy to study drugs, asthma, pregnancy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: 50 mg indomethacin IV<BR/>Group 2: 2 mg hydromorphine chloride-atropine SCI</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pain score VAS<BR/>Complete pain relief in 30 min<BR/>Rescue analgesia<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Al-Walli-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>NSAID verus antimuscarinic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Altay-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>NSAID versus NSAID via different routes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Anonymous-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review article only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Basar-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>NSAID versus spasmolytic (tropenzilium)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bertolotto-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>NSAID versus NSAID</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Broggini-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Diclofenac was compared to placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chang-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Opioid versus opioid</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chaudhary-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Combination drug regime in both arms</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Clayman-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>No NSAID arm</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Daljord-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>No relevant outcome measures</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dellabella-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not in acute treatment of renal colic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dubinsky-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>No NSAID or narcotic arm</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-el_x002d_Sherif-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>NSAID versus spasmolytic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Engeler-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>NSAID versus NSAID</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Eray-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Opioid versus opioid</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ergene-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>NSAID versus antiemetic (non opioid)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Finlay-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Opiod versus opioid</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Flannigan-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fraga-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>NSAID versus NSAID</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Graiff-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>No NSAID</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hedenbro-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>No NSAID or opioid</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ho-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>NSAID versus NSAID</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hofstetter-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>GTN versus buscopan</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Holdgate-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Buscopan versus placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hussain-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not in acute renal colic, not NSAIDs or opioids</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Iguchi-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Trigger point therapy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jones-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>NSAID versus antimuscarinic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jones-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>NSAID versus NSAID/antimuscarin</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Khalifa-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not restricted to patients with renal colic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lloret-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Nifedipine versus multianalgesics</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lopes-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Desmopressin</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Muller-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Metaclopramide versus opioid</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Muriel-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>NSAID versus dipyrone</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Muriel_x002d_Villoria-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Dipyrone comparison</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nelson-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>NSAID by 2 routes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nissen-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>NSAID by 2 routes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Oosterlinck-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Opioid versus opioid</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pavlik-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not NSAID versus opioid</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Porpiglia-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>No opioid arm</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pourrat-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>NSAID versus NSAID/dipyrone equivalent</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Primus-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Tramadol versus metimazole</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Resim-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Alpha blocker versus placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Saita-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>No NSAID or opioid arm</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sanchez_x002d_Carpena-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>NSAID versus dypirone</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Servedio-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>Flavoxate</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Slade-1967">
<CHAR_REASON_FOR_EXCLUSION>
<P>NSAID was not compared to opioid</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Stankov-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Dipyrone versus tramadol/buscopan</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Stein-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>NSAID versus NSAID</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Torchi-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Dose response study for indoprofen</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tura-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Ceruletide study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Xue-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not NSAID versus opioid</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Arnau-1991">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Cordell-1994">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Cordell-1996">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Curry-1995">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hetherington-1986">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Indudhara-1990">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Jonsson-1987">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Larkin-1999">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Lehtonen-1983">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lundstam-1982">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Marthak-1991">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Oosterlinck-1990">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Persson-1985">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Quilez-1984">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Sandhu-1994">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Sommer-1989">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Thompson-1989">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Torralba-1999">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Uden-1983">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-al_x002d_Sahlawi-1996">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-10-14 13:58:18 +1100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2008-10-14 13:58:18 +1100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE>Electronic search strategies</TITLE>
<TABLE COLS="2" ROWS="3">
<TR>
<TH VALIGN="TOP">
<P>Database searched</P>
</TH>
<TH VALIGN="TOP">
<P>Search terms</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>CENTRAL<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>#1 Kidney Diseases explode MeSH<BR/>#2 Ureteral Diseases explode MeSH<BR/>#3 Colic explode MeSH<BR/>#4 (( #1 OR #2 ) AND #3)<BR/>#5 Urinary Calculi explode MeSH<BR/>#6 Ureteral Obstruction explode MeSH<BR/>#7 urolithiasis*<BR/>#8 (ureter* next stone*) or (ureter* next calcul*) or (ureter* next colic)<BR/>#9 (kidney* next stone*) or (kidney* next calcul*) or (kidney* next colic)<BR/>#10(renal* next calcul*) or (renal* next stone*) or (renal* next colic*)<BR/>#11(urin* next calcul*) or (urin* next stone*) or (urin* next colic*)<BR/>#12 (#4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11)<BR/>#13 Anti-Inflammatory Agents, Non-Steroidal explode all MeSH<BR/>#14 Indomethacin explode MeSH<BR/>#15 Piroxicam explode MeSH<BR/>#16 indomethacin*<BR/>#17 piroxicam*<BR/>#18 ketorolac*<BR/>#19 tenoxicam*<BR/>#20 aspirin*<BR/>#21 salicylate*<BR/>#22 apazone*<BR/>#23 diclofenac*<BR/>#24 diflunisal*<BR/>#25 etodolac*<BR/>#26 fenoprofen*<BR/>#27 flurbiprofen*<BR/>#28 ibuprofen*<BR/>#29 ketoprofen*<BR/>#30 meclofenamate*<BR/>#31 nabumetone*<BR/>#32 naproxen*<BR/>#33 oxaprozin*<BR/>#34 phenylbutazone*<BR/>#35 sulindac*<BR/>#36 tolmetin*<BR/>#37 nsaid*<BR/>#38 (non* next steroid* next antiinflammatory next agent*)<BR/>#39 (non* next steroid* next anti* next inflammatory next agent*)<BR/>#40 Narcotics MeSH 8024<BR/>#41 Analgesics, Opioid explode MeSH<BR/>#42 Morphine explode MeSH<BR/>#43 Meperidine explode MeSH<BR/>#44 morphine*<BR/>#45 meperidine*<BR/>#46 pethidine*<BR/>#47 opioid*<BR/>#48<BR/>(#13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45 OR #46 OR #47)<BR/>#49 #12 AND #48<BR/>#50 from 2005 to 2006<BR/>#51 #49 AND #50</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>MEDLINE and pre-MEDLINE</P>
</TD>
<TD VALIGN="TOP">
<P>1 exp Kidney Diseases/<BR/>2 exp Ureteral Diseases/<BR/>3 Colic/<BR/>4 (1 or 2) and 3<BR/>5 exp Urinary Calculi/<BR/>6 Ureteral Obstruction/<BR/>7 urolithiasis.tw.<BR/>8 (ureter$ stone$ or ureter$ calcul$ or ureter$ colic).tw.<BR/>9 (kidney stone$ or kidney calcul$ or kidney colic).tw.<BR/>10 (renal stone$ or renal calcul$ or renal colic).tw.<BR/>11 (urin$ stone$ or urin$ calcul$).tw.<BR/>12 (urin$ tract stone$ or urin$ tract calcul$).tw.<BR/>13 or/4-12<BR/>14 exp Anti-Inflammatory Agents, Non-Steroidal/<BR/>15 exp indomethacin/<BR/>16 piroxicam/<BR/>17 indomethacin.tw.<BR/>18 piroxicam.tw.<BR/>19 ketorolac.tw.<BR/>20 tenoxicam.tw.<BR/>21 aspirin.tw.<BR/>22 salicylate.tw.<BR/>23 apazone.tw.<BR/>24 diclofenac.tw.<BR/>25 diflunisal.tw.<BR/>26 etodolac.tw.<BR/>27 fenoprofen.tw.<BR/>28 flurbiprofen.tw.<BR/>29 ibuprofen.tw.<BR/>30 ketoprofen.tw.<BR/>31 meclofenamate.tw.<BR/>32 nabumetone.tw.<BR/>33 naproxen.tw.<BR/>34 oxaprozin.tw.<BR/>35 phenylbutazone.tw.<BR/>36 sulindac.tw.<BR/>37 tolmetin.tw.<BR/>38 NSAID$.tw.<BR/>39 non steroid$ antiinflammatory agent$.tw.<BR/>40 non steroid$ anti inflammatory agent$.tw.<BR/>41 exp NARCOTICS/<BR/>42 exp analgesics, opioid/<BR/>43 exp morphine/<BR/>44 meperidine/<BR/>45 morphine.tw.<BR/>46 meperidine.tw.<BR/>47 pethidine.tw.<BR/>48 opioid$.tw.<BR/>49 or/14-48<BR/>50 13 and 49</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-10-14 14:11:32 +1100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2008-10-14 14:11:32 +1100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>NSAIDs versus opioids</NAME>
<CONT_OUTCOME CHI2="34.929903707523" CI_END="-0.21838952092670194" CI_START="-10.86949792327174" CI_STUDY="95" CI_TOTAL="95" DF="8.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.543943722099221" ESTIMABLE="YES" I2="77.09698810799468" I2_Q="83.2787535498491" ID="CMP-001.01" MODIFIED="2008-10-14 14:06:07 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="2.7536153244578365E-5" P_Q="0.014465644530357702" P_Z="0.04131668331987415" Q="5.980415413295791" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="46.70059046569725" TOTALS="SUB" TOTAL_1="369" TOTAL_2="373" UNITS="" WEIGHT="200.00000000000003" Z="2.040337891076026">
<NAME>VAS at 30 minutes by variance measure</NAME>
<GROUP_LABEL_1>NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Opioids</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NSAIDs</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Opioids</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="14.024807095774008" CI_END="-1.1202092691215846" CI_START="-19.890478598804904" DF="4.0" EFFECT_SIZE="-10.505343933963244" ESTIMABLE="YES" I2="71.47910860602646" ID="CMP-001.01.01" NO="1" P_CHI2="0.007216330680573146" P_Z="0.028242225402099932" STUDIES="5" TAU2="80.54903854233996" TOTAL_1="160" TOTAL_2="156" WEIGHT="100.00000000000003" Z="2.1939052012656095">
<NAME>True variance given</NAME>
<CONT_DATA CI_END="-18.45659002788445" CI_START="-45.34340997211555" EFFECT_SIZE="-31.900000000000002" ESTIMABLE="YES" MEAN_1="24.7" MEAN_2="56.6" ORDER="11953" SD_1="27.6" SD_2="30.1" SE="6.859008674728441" STUDY_ID="STD-Cordell-1996" TOTAL_1="36" TOTAL_2="35" WEIGHT="17.13000457163124"/>
<CONT_DATA CI_END="11.604361642012151" CI_START="-11.604361642012151" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="26.8" MEAN_2="26.8" ORDER="11954" SD_1="19.9" SD_2="16.8" SE="5.9207014687748725" STUDY_ID="STD-Curry-1995" TOTAL_1="17" TOTAL_2="24" WEIGHT="19.642513635026837"/>
<CONT_DATA CI_END="2.6724096327646993" CI_START="-20.672409632764698" EFFECT_SIZE="-9.0" ESTIMABLE="YES" MEAN_1="24.0" MEAN_2="33.0" ORDER="11955" SD_1="20.0" SD_2="25.0" SE="5.955420469373507" STUDY_ID="STD-Jonsson-1987" TOTAL_1="35" TOTAL_2="26" WEIGHT="19.543945122946784"/>
<CONT_DATA CI_END="1.8321464611863947" CI_START="-13.832146461186394" EFFECT_SIZE="-6.0" ESTIMABLE="YES" MEAN_1="17.0" MEAN_2="23.0" ORDER="11956" SD_1="16.0" SD_2="22.0" SE="3.996066521102105" STUDY_ID="STD-Persson-1985" TOTAL_1="47" TOTAL_2="46" WEIGHT="25.624726488439574"/>
<CONT_DATA CI_END="4.335905693295514" CI_START="-21.135905693295513" EFFECT_SIZE="-8.399999999999999" ESTIMABLE="YES" MEAN_1="13.0" MEAN_2="21.4" ORDER="11957" SD_1="21.9" SD_2="24.0" SE="6.498030470842684" STUDY_ID="STD-Uden-1983" TOTAL_1="25" TOTAL_2="25" WEIGHT="18.05881018195557"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="14.924681198453204" CI_END="4.50985201580288" CI_START="-7.670129327224351" DF="3.0" EFFECT_SIZE="-1.5801386557107353" ESTIMABLE="YES" I2="79.89906812675557" ID="CMP-001.01.02" NO="2" P_CHI2="0.0018821620096454161" P_Z="0.611073430250149" STUDIES="4" TAU2="30.684254141308497" TOTAL_1="209" TOTAL_2="217" WEIGHT="100.0" Z="0.5085418061901301">
<NAME>Variance estimated from other data</NAME>
<CONT_DATA CI_END="1.61273522625297" CI_START="-7.61273522625297" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="20.0" MEAN_2="23.0" ORDER="11958" SD_1="18.0" SD_2="18.0" SE="2.3534795856646533" STUDY_ID="STD-Arnau-1991" TOTAL_1="116" TOTAL_2="118" WEIGHT="26.160072039071572"/>
<CONT_DATA CI_END="15.61259228793865" CI_START="2.587407712061353" EFFECT_SIZE="9.100000000000001" ESTIMABLE="YES" MEAN_1="35.2" MEAN_2="26.1" ORDER="11959" SD_1="13.2" SD_2="14.6" SE="3.322812224770019" STUDY_ID="STD-Larkin-1999" TOTAL_1="33" TOTAL_2="37" WEIGHT="23.66727377309728"/>
<CONT_DATA CI_END="-0.12269316152324983" CI_START="-10.87730683847675" EFFECT_SIZE="-5.5" ESTIMABLE="YES" MEAN_1="39.1" MEAN_2="44.6" ORDER="11960" SD_1="9.7" SD_2="9.7" SE="2.7435743110038042" STUDY_ID="STD-Marthak-1991" TOTAL_1="25" TOTAL_2="25" WEIGHT="25.200878311247507"/>
<CONT_DATA CI_END="-0.44782973563310424" CI_START="-11.552170264366897" EFFECT_SIZE="-6.0" ESTIMABLE="YES" MEAN_1="17.0" MEAN_2="23.0" ORDER="11961" SD_1="11.0" SD_2="13.0" SE="2.8327919840169034" STUDY_ID="STD-Oosterlinck-1990" TOTAL_1="35" TOTAL_2="37" WEIGHT="24.971775876583653"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="34.929903707523" CI_END="-0.21838952092670283" CI_START="-10.869497923271739" CI_STUDY="95" CI_TOTAL="95" DF="8.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.543943722099221" ESTIMABLE="YES" I2="77.09698810799468" I2_Q="0.0" ID="CMP-001.02" MODIFIED="2008-10-14 14:06:37 +1100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="2.7536153244578365E-5" P_Q="0.6468879891981567" P_Z="0.0413166833198741" Q="1.6554292478819974" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="46.700590465697246" TOTALS="YES" TOTAL_1="369" TOTAL_2="373" UNITS="" WEIGHT="100.0" Z="2.0403378910760264">
<NAME>VAS at 30 minutes by NSAID type</NAME>
<GROUP_LABEL_1>NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Opioids</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NSAIDs</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Opioids</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="32.085941782970615" CI_END="9.158629350476323" CI_START="-26.271170457027146" DF="2.0" EFFECT_SIZE="-8.556270553275413" ESTIMABLE="YES" I2="93.76674054472826" ID="CMP-001.02.01" NO="1" P_CHI2="1.0780276704647207E-7" P_Z="0.3438122151509486" STUDIES="3" TAU2="224.25517594750772" TOTAL_1="104" TOTAL_2="109" WEIGHT="34.15280827494826" Z="0.9466597168211375">
<NAME>Ketorolac</NAME>
<CONT_DATA CI_END="-18.45659002788445" CI_START="-45.34340997211555" EFFECT_SIZE="-31.900000000000002" ESTIMABLE="YES" MEAN_1="24.7" MEAN_2="56.6" ORDER="11962" SD_1="27.6" SD_2="30.1" SE="6.859008674728441" STUDY_ID="STD-Cordell-1996" TOTAL_1="36" TOTAL_2="35" WEIGHT="7.875496714046523"/>
<CONT_DATA CI_END="15.61259228793865" CI_START="2.587407712061353" EFFECT_SIZE="9.100000000000001" ESTIMABLE="YES" MEAN_1="35.2" MEAN_2="26.1" ORDER="11963" SD_1="13.2" SD_2="14.6" SE="3.322812224770019" STUDY_ID="STD-Larkin-1999" TOTAL_1="33" TOTAL_2="37" WEIGHT="12.786276278260205"/>
<CONT_DATA CI_END="-0.44782973563310424" CI_START="-11.552170264366897" EFFECT_SIZE="-6.0" ESTIMABLE="YES" MEAN_1="17.0" MEAN_2="23.0" ORDER="11964" SD_1="11.0" SD_2="13.0" SE="2.8327919840169034" STUDY_ID="STD-Oosterlinck-1990" TOTAL_1="35" TOTAL_2="37" WEIGHT="13.491035282641533"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.004633715536599274" CI_END="-0.12099752914182993" CI_START="-17.33118866520344" DF="1.0" EFFECT_SIZE="-8.726093097172635" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.02" NO="2" P_CHI2="0.9457287968518721" P_Z="0.04686443320377274" STUDIES="2" TAU2="0.0" TOTAL_1="60" TOTAL_2="51" WEIGHT="17.287816509593227" Z="1.9875233297514396">
<NAME>Indomethacin</NAME>
<CONT_DATA CI_END="2.6724096327646993" CI_START="-20.672409632764698" EFFECT_SIZE="-9.0" ESTIMABLE="YES" MEAN_1="24.0" MEAN_2="33.0" ORDER="11965" SD_1="20.0" SD_2="25.0" SE="5.955420469373507" STUDY_ID="STD-Jonsson-1987" TOTAL_1="35" TOTAL_2="26" WEIGHT="8.985302657196886"/>
<CONT_DATA CI_END="4.335905693295514" CI_START="-21.135905693295513" EFFECT_SIZE="-8.399999999999999" ESTIMABLE="YES" MEAN_1="13.0" MEAN_2="21.4" ORDER="11966" SD_1="21.9" SD_2="24.0" SE="6.498030470842684" STUDY_ID="STD-Uden-1983" TOTAL_1="25" TOTAL_2="25" WEIGHT="8.30251385239634"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.4783383095875051" CI_END="-0.5586943550442109" CI_START="-7.560867145814135" DF="1.0" EFFECT_SIZE="-4.059780750429173" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.03" NO="3" P_CHI2="0.4891759994857984" P_Z="0.023042456107795862" STUDIES="2" TAU2="0.0" TOTAL_1="141" TOTAL_2="143" WEIGHT="27.74782205121052" Z="2.272729992170119">
<NAME>Diclofenac</NAME>
<CONT_DATA CI_END="1.61273522625297" CI_START="-7.61273522625297" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="20.0" MEAN_2="23.0" ORDER="11967" SD_1="18.0" SD_2="18.0" SE="2.3534795856646533" STUDY_ID="STD-Arnau-1991" TOTAL_1="116" TOTAL_2="118" WEIGHT="14.133013872133235"/>
<CONT_DATA CI_END="-0.12269316152324983" CI_START="-10.87730683847675" EFFECT_SIZE="-5.5" ESTIMABLE="YES" MEAN_1="39.1" MEAN_2="44.6" ORDER="11968" SD_1="9.7" SD_2="9.7" SE="2.7435743110038042" STUDY_ID="STD-Marthak-1991" TOTAL_1="25" TOTAL_2="25" WEIGHT="13.614808179077283"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.7055606515462901" CI_END="2.369667607295459" CI_START="-10.614074648000962" DF="1.0" EFFECT_SIZE="-4.122203520352751" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.04" NO="4" P_CHI2="0.4009219701526665" P_Z="0.21330220614218998" STUDIES="2" TAU2="0.0" TOTAL_1="64" TOTAL_2="70" WEIGHT="20.811553164247993" Z="1.2445364792326838">
<NAME>Other</NAME>
<CONT_DATA CI_END="11.604361642012151" CI_START="-11.604361642012151" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="26.8" MEAN_2="26.8" ORDER="11969" SD_1="19.9" SD_2="16.8" SE="5.9207014687748725" STUDY_ID="STD-Curry-1995" TOTAL_1="17" TOTAL_2="24" WEIGHT="9.03061939892622"/>
<CONT_DATA CI_END="1.8321464611863947" CI_START="-13.832146461186394" EFFECT_SIZE="-6.0" ESTIMABLE="YES" MEAN_1="17.0" MEAN_2="23.0" ORDER="11970" SD_1="16.0" SD_2="22.0" SE="3.996066521102105" STUDY_ID="STD-Persson-1985" TOTAL_1="47" TOTAL_2="46" WEIGHT="11.780933765321773"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="34.929903707523" CI_END="-0.21838952092670372" CI_START="-10.86949792327174" CI_STUDY="95" CI_TOTAL="95" DF="8.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.543943722099222" ESTIMABLE="YES" I2="77.09698810799468" I2_Q="34.45139814717676" ID="CMP-001.03" MODIFIED="2008-10-14 14:06:59 +1100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="2.7536153244578365E-5" P_Q="0.21677661071573162" P_Z="0.041316683319874065" Q="1.5255855529082183" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="46.70059046569724" TOTALS="YES" TOTAL_1="369" TOTAL_2="373" UNITS="" WEIGHT="100.0" Z="2.040337891076027">
<NAME>VAS at 30 minutes pethidine or not</NAME>
<GROUP_LABEL_1>NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Opioids</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NSAIDs</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Opioids</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="33.188826305919065" CI_END="2.1885283226245447" CI_START="-12.05359380654627" DF="5.0" EFFECT_SIZE="-4.9325327419608636" ESTIMABLE="YES" I2="84.93468869940642" ID="CMP-001.03.01" NO="1" P_CHI2="3.4520949496741338E-6" P_Z="0.1745891260042211" STUDIES="6" TAU2="62.88409080859623" TOTAL_1="262" TOTAL_2="276" WEIGHT="70.931249725085" Z="1.3576047781540468">
<NAME>Pethidine</NAME>
<CONT_DATA CI_END="1.61273522625297" CI_START="-7.61273522625297" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="20.0" MEAN_2="23.0" ORDER="11971" SD_1="18.0" SD_2="18.0" SE="2.3534795856646533" STUDY_ID="STD-Arnau-1991" TOTAL_1="116" TOTAL_2="118" WEIGHT="14.133013872133235"/>
<CONT_DATA CI_END="-18.45659002788445" CI_START="-45.34340997211555" EFFECT_SIZE="-31.900000000000002" ESTIMABLE="YES" MEAN_1="24.7" MEAN_2="56.6" ORDER="11972" SD_1="27.6" SD_2="30.1" SE="6.859008674728441" STUDY_ID="STD-Cordell-1996" TOTAL_1="36" TOTAL_2="35" WEIGHT="7.875496714046525"/>
<CONT_DATA CI_END="11.604361642012151" CI_START="-11.604361642012151" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="26.8" MEAN_2="26.8" ORDER="11973" SD_1="19.9" SD_2="16.8" SE="5.9207014687748725" STUDY_ID="STD-Curry-1995" TOTAL_1="17" TOTAL_2="24" WEIGHT="9.030619398926222"/>
<CONT_DATA CI_END="15.61259228793865" CI_START="2.587407712061353" EFFECT_SIZE="9.100000000000001" ESTIMABLE="YES" MEAN_1="35.2" MEAN_2="26.1" ORDER="11974" SD_1="13.2" SD_2="14.6" SE="3.322812224770019" STUDY_ID="STD-Larkin-1999" TOTAL_1="33" TOTAL_2="37" WEIGHT="12.786276278260205"/>
<CONT_DATA CI_END="-0.12269316152324983" CI_START="-10.87730683847675" EFFECT_SIZE="-5.5" ESTIMABLE="YES" MEAN_1="39.1" MEAN_2="44.6" ORDER="11975" SD_1="9.7" SD_2="9.7" SE="2.7435743110038042" STUDY_ID="STD-Marthak-1991" TOTAL_1="25" TOTAL_2="25" WEIGHT="13.614808179077283"/>
<CONT_DATA CI_END="-0.44782973563310424" CI_START="-11.552170264366897" EFFECT_SIZE="-6.0" ESTIMABLE="YES" MEAN_1="17.0" MEAN_2="23.0" ORDER="11976" SD_1="11.0" SD_2="13.0" SE="2.8327919840169034" STUDY_ID="STD-Oosterlinck-1990" TOTAL_1="35" TOTAL_2="37" WEIGHT="13.491035282641533"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.21549184869572025" CI_END="-1.442945512865279" CI_START="-13.027328263442167" DF="2.0" EFFECT_SIZE="-7.235136888153723" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.02" NO="2" P_CHI2="0.8978556927042922" P_Z="0.014356059838059605" STUDIES="3" TAU2="0.0" TOTAL_1="107" TOTAL_2="97" WEIGHT="29.068750274915" Z="2.4482284519289252">
<NAME>Non-pethidine</NAME>
<CONT_DATA CI_END="2.6724096327646993" CI_START="-20.672409632764698" EFFECT_SIZE="-9.0" ESTIMABLE="YES" MEAN_1="24.0" MEAN_2="33.0" ORDER="11977" SD_1="20.0" SD_2="25.0" SE="5.955420469373507" STUDY_ID="STD-Jonsson-1987" TOTAL_1="35" TOTAL_2="26" WEIGHT="8.985302657196886"/>
<CONT_DATA CI_END="1.8321464611863947" CI_START="-13.832146461186394" EFFECT_SIZE="-6.0" ESTIMABLE="YES" MEAN_1="17.0" MEAN_2="23.0" ORDER="11978" SD_1="16.0" SD_2="22.0" SE="3.996066521102105" STUDY_ID="STD-Persson-1985" TOTAL_1="47" TOTAL_2="46" WEIGHT="11.780933765321773"/>
<CONT_DATA CI_END="4.335905693295514" CI_START="-21.135905693295513" EFFECT_SIZE="-8.399999999999999" ESTIMABLE="YES" MEAN_1="13.0" MEAN_2="21.4" ORDER="11979" SD_1="21.9" SD_2="24.0" SE="6.498030470842684" STUDY_ID="STD-Uden-1983" TOTAL_1="25" TOTAL_2="25" WEIGHT="8.302513852396341"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.03.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Other</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="7.939811409248886" CI_END="1.0311723810682716" CI_START="0.7362938259819771" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8713471510848606" ESTIMABLE="YES" EVENTS_1="186" EVENTS_2="147" I2="11.836696878645297" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.013331272353222842" LOG_CI_START="-0.13294884118186193" LOG_EFFECT_SIZE="-0.059808784414319555" METHOD="MH" MODIFIED="2008-10-14 14:07:30 +1100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.3379313165814156" P_Q="0.0" P_Z="0.10899639039571198" Q="0.0" RANDOM="YES" SCALE="200.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0070725425237520055" TOTALS="YES" TOTAL_1="393" TOTAL_2="281" WEIGHT="100.0" Z="1.602720432440344">
<NAME>Failure of complete pain relief at 30 minutes or next earliest</NAME>
<GROUP_LABEL_1>NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Opioids</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NSAIDs</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Opioids</GRAPH_LABEL_2>
<DICH_DATA CI_END="101.58460526662178" CI_START="0.24610028197072092" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.006827897373713" LOG_CI_START="-0.6088878887016753" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="11980" O_E="0.0" SE="1.5364844007426468" STUDY_ID="STD-al_x002d_Sahlawi-1996" TOTAL_1="50" TOTAL_2="50" VAR="2.3607843137254902" WEIGHT="0.3118102137888957"/>
<DICH_DATA CI_END="1.3087348535066419" CI_START="0.5448669895528746" EFFECT_SIZE="0.8444444444444444" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="15" LOG_CI_END="0.11685166845839784" LOG_CI_START="-0.26370950277546495" LOG_EFFECT_SIZE="-0.07342891715853352" ORDER="11981" O_E="0.0" SE="0.22354351579095025" STUDY_ID="STD-Lehtonen-1983" TOTAL_1="93" TOTAL_2="31" VAR="0.04997170345217883" WEIGHT="12.94296979365991"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="25" EVENTS_2="25" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11982" O_E="0.0" SE="0.0" STUDY_ID="STD-Marthak-1991" TOTAL_1="25" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.164408466738485" CI_START="0.6720531506354778" EFFECT_SIZE="0.8846153846153846" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="26" LOG_CI_END="0.06610535465447095" LOG_CI_START="-0.17259637856092114" LOG_EFFECT_SIZE="-0.0532455119532251" ORDER="11983" O_E="0.0" SE="0.1402145796833572" STUDY_ID="STD-Oosterlinck-1990" TOTAL_1="74" TOTAL_2="37" VAR="0.01966012835578053" WEIGHT="27.618712544501637"/>
<DICH_DATA CI_END="1.1604389792095564" CI_START="0.6181778451406165" EFFECT_SIZE="0.8469696969696969" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="30" LOG_CI_END="0.06462230835132819" LOG_CI_START="-0.208886563662219" LOG_EFFECT_SIZE="-0.0721321276554454" ORDER="11984" O_E="0.0" SE="0.16066046531150932" STUDY_ID="STD-Persson-1985" TOTAL_1="44" TOTAL_2="43" VAR="0.02581178511411069" WEIGHT="22.452092093818028"/>
<DICH_DATA CI_END="4.434098798328407" CI_START="0.4178128501531218" EFFECT_SIZE="1.3611111111111112" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.646805365614469" LOG_CI_START="-0.37901820709201606" LOG_EFFECT_SIZE="0.13389357926122641" ORDER="11985" O_E="0.0" SE="0.6025738445163696" STUDY_ID="STD-Quilez-1984" TOTAL_1="24" TOTAL_2="14" VAR="0.363095238095238" WEIGHT="1.994560281108112"/>
<DICH_DATA CI_END="2.181896214298587" CI_START="0.8486291413077123" EFFECT_SIZE="1.3607427055702919" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="13" LOG_CI_END="0.3388340887686345" LOG_CI_START="-0.07128205895658765" LOG_EFFECT_SIZE="0.13377601490602345" ORDER="11986" O_E="0.0" SE="0.24090425528146792" STUDY_ID="STD-Sommer-1989" TOTAL_1="29" TOTAL_2="27" VAR="0.058034860212718656" WEIGHT="11.340061521990329"/>
<DICH_DATA CI_END="1.1504232669717585" CI_START="0.28383519494039733" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="14" LOG_CI_END="0.06085765660562079" LOG_CI_START="-0.5469337539782099" LOG_EFFECT_SIZE="-0.24303804868629447" ORDER="11987" O_E="0.0" SE="0.3570196831929468" STUDY_ID="STD-Thompson-1989" TOTAL_1="29" TOTAL_2="29" VAR="0.12746305418719212" WEIGHT="5.487930113803986"/>
<DICH_DATA CI_END="1.0267952805376401" CI_START="0.496889780566098" EFFECT_SIZE="0.7142857142857143" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="21" LOG_CI_END="0.0114838638549075" LOG_CI_START="-0.30373993521138354" LOG_EFFECT_SIZE="-0.146128035678238" ORDER="11988" O_E="0.0" SE="0.1851640199545103" STUDY_ID="STD-Uden-1983" TOTAL_1="25" TOTAL_2="25" VAR="0.03428571428571429" WEIGHT="17.8518634373291"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.939811409248884" CI_END="1.0311723810682716" CI_START="0.7362938259819771" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8713471510848606" ESTIMABLE="YES" EVENTS_1="186" EVENTS_2="147" I2="11.836696878645276" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.013331272353222842" LOG_CI_START="-0.13294884118186193" LOG_EFFECT_SIZE="-0.059808784414319555" METHOD="MH" MODIFIED="2008-10-14 14:07:50 +1100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.33793131658141606" P_Q="0.0" P_Z="0.10899639039571184" Q="0.0" RANDOM="YES" SCALE="200.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.007072542523751993" TOTALS="YES" TOTAL_1="393" TOTAL_2="281" WEIGHT="100.0" Z="1.6027204324403443">
<NAME>Failure of complete relief by NSAID type</NAME>
<GROUP_LABEL_1>NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Opioids</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NSAIDs</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Opioids</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.3296859237940115" CI_END="1.8676523735505952" CI_START="0.541499233560512" DF="2.0" EFFECT_SIZE="1.0056502020260913" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="55" I2="53.80727297079686" ID="CMP-001.05.01" LOG_CI_END="0.27129604411135855" LOG_CI_START="-0.26640215373981674" LOG_EFFECT_SIZE="0.002446945185770914" NO="1" P_CHI2="0.11476803239040045" P_Z="0.9857675136795266" STUDIES="4" TAU2="0.15872024278743913" TOTAL_1="107" TOTAL_2="95" WEIGHT="18.822551916902423" Z="0.01783872237407822">
<NAME>Diclofenac</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="25" EVENTS_2="25" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11989" O_E="0.0" SE="0.0" STUDY_ID="STD-Marthak-1991" TOTAL_1="25" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.434098798328407" CI_START="0.4178128501531218" EFFECT_SIZE="1.3611111111111112" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.646805365614469" LOG_CI_START="-0.37901820709201606" LOG_EFFECT_SIZE="0.13389357926122641" ORDER="11990" O_E="0.0" SE="0.6025738445163696" STUDY_ID="STD-Quilez-1984" TOTAL_1="24" TOTAL_2="14" VAR="0.363095238095238" WEIGHT="1.9945602811081118"/>
<DICH_DATA CI_END="2.181896214298587" CI_START="0.8486291413077123" EFFECT_SIZE="1.3607427055702919" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="13" LOG_CI_END="0.3388340887686345" LOG_CI_START="-0.07128205895658765" LOG_EFFECT_SIZE="0.13377601490602345" ORDER="11991" O_E="0.0" SE="0.24090425528146792" STUDY_ID="STD-Sommer-1989" TOTAL_1="29" TOTAL_2="27" VAR="0.058034860212718656" WEIGHT="11.340061521990329"/>
<DICH_DATA CI_END="1.1504232669717585" CI_START="0.28383519494039733" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="14" LOG_CI_END="0.06085765660562079" LOG_CI_START="-0.5469337539782099" LOG_EFFECT_SIZE="-0.24303804868629447" ORDER="11992" O_E="0.0" SE="0.3570196831929468" STUDY_ID="STD-Thompson-1989" TOTAL_1="29" TOTAL_2="29" VAR="0.12746305418719212" WEIGHT="5.487930113803985"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.164408466738485" CI_START="0.6720531506354778" DF="0.0" EFFECT_SIZE="0.8846153846153846" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="26" I2="0.0" ID="CMP-001.05.02" LOG_CI_END="0.06610535465447095" LOG_CI_START="-0.17259637856092114" LOG_EFFECT_SIZE="-0.0532455119532251" NO="2" P_CHI2="1.0" P_Z="0.3819055388224034" STUDIES="1" TAU2="0.0" TOTAL_1="74" TOTAL_2="37" WEIGHT="27.61871254450164" Z="0.8743906829746372">
<NAME>Ketorolac</NAME>
<DICH_DATA CI_END="1.164408466738485" CI_START="0.6720531506354778" EFFECT_SIZE="0.8846153846153846" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="26" LOG_CI_END="0.06610535465447095" LOG_CI_START="-0.17259637856092114" LOG_EFFECT_SIZE="-0.0532455119532251" ORDER="11993" O_E="0.0" SE="0.1402145796833572" STUDY_ID="STD-Oosterlinck-1990" TOTAL_1="74" TOTAL_2="37" VAR="0.01966012835578053" WEIGHT="27.61871254450164"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.025863089680456" CI_END="1.0309377685108465" CI_START="0.5865441637158285" DF="2.0" EFFECT_SIZE="0.7776184998276835" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="36" I2="1.2766454856796658" ID="CMP-001.05.03" LOG_CI_END="0.013232450338758337" LOG_CI_START="-0.23169928220831998" LOG_EFFECT_SIZE="-0.10923341593478078" NO="3" P_CHI2="0.3631529440475946" P_Z="0.08043119144558897" STUDIES="3" TAU2="0.0010610926567352426" TOTAL_1="168" TOTAL_2="106" WEIGHT="31.10664344477791" Z="1.7481896601478795">
<NAME>Indomethacin</NAME>
<DICH_DATA CI_END="101.58460526662178" CI_START="0.24610028197072092" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.006827897373713" LOG_CI_START="-0.6088878887016753" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="11994" O_E="0.0" SE="1.5364844007426468" STUDY_ID="STD-al_x002d_Sahlawi-1996" TOTAL_1="50" TOTAL_2="50" VAR="2.3607843137254902" WEIGHT="0.3118102137888956"/>
<DICH_DATA CI_END="1.3087348535066419" CI_START="0.5448669895528746" EFFECT_SIZE="0.8444444444444444" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="15" LOG_CI_END="0.11685166845839784" LOG_CI_START="-0.26370950277546495" LOG_EFFECT_SIZE="-0.07342891715853352" ORDER="11995" O_E="0.0" SE="0.22354351579095025" STUDY_ID="STD-Lehtonen-1983" TOTAL_1="93" TOTAL_2="31" VAR="0.04997170345217883" WEIGHT="12.94296979365991"/>
<DICH_DATA CI_END="1.0267952805376401" CI_START="0.496889780566098" EFFECT_SIZE="0.7142857142857143" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="21" LOG_CI_END="0.0114838638549075" LOG_CI_START="-0.30373993521138354" LOG_EFFECT_SIZE="-0.146128035678238" ORDER="11996" O_E="0.0" SE="0.1851640199545103" STUDY_ID="STD-Uden-1983" TOTAL_1="25" TOTAL_2="25" VAR="0.03428571428571429" WEIGHT="17.851863437329104"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1604389792095564" CI_START="0.6181778451406165" DF="0.0" EFFECT_SIZE="0.8469696969696969" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="30" I2="0.0" ID="CMP-001.05.04" LOG_CI_END="0.06462230835132819" LOG_CI_START="-0.208886563662219" LOG_EFFECT_SIZE="-0.0721321276554454" NO="4" P_CHI2="1.0" P_Z="0.30123092956936925" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="43" WEIGHT="22.452092093818035" Z="1.0337973411401158">
<NAME>Indoprofen</NAME>
<DICH_DATA CI_END="1.1604389792095564" CI_START="0.6181778451406165" EFFECT_SIZE="0.8469696969696969" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="30" LOG_CI_END="0.06462230835132819" LOG_CI_START="-0.208886563662219" LOG_EFFECT_SIZE="-0.0721321276554454" ORDER="11997" O_E="0.0" SE="0.16066046531150932" STUDY_ID="STD-Persson-1985" TOTAL_1="44" TOTAL_2="43" VAR="0.02581178511411069" WEIGHT="22.452092093818035"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.0164339815152665" CI_END="0.925248548405878" CI_START="0.6103644038471372" CI_STUDY="95" CI_TOTAL="95" DF="8.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7514910369779422" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="100" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="-0.033741587583633284" LOG_CI_START="-0.21441080215596658" LOG_EFFECT_SIZE="-0.12407619486979989" METHOD="MH" MODIFIED="2008-10-14 14:08:05 +1100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.5348607984626721" P_Q="0.0" P_Z="0.007101525549873019" Q="0.0" RANDOM="YES" SCALE="200.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="453" TOTAL_2="401" WEIGHT="100.00000000000001" Z="2.692045502707591">
<NAME>Rescue analgesia required</NAME>
<GROUP_LABEL_1>NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Opioids</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NSAIDs</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Opioids</GRAPH_LABEL_2>
<DICH_DATA CI_END="101.58460526662178" CI_START="0.24610028197072092" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.006827897373713" LOG_CI_START="-0.6088878887016753" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="11998" O_E="0.0" SE="1.5364844007426468" STUDY_ID="STD-al_x002d_Sahlawi-1996" TOTAL_1="50" TOTAL_2="50" VAR="2.3607843137254902" WEIGHT="0.47707560124021037"/>
<DICH_DATA CI_END="1.4578691487365771" CI_START="0.48437421996458446" EFFECT_SIZE="0.8403298350824587" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="23" LOG_CI_END="0.1637185455650283" LOG_CI_START="-0.31481897953614235" LOG_EFFECT_SIZE="-0.07555021698555703" ORDER="11999" O_E="0.0" SE="0.28109531104338037" STUDY_ID="STD-Arnau-1991" TOTAL_1="116" TOTAL_2="118" VAR="0.07901457389057477" WEIGHT="14.253985567634539"/>
<DICH_DATA CI_END="0.9476565651843566" CI_START="0.5490506321046889" EFFECT_SIZE="0.7213261648745519" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="31" LOG_CI_END="-0.023349024337775828" LOG_CI_START="-0.2603876041296071" LOG_EFFECT_SIZE="-0.14186831423369145" ORDER="12000" O_E="0.0" SE="0.13923763512961537" STUDY_ID="STD-Cordell-1996" TOTAL_1="36" TOTAL_2="35" VAR="0.0193871190364879" WEIGHT="58.09386086449062"/>
<DICH_DATA CI_END="4.133303326137978" CI_START="0.27123759810860815" EFFECT_SIZE="1.0588235294117647" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.6162972775377342" LOG_CI_START="-0.56665011008767" LOG_EFFECT_SIZE="0.024823583725032145" ORDER="12001" O_E="0.0" SE="0.6948691511751705" STUDY_ID="STD-Curry-1995" TOTAL_1="17" TOTAL_2="24" VAR="0.48284313725490186" WEIGHT="2.3325848686018817"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="12002" O_E="0.0" SE="0.0" STUDY_ID="STD-Hetherington-1986" TOTAL_1="30" TOTAL_2="28" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.4151555488967953" CI_START="0.41987188492528793" EFFECT_SIZE="0.7708333333333334" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="16" LOG_CI_END="0.15080417859865414" LOG_CI_START="-0.3768832052158385" LOG_EFFECT_SIZE="-0.11303951330859219" ORDER="12003" O_E="0.0" SE="0.3099661813473102" STUDY_ID="STD-Larkin-1999" TOTAL_1="33" TOTAL_2="37" VAR="0.09607903357903358" WEIGHT="11.72235558492151"/>
<DICH_DATA CI_END="1.698490163782303" CI_START="0.40885985639034417" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="8" LOG_CI_END="0.23006303614720783" LOG_CI_START="-0.3884255282424574" LOG_EFFECT_SIZE="-0.07918124604762482" ORDER="12004" O_E="0.0" SE="0.36330324429025945" STUDY_ID="STD-Lehtonen-1983" TOTAL_1="93" TOTAL_2="31" VAR="0.13198924731182796" WEIGHT="8.533063251798065"/>
<DICH_DATA CI_END="0.5999477688059816" CI_START="0.01157508170797152" EFFECT_SIZE="0.08333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="12" LOG_CI_END="-0.22188655746091338" LOG_CI_START="-1.9364759346343363" LOG_EFFECT_SIZE="-1.0791812460476249" ORDER="12005" O_E="0.0" SE="1.007158287505968" STUDY_ID="STD-Thompson-1989" TOTAL_1="29" TOTAL_2="29" VAR="1.0143678160919538" WEIGHT="1.1103197262391726"/>
<DICH_DATA CI_END="2.998828618438036" CI_START="0.18757323994492983" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.4769516467553787" LOG_CI_START="-0.7268291199719785" LOG_EFFECT_SIZE="-0.12493873660829993" ORDER="12006" O_E="0.0" SE="0.7071067811865475" STUDY_ID="STD-Torralba-1999" TOTAL_1="24" TOTAL_2="24" VAR="0.49999999999999994" WEIGHT="2.2525451917380916"/>
<DICH_DATA CI_END="6.553055387930549" CI_START="0.15260057191669785" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8164438387284481" LOG_CI_START="-0.8164438387284481" LOG_EFFECT_SIZE="0.0" ORDER="12007" O_E="0.0" SE="0.9591663046625438" STUDY_ID="STD-Uden-1983" TOTAL_1="25" TOTAL_2="25" VAR="0.9199999999999999" WEIGHT="1.2242093433359194"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.016433981515266" CI_END="0.925248548405878" CI_START="0.6103644038471372" CI_STUDY="95" CI_TOTAL="95" DF="8.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7514910369779422" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="100" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="-0.033741587583633284" LOG_CI_START="-0.21441080215596658" LOG_EFFECT_SIZE="-0.12407619486979989" METHOD="MH" MODIFIED="2008-10-14 14:08:23 +1100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.5348607984626723" P_Q="0.0" P_Z="0.007101525549873019" Q="0.0" RANDOM="YES" SCALE="200.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="453" TOTAL_2="401" WEIGHT="200.0" Z="2.692045502707591">
<NAME>Rescue analgesia required by study quality</NAME>
<GROUP_LABEL_1>NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Opioids</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NSAIDs</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Opioids</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.36466402819607" CI_END="0.9430947655330625" CI_START="0.577902139980363" DF="2.0" EFFECT_SIZE="0.7382523167629313" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="51" I2="0.0" ID="CMP-001.07.01" LOG_CI_END="-0.02544466560810539" LOG_CI_START="-0.2381456973316057" LOG_EFFECT_SIZE="-0.13179518146985555" NO="1" P_CHI2="0.833324662618769" P_Z="0.015145085507704202" STUDIES="3" TAU2="0.0" TOTAL_1="86" TOTAL_2="96" WEIGHT="100.0" Z="2.42889098302665">
<NAME>Blinded assessors and participants</NAME>
<DICH_DATA CI_END="0.9476565651843566" CI_START="0.5490506321046889" EFFECT_SIZE="0.7213261648745519" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="31" LOG_CI_END="-0.023349024337775828" LOG_CI_START="-0.2603876041296071" LOG_EFFECT_SIZE="-0.14186831423369145" ORDER="12008" O_E="0.0" SE="0.13923763512961537" STUDY_ID="STD-Cordell-1996" TOTAL_1="36" TOTAL_2="35" VAR="0.0193871190364879" WEIGHT="80.5195094072697"/>
<DICH_DATA CI_END="4.133303326137978" CI_START="0.27123759810860815" EFFECT_SIZE="1.0588235294117647" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.6162972775377342" LOG_CI_START="-0.56665011008767" LOG_EFFECT_SIZE="0.024823583725032145" ORDER="12009" O_E="0.0" SE="0.6948691511751705" STUDY_ID="STD-Curry-1995" TOTAL_1="17" TOTAL_2="24" VAR="0.48284313725490186" WEIGHT="3.233019573423578"/>
<DICH_DATA CI_END="1.4151555488967953" CI_START="0.41987188492528793" EFFECT_SIZE="0.7708333333333334" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="16" LOG_CI_END="0.15080417859865414" LOG_CI_START="-0.3768832052158385" LOG_EFFECT_SIZE="-0.11303951330859219" ORDER="12010" O_E="0.0" SE="0.3099661813473102" STUDY_ID="STD-Larkin-1999" TOTAL_1="33" TOTAL_2="37" VAR="0.09607903357903358" WEIGHT="16.24747101930672"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.851380836220058" CI_END="1.303381218191373" CI_START="0.43831906136689575" DF="5.0" EFFECT_SIZE="0.7558418036605833" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="49" I2="27.022010314076695" ID="CMP-001.07.02" LOG_CI_END="0.11507145849277321" LOG_CI_START="-0.3582096425870676" LOG_EFFECT_SIZE="-0.12156909204714723" NO="2" P_CHI2="0.23193009118762542" P_Z="0.31398757429292123" STUDIES="7" TAU2="0.11811693510480542" TOTAL_1="367" TOTAL_2="305" WEIGHT="100.0" Z="1.0068901610565169">
<NAME>Assessors and participants not blinded</NAME>
<DICH_DATA CI_END="101.58460526662178" CI_START="0.24610028197072092" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.006827897373713" LOG_CI_START="-0.6088878887016753" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="12011" O_E="0.0" SE="1.5364844007426468" STUDY_ID="STD-al_x002d_Sahlawi-1996" TOTAL_1="50" TOTAL_2="50" VAR="2.3607843137254902" WEIGHT="1.7129445905995428"/>
<DICH_DATA CI_END="1.4578691487365771" CI_START="0.48437421996458446" EFFECT_SIZE="0.8403298350824587" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="23" LOG_CI_END="0.1637185455650283" LOG_CI_START="-0.31481897953614235" LOG_EFFECT_SIZE="-0.07555021698555703" ORDER="12012" O_E="0.0" SE="0.28109531104338037" STUDY_ID="STD-Arnau-1991" TOTAL_1="116" TOTAL_2="118" VAR="0.07901457389057477" WEIGHT="51.179073943607094"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="12013" O_E="0.0" SE="0.0" STUDY_ID="STD-Hetherington-1986" TOTAL_1="30" TOTAL_2="28" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.698490163782303" CI_START="0.40885985639034417" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="8" LOG_CI_END="0.23006303614720783" LOG_CI_START="-0.3884255282424574" LOG_EFFECT_SIZE="-0.07918124604762482" ORDER="12014" O_E="0.0" SE="0.36330324429025945" STUDY_ID="STD-Lehtonen-1983" TOTAL_1="93" TOTAL_2="31" VAR="0.13198924731182796" WEIGHT="30.638046675230544"/>
<DICH_DATA CI_END="0.5999477688059816" CI_START="0.01157508170797152" EFFECT_SIZE="0.08333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="12" LOG_CI_END="-0.22188655746091338" LOG_CI_START="-1.9364759346343363" LOG_EFFECT_SIZE="-1.0791812460476249" ORDER="12015" O_E="0.0" SE="1.007158287505968" STUDY_ID="STD-Thompson-1989" TOTAL_1="29" TOTAL_2="29" VAR="1.0143678160919538" WEIGHT="3.9866137860605666"/>
<DICH_DATA CI_END="2.998828618438036" CI_START="0.18757323994492983" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.4769516467553787" LOG_CI_START="-0.7268291199719785" LOG_EFFECT_SIZE="-0.12493873660829993" ORDER="12016" O_E="0.0" SE="0.7071067811865475" STUDY_ID="STD-Torralba-1999" TOTAL_1="24" TOTAL_2="24" VAR="0.49999999999999994" WEIGHT="8.087785439536667"/>
<DICH_DATA CI_END="6.553055387930549" CI_START="0.15260057191669785" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8164438387284481" LOG_CI_START="-0.8164438387284481" LOG_EFFECT_SIZE="0.0" ORDER="12017" O_E="0.0" SE="0.9591663046625438" STUDY_ID="STD-Uden-1983" TOTAL_1="25" TOTAL_2="25" VAR="0.9199999999999999" WEIGHT="4.39553556496558"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="29.659734227984224" CI_END="0.756848585778815" CI_START="0.4273401409571191" CI_STUDY="95" CI_TOTAL="95" DF="15.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5687106305757921" ESTIMABLE="YES" EVENTS_1="137" EVENTS_2="209" I2="49.426384320573696" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="-0.12099099624374911" LOG_CI_START="-0.3692263110737688" LOG_EFFECT_SIZE="-0.24510865365875892" METHOD="MH" NO="8" P_CHI2="0.01320937645697351" P_Q="0.0" P_Z="1.0858816259772603E-4" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="16" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.12100579006322697" TOTALS="YES" TOTAL_1="672" TOTAL_2="560" WEIGHT="100.0" Z="3.870554306902129">
<NAME>Number of patients with adverse events</NAME>
<GROUP_LABEL_1>NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Opioids</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NSAIDs</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Opioids</GRAPH_LABEL_2>
<DICH_DATA CI_END="101.58460526662178" CI_START="0.24610028197072092" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.006827897373713" LOG_CI_START="-0.6088878887016753" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="12018" O_E="0.0" SE="1.5364844007426468" STUDY_ID="STD-al_x002d_Sahlawi-1996" TOTAL_1="50" TOTAL_2="50" VAR="2.3607843137254902" WEIGHT="0.8567168075239248"/>
<DICH_DATA CI_END="0.9367435761958234" CI_START="0.46462385390603733" EFFECT_SIZE="0.6597222222222222" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="28" LOG_CI_END="-0.028379276437817968" LOG_CI_START="-0.33289849717498576" LOG_EFFECT_SIZE="-0.1806388868064019" ORDER="12019" O_E="0.0" SE="0.17887609765546594" STUDY_ID="STD-Cordell-1996" TOTAL_1="36" TOTAL_2="35" VAR="0.03199665831244779" WEIGHT="13.896452751146787"/>
<DICH_DATA CI_END="2.68992586628811" CI_START="0.0088533916599969" EFFECT_SIZE="0.15432098765432098" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.42974031111555" LOG_CI_START="-2.0528903228567366" LOG_EFFECT_SIZE="-0.8115750058705933" ORDER="12020" O_E="0.0" SE="1.4583095236151573" STUDY_ID="STD-Curry-1995" TOTAL_1="17" TOTAL_2="24" VAR="2.126666666666667" WEIGHT="0.9459524621998103"/>
<DICH_DATA CI_END="0.8050202969855016" CI_START="0.13802274492603533" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="14" LOG_CI_END="-0.09419316962259486" LOG_CI_START="-0.8600493398167302" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="12021" O_E="0.0" SE="0.44986770542121873" STUDY_ID="STD-Hetherington-1986" TOTAL_1="30" TOTAL_2="28" VAR="0.20238095238095244" WEIGHT="6.574763327007282"/>
<DICH_DATA CI_END="94.30721448849083" CI_START="0.2348211516991183" EFFECT_SIZE="4.705882352941177" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9745449174742649" LOG_CI_START="-0.6292627862469253" LOG_EFFECT_SIZE="0.6726410656136697" ORDER="12022" O_E="0.0" SE="1.5294895342218324" STUDY_ID="STD-Indudhara-1990" TOTAL_1="33" TOTAL_2="31" VAR="2.3393382352941177" WEIGHT="0.8641845501071859"/>
<DICH_DATA CI_END="1.17356876826614" CI_START="0.5744251568816777" EFFECT_SIZE="0.8210526315789474" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="19" LOG_CI_END="0.06950854327715046" LOG_CI_START="-0.24076654847388515" LOG_EFFECT_SIZE="-0.08562900259836737" ORDER="12023" O_E="0.0" SE="0.18225712478103293" STUDY_ID="STD-Jonsson-1987" TOTAL_1="35" TOTAL_2="26" VAR="0.033217659533449004" WEIGHT="13.786433257865387"/>
<DICH_DATA CI_END="3.0631583245962513" CI_START="0.2626552570990455" EFFECT_SIZE="0.896969696969697" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.48616944464251605" LOG_CI_START="-0.5806139022804139" LOG_EFFECT_SIZE="-0.04722222881894889" ORDER="12024" O_E="0.0" SE="0.6266338186452617" STUDY_ID="STD-Larkin-1999" TOTAL_1="33" TOTAL_2="37" VAR="0.39266994266994265" WEIGHT="4.139170218046481"/>
<DICH_DATA CI_END="0.7835764752727904" CI_START="0.2930163190064025" EFFECT_SIZE="0.4791666666666667" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="16" LOG_CI_END="-0.10591861097819126" LOG_CI_START="-0.5331081917377974" LOG_EFFECT_SIZE="-0.31951340135799433" ORDER="12025" O_E="0.0" SE="0.2509332743607216" STUDY_ID="STD-Lehtonen-1983" TOTAL_1="93" TOTAL_2="31" VAR="0.06296750818139317" WEIGHT="11.55706461181801"/>
<DICH_DATA CI_END="1.5155511236119343" CI_START="0.5091492225213367" EFFECT_SIZE="0.8784313725490196" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="15" LOG_CI_END="0.18057059087063246" LOG_CI_START="-0.2931549150702171" LOG_EFFECT_SIZE="-0.056292162099792376" ORDER="12026" O_E="0.0" SE="0.2782687071687288" STUDY_ID="STD-Lundstam-1982" TOTAL_1="34" TOTAL_2="32" VAR="0.07743347338935574" WEIGHT="10.714569574938961"/>
<DICH_DATA CI_END="0.36401985585882474" CI_START="0.0014857235778067334" EFFECT_SIZE="0.023255813953488372" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="21" LOG_CI_END="-0.43887492664013794" LOG_CI_START="-2.828061984519035" LOG_EFFECT_SIZE="-1.6334684555795866" ORDER="12027" O_E="0.0" SE="1.4034203044647386" STUDY_ID="STD-Marthak-1991" TOTAL_1="25" TOTAL_2="25" VAR="1.9695885509839" WEIGHT="1.017027193136562"/>
<DICH_DATA CI_END="0.9254854201462331" CI_START="0.25741838419626756" EFFECT_SIZE="0.4880952380952381" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" LOG_CI_END="-0.033630418618169004" LOG_CI_START="-0.5893604400661234" LOG_EFFECT_SIZE="-0.3114954293421462" ORDER="12028" O_E="0.0" SE="0.32643856550650063" STUDY_ID="STD-Oosterlinck-1990" TOTAL_1="84" TOTAL_2="41" VAR="0.10656213704994191" WEIGHT="9.343106129384354"/>
<DICH_DATA CI_END="0.6481190611137947" CI_START="0.011710974197280389" EFFECT_SIZE="0.08712121212121213" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="11" LOG_CI_END="-0.18834520580373956" LOG_CI_START="-1.9314069759007366" LOG_EFFECT_SIZE="-1.0598760908522382" ORDER="12029" O_E="0.0" SE="1.0238831120498935" STUDY_ID="STD-Persson-1985" TOTAL_1="48" TOTAL_2="46" VAR="1.0483366271409749" WEIGHT="1.818279456368206"/>
<DICH_DATA CI_END="0.822753199489386" CI_START="0.35286700211719435" EFFECT_SIZE="0.5388157894736842" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="40" LOG_CI_END="-0.08473042016347825" LOG_CI_START="-0.4523889522052299" LOG_EFFECT_SIZE="-0.26855968618435405" ORDER="12030" O_E="0.0" SE="0.21596444166041012" STUDY_ID="STD-Sandhu-1994" TOTAL_1="76" TOTAL_2="78" VAR="0.04664064006169269" WEIGHT="12.682592126047867"/>
<DICH_DATA CI_END="0.6995892973708534" CI_START="0.19824779168995368" EFFECT_SIZE="0.3724137931034483" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="20" LOG_CI_END="-0.1551568431732558" LOG_CI_START="-0.7027916416507569" LOG_EFFECT_SIZE="-0.4289742424120064" ORDER="12031" O_E="0.0" SE="0.3216833914616564" STUDY_ID="STD-Sommer-1989" TOTAL_1="29" TOTAL_2="27" VAR="0.10348020434227329" WEIGHT="9.471376155528413"/>
<DICH_DATA CI_END="7.796078149940863" CI_START="0.01425218025962887" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.891876183949684" LOG_CI_START="-1.8461186933890088" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="12032" O_E="0.0" SE="1.6083117442419756" STUDY_ID="STD-Torralba-1999" TOTAL_1="24" TOTAL_2="24" VAR="2.5866666666666664" WEIGHT="0.7852468600394084"/>
<DICH_DATA CI_END="26.919163659736427" CI_START="0.3343343097044836" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4300615628474913" LOG_CI_START="-0.47581905340816655" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="12033" O_E="0.0" SE="1.1195237082497775" STUDY_ID="STD-Uden-1983" TOTAL_1="25" TOTAL_2="25" VAR="1.2533333333333332" WEIGHT="1.5470645188413485"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="29.659734227984217" CI_END="0.756848585778815" CI_START="0.42734014095711914" CI_STUDY="95" CI_TOTAL="95" DF="15.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5687106305757921" ESTIMABLE="YES" EVENTS_1="137" EVENTS_2="209" I2="49.42638432057369" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="-0.12099099624374911" LOG_CI_START="-0.36922631107376874" LOG_EFFECT_SIZE="-0.24510865365875892" METHOD="MH" NO="9" P_CHI2="0.01320937645697351" P_Q="0.0" P_Z="1.0858816259772562E-4" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="16" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.12100579006322691" TOTALS="YES" TOTAL_1="672" TOTAL_2="560" WEIGHT="100.0" Z="3.8705543069021298">
<NAME>Number of patients with adverse events by type of opioid</NAME>
<GROUP_LABEL_1>NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Opioids</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NSAIDs</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Opioids</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="14.668155201032334" CI_END="0.7390281355795045" CI_START="0.3824808997059694" DF="9.0" EFFECT_SIZE="0.5316616839724996" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="142" I2="38.64259085991546" ID="CMP-001.09.01" LOG_CI_END="-0.1313390272420843" LOG_CI_START="-0.4173902477245284" LOG_EFFECT_SIZE="-0.27436463748330636" NO="1" P_CHI2="0.1004639811453687" P_Z="1.7006294208648186E-4" STUDIES="10" TAU2="0.08516542231613775" TOTAL_1="477" TOTAL_2="380" WEIGHT="61.87703017641827" Z="3.759779854752773">
<NAME>Pethidine</NAME>
<DICH_DATA CI_END="101.58460526662178" CI_START="0.24610028197072092" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.006827897373713" LOG_CI_START="-0.6088878887016753" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="12034" O_E="0.0" SE="1.5364844007426468" STUDY_ID="STD-al_x002d_Sahlawi-1996" TOTAL_1="50" TOTAL_2="50" VAR="2.3607843137254902" WEIGHT="0.8567168075239245"/>
<DICH_DATA CI_END="0.9367435761958234" CI_START="0.46462385390603733" EFFECT_SIZE="0.6597222222222222" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="28" LOG_CI_END="-0.028379276437817968" LOG_CI_START="-0.33289849717498576" LOG_EFFECT_SIZE="-0.1806388868064019" ORDER="12035" O_E="0.0" SE="0.17887609765546594" STUDY_ID="STD-Cordell-1996" TOTAL_1="36" TOTAL_2="35" VAR="0.03199665831244779" WEIGHT="13.896452751146791"/>
<DICH_DATA CI_END="2.68992586628811" CI_START="0.0088533916599969" EFFECT_SIZE="0.15432098765432098" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.42974031111555" LOG_CI_START="-2.0528903228567366" LOG_EFFECT_SIZE="-0.8115750058705933" ORDER="12036" O_E="0.0" SE="1.4583095236151573" STUDY_ID="STD-Curry-1995" TOTAL_1="17" TOTAL_2="24" VAR="2.126666666666667" WEIGHT="0.9459524621998101"/>
<DICH_DATA CI_END="0.8050202969855016" CI_START="0.13802274492603533" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="14" LOG_CI_END="-0.09419316962259486" LOG_CI_START="-0.8600493398167302" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="12037" O_E="0.0" SE="0.44986770542121873" STUDY_ID="STD-Hetherington-1986" TOTAL_1="30" TOTAL_2="28" VAR="0.20238095238095244" WEIGHT="6.574763327007281"/>
<DICH_DATA CI_END="94.30721448849083" CI_START="0.2348211516991183" EFFECT_SIZE="4.705882352941177" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9745449174742649" LOG_CI_START="-0.6292627862469253" LOG_EFFECT_SIZE="0.6726410656136697" ORDER="12038" O_E="0.0" SE="1.5294895342218324" STUDY_ID="STD-Indudhara-1990" TOTAL_1="33" TOTAL_2="31" VAR="2.3393382352941177" WEIGHT="0.8641845501071856"/>
<DICH_DATA CI_END="3.0631583245962513" CI_START="0.2626552570990455" EFFECT_SIZE="0.896969696969697" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.48616944464251605" LOG_CI_START="-0.5806139022804139" LOG_EFFECT_SIZE="-0.04722222881894889" ORDER="12039" O_E="0.0" SE="0.6266338186452617" STUDY_ID="STD-Larkin-1999" TOTAL_1="33" TOTAL_2="37" VAR="0.39266994266994265" WEIGHT="4.13917021804648"/>
<DICH_DATA CI_END="0.7835764752727904" CI_START="0.2930163190064025" EFFECT_SIZE="0.4791666666666667" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="16" LOG_CI_END="-0.10591861097819126" LOG_CI_START="-0.5331081917377974" LOG_EFFECT_SIZE="-0.31951340135799433" ORDER="12040" O_E="0.0" SE="0.2509332743607216" STUDY_ID="STD-Lehtonen-1983" TOTAL_1="93" TOTAL_2="31" VAR="0.06296750818139317" WEIGHT="11.55706461181801"/>
<DICH_DATA CI_END="0.36401985585882474" CI_START="0.0014857235778067334" EFFECT_SIZE="0.023255813953488372" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="21" LOG_CI_END="-0.43887492664013794" LOG_CI_START="-2.828061984519035" LOG_EFFECT_SIZE="-1.6334684555795866" ORDER="12041" O_E="0.0" SE="1.4034203044647386" STUDY_ID="STD-Marthak-1991" TOTAL_1="25" TOTAL_2="25" VAR="1.9695885509839" WEIGHT="1.0170271931365618"/>
<DICH_DATA CI_END="0.9254854201462331" CI_START="0.25741838419626756" EFFECT_SIZE="0.4880952380952381" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" LOG_CI_END="-0.033630418618169004" LOG_CI_START="-0.5893604400661234" LOG_EFFECT_SIZE="-0.3114954293421462" ORDER="12042" O_E="0.0" SE="0.32643856550650063" STUDY_ID="STD-Oosterlinck-1990" TOTAL_1="84" TOTAL_2="41" VAR="0.10656213704994191" WEIGHT="9.343106129384354"/>
<DICH_DATA CI_END="0.822753199489386" CI_START="0.35286700211719435" EFFECT_SIZE="0.5388157894736842" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="40" LOG_CI_END="-0.08473042016347825" LOG_CI_START="-0.4523889522052299" LOG_EFFECT_SIZE="-0.26855968618435405" ORDER="12043" O_E="0.0" SE="0.21596444166041012" STUDY_ID="STD-Sandhu-1994" TOTAL_1="76" TOTAL_2="78" VAR="0.04664064006169269" WEIGHT="12.682592126047869"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="12.533012630758408" CI_END="1.0898583857727324" CI_START="0.3523116203525619" DF="5.0" EFFECT_SIZE="0.6196529462904368" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="67" I2="60.1053621558711" ID="CMP-001.09.02" LOG_CI_END="0.037370070167196484" LOG_CI_START="-0.45307303217564887" LOG_EFFECT_SIZE="-0.20785148100422615" NO="2" P_CHI2="0.028170954866570175" P_Z="0.09665742267784425" STUDIES="6" TAU2="0.22478231550198072" TOTAL_1="195" TOTAL_2="180" WEIGHT="38.12296982358173" Z="1.6612790146524017">
<NAME>Other opioids</NAME>
<DICH_DATA CI_END="1.17356876826614" CI_START="0.5744251568816777" EFFECT_SIZE="0.8210526315789474" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="19" LOG_CI_END="0.06950854327715046" LOG_CI_START="-0.24076654847388515" LOG_EFFECT_SIZE="-0.08562900259836737" ORDER="12044" O_E="0.0" SE="0.18225712478103293" STUDY_ID="STD-Jonsson-1987" TOTAL_1="35" TOTAL_2="26" VAR="0.033217659533449004" WEIGHT="13.78643325786539"/>
<DICH_DATA CI_END="1.5155511236119343" CI_START="0.5091492225213367" EFFECT_SIZE="0.8784313725490196" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="15" LOG_CI_END="0.18057059087063246" LOG_CI_START="-0.2931549150702171" LOG_EFFECT_SIZE="-0.056292162099792376" ORDER="12045" O_E="0.0" SE="0.2782687071687288" STUDY_ID="STD-Lundstam-1982" TOTAL_1="34" TOTAL_2="32" VAR="0.07743347338935574" WEIGHT="10.714569574938963"/>
<DICH_DATA CI_END="0.6481190611137947" CI_START="0.011710974197280389" EFFECT_SIZE="0.08712121212121213" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="11" LOG_CI_END="-0.18834520580373956" LOG_CI_START="-1.9314069759007366" LOG_EFFECT_SIZE="-1.0598760908522382" ORDER="12046" O_E="0.0" SE="1.0238831120498935" STUDY_ID="STD-Persson-1985" TOTAL_1="48" TOTAL_2="46" VAR="1.0483366271409749" WEIGHT="1.8182794563682056"/>
<DICH_DATA CI_END="0.6995892973708534" CI_START="0.19824779168995368" EFFECT_SIZE="0.3724137931034483" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="20" LOG_CI_END="-0.1551568431732558" LOG_CI_START="-0.7027916416507569" LOG_EFFECT_SIZE="-0.4289742424120064" ORDER="12047" O_E="0.0" SE="0.3216833914616564" STUDY_ID="STD-Sommer-1989" TOTAL_1="29" TOTAL_2="27" VAR="0.10348020434227329" WEIGHT="9.471376155528413"/>
<DICH_DATA CI_END="7.796078149940863" CI_START="0.01425218025962887" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.891876183949684" LOG_CI_START="-1.8461186933890088" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="12048" O_E="0.0" SE="1.6083117442419756" STUDY_ID="STD-Torralba-1999" TOTAL_1="24" TOTAL_2="24" VAR="2.5866666666666664" WEIGHT="0.7852468600394082"/>
<DICH_DATA CI_END="26.919163659736427" CI_START="0.3343343097044836" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4300615628474913" LOG_CI_START="-0.47581905340816655" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="12049" O_E="0.0" SE="1.1195237082497775" STUDY_ID="STD-Uden-1983" TOTAL_1="25" TOTAL_2="25" VAR="1.2533333333333332" WEIGHT="1.547064518841348"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="21.729293144904034" CI_END="0.7543648884220311" CI_START="0.4651618546202279" CI_STUDY="95" CI_TOTAL="95" DF="14.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5923696232579565" ESTIMABLE="YES" EVENTS_1="137" EVENTS_2="188" I2="35.57084481929736" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="-0.12241853384367449" LOG_CI_START="-0.33239590659875584" LOG_EFFECT_SIZE="-0.22740722022121512" METHOD="MH" MODIFIED="2008-10-14 14:09:04 +1100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.08435049533053718" P_Q="0.0" P_Z="2.1828732170143943E-5" Q="0.0" RANDOM="YES" SCALE="200.0" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.06410732669277852" TOTALS="SUB" TOTAL_1="647" TOTAL_2="535" WEIGHT="400.0" Z="4.245314203238734">
<NAME>Number of patients with adverse events by NSAID type</NAME>
<GROUP_LABEL_1>NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Opioids</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NSAIDs</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Opioids</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.423750698696367" CI_END="1.3640381924473768" CI_START="0.4228820881915254" DF="3.0" EFFECT_SIZE="0.7594914872433662" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="36" I2="53.298312143265164" ID="CMP-001.10.01" LOG_CI_END="0.13482653053815288" LOG_CI_START="-0.3737807096611505" LOG_EFFECT_SIZE="-0.11947708956149887" NO="1" P_CHI2="0.09271871349221772" P_Z="0.3571383994135112" STUDIES="4" TAU2="0.1511640255644702" TOTAL_1="203" TOTAL_2="132" WEIGHT="100.0" Z="0.920831533685764">
<NAME>Indomethacin</NAME>
<DICH_DATA CI_END="101.58460526662178" CI_START="0.24610028197072092" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.006827897373713" LOG_CI_START="-0.6088878887016753" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="12050" O_E="0.0" SE="1.5364844007426468" STUDY_ID="STD-al_x002d_Sahlawi-1996" TOTAL_1="50" TOTAL_2="50" VAR="2.3607843137254902" WEIGHT="2.1350000916272935"/>
<DICH_DATA CI_END="1.17356876826614" CI_START="0.5744251568816777" EFFECT_SIZE="0.8210526315789474" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="19" LOG_CI_END="0.06950854327715046" LOG_CI_START="-0.24076654847388515" LOG_EFFECT_SIZE="-0.08562900259836737" ORDER="12051" O_E="0.0" SE="0.18225712478103293" STUDY_ID="STD-Jonsson-1987" TOTAL_1="35" TOTAL_2="26" VAR="0.033217659533449004" WEIGHT="53.194396169193645"/>
<DICH_DATA CI_END="0.7835764752727904" CI_START="0.2930163190064025" EFFECT_SIZE="0.4791666666666667" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="16" LOG_CI_END="-0.10591861097819126" LOG_CI_START="-0.5331081917377974" LOG_EFFECT_SIZE="-0.31951340135799433" ORDER="12052" O_E="0.0" SE="0.2509332743607216" STUDY_ID="STD-Lehtonen-1983" TOTAL_1="93" TOTAL_2="31" VAR="0.06296750818139317" WEIGHT="40.74090577891067"/>
<DICH_DATA CI_END="26.919163659736427" CI_START="0.3343343097044836" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4300615628474913" LOG_CI_START="-0.47581905340816655" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="12053" O_E="0.0" SE="1.1195237082497775" STUDY_ID="STD-Uden-1983" TOTAL_1="25" TOTAL_2="25" VAR="1.2533333333333332" WEIGHT="3.9296979602683964"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.494532474676092" CI_END="1.0877669132434058" CI_START="0.28153186646411565" DF="3.0" EFFECT_SIZE="0.5533905034994058" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="49" I2="59.9708185915939" ID="CMP-001.10.02" LOG_CI_END="0.03653584468475197" LOG_CI_START="-0.5504724404351775" LOG_EFFECT_SIZE="-0.25696829787521275" NO="2" P_CHI2="0.05769914577581636" P_Z="0.0861648483990201" STUDIES="4" TAU2="0.25311218572557365" TOTAL_1="126" TOTAL_2="118" WEIGHT="99.99999999999999" Z="1.7159846692830885">
<NAME>Diclofenac</NAME>
<DICH_DATA CI_END="0.8050202969855016" CI_START="0.13802274492603533" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="14" LOG_CI_END="-0.09419316962259486" LOG_CI_START="-0.8600493398167302" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="12054" O_E="0.0" SE="0.44986770542121873" STUDY_ID="STD-Hetherington-1986" TOTAL_1="30" TOTAL_2="28" VAR="0.20238095238095244" WEIGHT="21.816017900972852"/>
<DICH_DATA CI_END="94.30721448849083" CI_START="0.2348211516991183" EFFECT_SIZE="4.705882352941177" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9745449174742649" LOG_CI_START="-0.6292627862469253" LOG_EFFECT_SIZE="0.6726410656136697" ORDER="12055" O_E="0.0" SE="1.5294895342218324" STUDY_ID="STD-Indudhara-1990" TOTAL_1="33" TOTAL_2="31" VAR="2.3393382352941177" WEIGHT="2.4189077375506876"/>
<DICH_DATA CI_END="1.5155511236119343" CI_START="0.5091492225213367" EFFECT_SIZE="0.8784313725490196" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="15" LOG_CI_END="0.18057059087063246" LOG_CI_START="-0.2931549150702171" LOG_EFFECT_SIZE="-0.056292162099792376" ORDER="12056" O_E="0.0" SE="0.2782687071687288" STUDY_ID="STD-Lundstam-1982" TOTAL_1="34" TOTAL_2="32" VAR="0.07743347338935574" WEIGHT="41.074468021223154"/>
<DICH_DATA CI_END="0.6995892973708534" CI_START="0.19824779168995368" EFFECT_SIZE="0.3724137931034483" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="20" LOG_CI_END="-0.1551568431732558" LOG_CI_START="-0.7027916416507569" LOG_EFFECT_SIZE="-0.4289742424120064" ORDER="12057" O_E="0.0" SE="0.3216833914616564" STUDY_ID="STD-Sommer-1989" TOTAL_1="29" TOTAL_2="27" VAR="0.10348020434227329" WEIGHT="34.6906063402533"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.5146446719371514" CI_END="0.7594670545761191" CI_START="0.46705723396882914" DF="4.0" EFFECT_SIZE="0.5955791985964385" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="88" I2="0.0" ID="CMP-001.10.03" LOG_CI_END="-0.1194910609402724" LOG_CI_START="-0.3306298970060385" LOG_EFFECT_SIZE="-0.2250604789731555" NO="3" P_CHI2="0.8240443345198409" P_Z="2.935770834956772E-5" STUDIES="5" TAU2="0.0" TOTAL_1="253" TOTAL_2="215" WEIGHT="100.0" Z="4.178392202496755">
<NAME>Ketorolac</NAME>
<DICH_DATA CI_END="0.9367435761958234" CI_START="0.46462385390603733" EFFECT_SIZE="0.6597222222222222" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="28" LOG_CI_END="-0.028379276437817968" LOG_CI_START="-0.33289849717498576" LOG_EFFECT_SIZE="-0.1806388868064019" ORDER="12058" O_E="0.0" SE="0.17887609765546594" STUDY_ID="STD-Cordell-1996" TOTAL_1="36" TOTAL_2="35" VAR="0.03199665831244779" WEIGHT="37.347953867617825"/>
<DICH_DATA CI_END="3.0631583245962513" CI_START="0.2626552570990455" EFFECT_SIZE="0.896969696969697" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.48616944464251605" LOG_CI_START="-0.5806139022804139" LOG_EFFECT_SIZE="-0.04722222881894889" ORDER="12059" O_E="0.0" SE="0.6266338186452617" STUDY_ID="STD-Larkin-1999" TOTAL_1="33" TOTAL_2="37" VAR="0.39266994266994265" WEIGHT="7.857849852023218"/>
<DICH_DATA CI_END="0.9254854201462331" CI_START="0.25741838419626756" EFFECT_SIZE="0.4880952380952381" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" LOG_CI_END="-0.033630418618169004" LOG_CI_START="-0.5893604400661234" LOG_EFFECT_SIZE="-0.3114954293421462" ORDER="12060" O_E="0.0" SE="0.32643856550650063" STUDY_ID="STD-Oosterlinck-1990" TOTAL_1="84" TOTAL_2="41" VAR="0.10656213704994191" WEIGHT="21.030635004983555"/>
<DICH_DATA CI_END="0.822753199489386" CI_START="0.35286700211719435" EFFECT_SIZE="0.5388157894736842" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="40" LOG_CI_END="-0.08473042016347825" LOG_CI_START="-0.4523889522052299" LOG_EFFECT_SIZE="-0.26855968618435405" ORDER="12061" O_E="0.0" SE="0.21596444166041012" STUDY_ID="STD-Sandhu-1994" TOTAL_1="76" TOTAL_2="78" VAR="0.04664064006169269" WEIGHT="32.40950875808759"/>
<DICH_DATA CI_END="7.796078149940863" CI_START="0.01425218025962887" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.891876183949684" LOG_CI_START="-1.8461186933890088" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="12062" O_E="0.0" SE="1.6083117442419756" STUDY_ID="STD-Torralba-1999" TOTAL_1="24" TOTAL_2="24" VAR="2.5866666666666664" WEIGHT="1.3540525172878142"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.10314956992208525" CI_END="0.5437379507155928" CI_START="0.020362376938932454" DF="1.0" EFFECT_SIZE="0.10522260740199123" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="15" I2="0.0" ID="CMP-001.10.04" LOG_CI_END="-0.264610353937462" LOG_CI_START="-1.6911715273564394" LOG_EFFECT_SIZE="-0.9778909406469507" NO="4" P_CHI2="0.7480823013909688" P_Z="0.0072083007267411394" STUDIES="2" TAU2="0.0" TOTAL_1="65" TOTAL_2="70" WEIGHT="100.0" Z="2.68706461410626">
<NAME>Other</NAME>
<DICH_DATA CI_END="2.68992586628811" CI_START="0.0088533916599969" EFFECT_SIZE="0.15432098765432098" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.42974031111555" LOG_CI_START="-2.0528903228567366" LOG_EFFECT_SIZE="-0.8115750058705933" ORDER="12063" O_E="0.0" SE="1.4583095236151573" STUDY_ID="STD-Curry-1995" TOTAL_1="17" TOTAL_2="24" VAR="2.126666666666667" WEIGHT="33.67758263662306"/>
<DICH_DATA CI_END="0.6481190611137947" CI_START="0.011710974197280389" EFFECT_SIZE="0.08712121212121213" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="11" LOG_CI_END="-0.18834520580373956" LOG_CI_START="-1.9314069759007366" LOG_EFFECT_SIZE="-1.0598760908522382" ORDER="12064" O_E="0.0" SE="1.0238831120498935" STUDY_ID="STD-Persson-1985" TOTAL_1="48" TOTAL_2="46" VAR="1.0483366271409749" WEIGHT="66.32241736337694"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="29.65973422798421" CI_END="0.7568485857788149" CI_START="0.4273401409571191" CI_STUDY="95" CI_TOTAL="95" DF="15.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5687106305757921" ESTIMABLE="YES" EVENTS_1="137" EVENTS_2="209" I2="49.42638432057367" I2_Q="0.0" ID="CMP-001.11" LOG_CI_END="-0.12099099624374918" LOG_CI_START="-0.3692263110737688" LOG_EFFECT_SIZE="-0.24510865365875892" METHOD="MH" NO="11" P_CHI2="0.01320937645697362" P_Q="0.0" P_Z="1.0858816259772497E-4" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="16" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.12100579006322686" TOTALS="SUB" TOTAL_1="672" TOTAL_2="560" WEIGHT="200.0" Z="3.870554306902131">
<NAME>Adverse events by study quality</NAME>
<GROUP_LABEL_1>NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Opioids</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NSAIDs</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Opioids</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.061173947858828" CI_END="0.9344402038768066" CI_START="0.5732858412728945" DF="3.0" EFFECT_SIZE="0.7319162099576222" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="56" I2="0.0" ID="CMP-001.11.01" LOG_CI_END="-0.02944848450154782" LOG_CI_START="-0.24162878408087196" LOG_EFFECT_SIZE="-0.13553863429120988" NO="1" P_CHI2="0.5598074280248624" P_Z="0.012279441381640506" STUDIES="4" TAU2="0.0" TOTAL_1="121" TOTAL_2="122" WEIGHT="100.0" Z="2.5040104312342413">
<NAME>Blinded assessors and participants</NAME>
<DICH_DATA CI_END="0.9367435761958234" CI_START="0.46462385390603733" EFFECT_SIZE="0.6597222222222222" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="28" LOG_CI_END="-0.028379276437817968" LOG_CI_START="-0.33289849717498576" LOG_EFFECT_SIZE="-0.1806388868064019" ORDER="12065" O_E="0.0" SE="0.17887609765546594" STUDY_ID="STD-Cordell-1996" TOTAL_1="36" TOTAL_2="35" VAR="0.03199665831244779" WEIGHT="42.40859700364436"/>
<DICH_DATA CI_END="2.68992586628811" CI_START="0.0088533916599969" EFFECT_SIZE="0.15432098765432098" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.42974031111555" LOG_CI_START="-2.0528903228567366" LOG_EFFECT_SIZE="-0.8115750058705933" ORDER="12066" O_E="0.0" SE="1.4583095236151573" STUDY_ID="STD-Curry-1995" TOTAL_1="17" TOTAL_2="24" VAR="2.126666666666667" WEIGHT="2.8868170512598113"/>
<DICH_DATA CI_END="1.17356876826614" CI_START="0.5744251568816777" EFFECT_SIZE="0.8210526315789474" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="19" LOG_CI_END="0.06950854327715046" LOG_CI_START="-0.24076654847388515" LOG_EFFECT_SIZE="-0.08562900259836737" ORDER="12067" O_E="0.0" SE="0.18225712478103293" STUDY_ID="STD-Jonsson-1987" TOTAL_1="35" TOTAL_2="26" VAR="0.033217659533449004" WEIGHT="42.07284424452883"/>
<DICH_DATA CI_END="3.0631583245962513" CI_START="0.2626552570990455" EFFECT_SIZE="0.896969696969697" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.48616944464251605" LOG_CI_START="-0.5806139022804139" LOG_EFFECT_SIZE="-0.04722222881894889" ORDER="12068" O_E="0.0" SE="0.6266338186452617" STUDY_ID="STD-Larkin-1999" TOTAL_1="33" TOTAL_2="37" VAR="0.39266994266994265" WEIGHT="12.631741700567002"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="21.64045698963718" CI_END="0.7392843054293727" CI_START="0.34442494567461995" DF="11.0" EFFECT_SIZE="0.5046067347307315" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="153" I2="49.16928045804441" ID="CMP-001.11.02" LOG_CI_END="-0.1311885135208233" LOG_CI_START="-0.46290540142135467" LOG_EFFECT_SIZE="-0.29704695747108906" NO="2" P_CHI2="0.027311414411340995" P_Z="4.4771870835256345E-4" STUDIES="12" TAU2="0.16693996426740493" TOTAL_1="551" TOTAL_2="438" WEIGHT="100.0" Z="3.5102303174574256">
<NAME>Assessors and participants not blinded</NAME>
<DICH_DATA CI_END="101.58460526662178" CI_START="0.24610028197072092" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.006827897373713" LOG_CI_START="-0.6088878887016753" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="12069" O_E="0.0" SE="1.5364844007426468" STUDY_ID="STD-al_x002d_Sahlawi-1996" TOTAL_1="50" TOTAL_2="50" VAR="2.3607843137254902" WEIGHT="1.2742695714072187"/>
<DICH_DATA CI_END="0.8050202969855016" CI_START="0.13802274492603533" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="14" LOG_CI_END="-0.09419316962259486" LOG_CI_START="-0.8600493398167302" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="12070" O_E="0.0" SE="0.44986770542121873" STUDY_ID="STD-Hetherington-1986" TOTAL_1="30" TOTAL_2="28" VAR="0.20238095238095244" WEIGHT="9.779218492308503"/>
<DICH_DATA CI_END="94.30721448849083" CI_START="0.2348211516991183" EFFECT_SIZE="4.705882352941177" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9745449174742649" LOG_CI_START="-0.6292627862469253" LOG_EFFECT_SIZE="0.6726410656136697" ORDER="12071" O_E="0.0" SE="1.5294895342218324" STUDY_ID="STD-Indudhara-1990" TOTAL_1="33" TOTAL_2="31" VAR="2.3393382352941177" WEIGHT="1.2853769957712329"/>
<DICH_DATA CI_END="0.7835764752727904" CI_START="0.2930163190064025" EFFECT_SIZE="0.4791666666666667" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="16" LOG_CI_END="-0.10591861097819126" LOG_CI_START="-0.5331081917377974" LOG_EFFECT_SIZE="-0.31951340135799433" ORDER="12072" O_E="0.0" SE="0.2509332743607216" STUDY_ID="STD-Lehtonen-1983" TOTAL_1="93" TOTAL_2="31" VAR="0.06296750818139317" WEIGHT="17.189829404876726"/>
<DICH_DATA CI_END="1.5155511236119343" CI_START="0.5091492225213367" EFFECT_SIZE="0.8784313725490196" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="15" LOG_CI_END="0.18057059087063246" LOG_CI_START="-0.2931549150702171" LOG_EFFECT_SIZE="-0.056292162099792376" ORDER="12073" O_E="0.0" SE="0.2782687071687288" STUDY_ID="STD-Lundstam-1982" TOTAL_1="34" TOTAL_2="32" VAR="0.07743347338935574" WEIGHT="15.93671311238868"/>
<DICH_DATA CI_END="0.36401985585882474" CI_START="0.0014857235778067334" EFFECT_SIZE="0.023255813953488372" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="21" LOG_CI_END="-0.43887492664013794" LOG_CI_START="-2.828061984519035" LOG_EFFECT_SIZE="-1.6334684555795866" ORDER="12074" O_E="0.0" SE="1.4034203044647386" STUDY_ID="STD-Marthak-1991" TOTAL_1="25" TOTAL_2="25" VAR="1.9695885509839" WEIGHT="1.5127131791113155"/>
<DICH_DATA CI_END="0.9254854201462331" CI_START="0.25741838419626756" EFFECT_SIZE="0.4880952380952381" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" LOG_CI_END="-0.033630418618169004" LOG_CI_START="-0.5893604400661234" LOG_EFFECT_SIZE="-0.3114954293421462" ORDER="12075" O_E="0.0" SE="0.32643856550650063" STUDY_ID="STD-Oosterlinck-1990" TOTAL_1="84" TOTAL_2="41" VAR="0.10656213704994191" WEIGHT="13.896816005644064"/>
<DICH_DATA CI_END="0.6481190611137947" CI_START="0.011710974197280389" EFFECT_SIZE="0.08712121212121213" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="11" LOG_CI_END="-0.18834520580373956" LOG_CI_START="-1.9314069759007366" LOG_EFFECT_SIZE="-1.0598760908522382" ORDER="12076" O_E="0.0" SE="1.0238831120498935" STUDY_ID="STD-Persson-1985" TOTAL_1="48" TOTAL_2="46" VAR="1.0483366271409749" WEIGHT="2.704485500011811"/>
<DICH_DATA CI_END="0.822753199489386" CI_START="0.35286700211719435" EFFECT_SIZE="0.5388157894736842" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="40" LOG_CI_END="-0.08473042016347825" LOG_CI_START="-0.4523889522052299" LOG_EFFECT_SIZE="-0.26855968618435405" ORDER="12077" O_E="0.0" SE="0.21596444166041012" STUDY_ID="STD-Sandhu-1994" TOTAL_1="76" TOTAL_2="78" VAR="0.04664064006169269" WEIGHT="18.86392456744264"/>
<DICH_DATA CI_END="0.6995892973708534" CI_START="0.19824779168995368" EFFECT_SIZE="0.3724137931034483" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="20" LOG_CI_END="-0.1551568431732558" LOG_CI_START="-0.7027916416507569" LOG_EFFECT_SIZE="-0.4289742424120064" ORDER="12078" O_E="0.0" SE="0.3216833914616564" STUDY_ID="STD-Sommer-1989" TOTAL_1="29" TOTAL_2="27" VAR="0.10348020434227329" WEIGHT="14.087603194366771"/>
<DICH_DATA CI_END="7.796078149940863" CI_START="0.01425218025962887" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.891876183949684" LOG_CI_START="-1.8461186933890088" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="12079" O_E="0.0" SE="1.6083117442419756" STUDY_ID="STD-Torralba-1999" TOTAL_1="24" TOTAL_2="24" VAR="2.5866666666666664" WEIGHT="1.167966089848585"/>
<DICH_DATA CI_END="26.919163659736427" CI_START="0.3343343097044836" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4300615628474913" LOG_CI_START="-0.47581905340816655" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="12080" O_E="0.0" SE="1.1195237082497775" STUDY_ID="STD-Uden-1983" TOTAL_1="25" TOTAL_2="25" VAR="1.2533333333333332" WEIGHT="2.3010838868224575"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="29.659734227984202" CI_END="0.756848585778815" CI_START="0.42734014095711914" CI_STUDY="95" CI_TOTAL="95" DF="15.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5687106305757921" ESTIMABLE="YES" EVENTS_1="137" EVENTS_2="209" I2="49.42638432057365" I2_Q="0.0" ID="CMP-001.12" LOG_CI_END="-0.12099099624374911" LOG_CI_START="-0.36922631107376874" LOG_EFFECT_SIZE="-0.24510865365875892" METHOD="MH" NO="12" P_CHI2="0.013209376456973843" P_Q="0.0" P_Z="1.085881625977254E-4" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="16" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.12100579006322681" TOTALS="SUB" TOTAL_1="672" TOTAL_2="560" WEIGHT="200.0" Z="3.87055430690213">
<NAME>Adverse events by opioid route</NAME>
<GROUP_LABEL_1>NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Opioids</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NSAIDs</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Opioids</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="7.519806922229019" CI_END="0.9480731538241359" CI_START="0.4898610965242273" DF="5.0" EFFECT_SIZE="0.6814867238013325" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="68" I2="33.50893112402012" ID="CMP-001.12.01" LOG_CI_END="-0.02315815097795252" LOG_CI_START="-0.30992704969602247" LOG_EFFECT_SIZE="-0.1665426003369875" NO="1" P_CHI2="0.18476152318369898" P_Z="0.022814933346201778" STUDIES="6" TAU2="0.04858383032181547" TOTAL_1="256" TOTAL_2="191" WEIGHT="100.0" Z="2.276519525034362">
<NAME>IV</NAME>
<DICH_DATA CI_END="101.58460526662178" CI_START="0.24610028197072092" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.006827897373713" LOG_CI_START="-0.6088878887016753" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="12081" O_E="0.0" SE="1.5364844007426468" STUDY_ID="STD-al_x002d_Sahlawi-1996" TOTAL_1="50" TOTAL_2="50" VAR="2.3607843137254902" WEIGHT="2.011559417272725"/>
<DICH_DATA CI_END="0.9367435761958234" CI_START="0.46462385390603733" EFFECT_SIZE="0.6597222222222222" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="28" LOG_CI_END="-0.028379276437817968" LOG_CI_START="-0.33289849717498576" LOG_EFFECT_SIZE="-0.1806388868064019" ORDER="12082" O_E="0.0" SE="0.17887609765546594" STUDY_ID="STD-Cordell-1996" TOTAL_1="36" TOTAL_2="35" VAR="0.03199665831244779" WEIGHT="32.6286821418222"/>
<DICH_DATA CI_END="2.68992586628811" CI_START="0.0088533916599969" EFFECT_SIZE="0.15432098765432098" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.42974031111555" LOG_CI_START="-2.0528903228567366" LOG_EFFECT_SIZE="-0.8115750058705933" ORDER="12083" O_E="0.0" SE="1.4583095236151573" STUDY_ID="STD-Curry-1995" TOTAL_1="17" TOTAL_2="24" VAR="2.126666666666667" WEIGHT="2.2210835213212636"/>
<DICH_DATA CI_END="1.17356876826614" CI_START="0.5744251568816777" EFFECT_SIZE="0.8210526315789474" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="19" LOG_CI_END="0.06950854327715046" LOG_CI_START="-0.24076654847388515" LOG_EFFECT_SIZE="-0.08562900259836737" ORDER="12084" O_E="0.0" SE="0.18225712478103293" STUDY_ID="STD-Jonsson-1987" TOTAL_1="35" TOTAL_2="26" VAR="0.033217659533449004" WEIGHT="32.37035786727761"/>
<DICH_DATA CI_END="0.7835764752727904" CI_START="0.2930163190064025" EFFECT_SIZE="0.4791666666666667" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="16" LOG_CI_END="-0.10591861097819126" LOG_CI_START="-0.5331081917377974" LOG_EFFECT_SIZE="-0.31951340135799433" ORDER="12085" O_E="0.0" SE="0.2509332743607216" STUDY_ID="STD-Lehtonen-1983" TOTAL_1="93" TOTAL_2="31" VAR="0.06296750818139317" WEIGHT="27.135830593918474"/>
<DICH_DATA CI_END="26.919163659736427" CI_START="0.3343343097044836" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4300615628474913" LOG_CI_START="-0.47581905340816655" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="12086" O_E="0.0" SE="1.1195237082497775" STUDY_ID="STD-Uden-1983" TOTAL_1="25" TOTAL_2="25" VAR="1.2533333333333332" WEIGHT="3.6324864583877154"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="18.448874962415136" CI_END="0.7384058588018134" CI_START="0.3143419916637321" DF="9.0" EFFECT_SIZE="0.4817799999086" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="141" I2="51.21653749437189" ID="CMP-001.12.02" LOG_CI_END="-0.13170486610564952" LOG_CI_START="-0.5025975994797023" LOG_EFFECT_SIZE="-0.3171512327926759" NO="2" P_CHI2="0.030308859472782945" P_Z="8.024756534406185E-4" STUDIES="10" TAU2="0.18949732765815816" TOTAL_1="416" TOTAL_2="369" WEIGHT="100.00000000000001" Z="3.3519394584591238">
<NAME>IM</NAME>
<DICH_DATA CI_END="0.8050202969855016" CI_START="0.13802274492603533" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="14" LOG_CI_END="-0.09419316962259486" LOG_CI_START="-0.8600493398167302" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="12087" O_E="0.0" SE="0.44986770542121873" STUDY_ID="STD-Hetherington-1986" TOTAL_1="30" TOTAL_2="28" VAR="0.20238095238095244" WEIGHT="11.452233382398006"/>
<DICH_DATA CI_END="94.30721448849083" CI_START="0.2348211516991183" EFFECT_SIZE="4.705882352941177" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9745449174742649" LOG_CI_START="-0.6292627862469253" LOG_EFFECT_SIZE="0.6726410656136697" ORDER="12088" O_E="0.0" SE="1.5294895342218324" STUDY_ID="STD-Indudhara-1990" TOTAL_1="33" TOTAL_2="31" VAR="2.3393382352941177" WEIGHT="1.5052774770822035"/>
<DICH_DATA CI_END="3.0631583245962513" CI_START="0.2626552570990455" EFFECT_SIZE="0.896969696969697" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.48616944464251605" LOG_CI_START="-0.5806139022804139" LOG_EFFECT_SIZE="-0.04722222881894889" ORDER="12089" O_E="0.0" SE="0.6266338186452617" STUDY_ID="STD-Larkin-1999" TOTAL_1="33" TOTAL_2="37" VAR="0.39266994266994265" WEIGHT="7.2098022375683675"/>
<DICH_DATA CI_END="1.5155511236119343" CI_START="0.5091492225213367" EFFECT_SIZE="0.8784313725490196" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="15" LOG_CI_END="0.18057059087063246" LOG_CI_START="-0.2931549150702171" LOG_EFFECT_SIZE="-0.056292162099792376" ORDER="12090" O_E="0.0" SE="0.2782687071687288" STUDY_ID="STD-Lundstam-1982" TOTAL_1="34" TOTAL_2="32" VAR="0.07743347338935574" WEIGHT="18.663143486869142"/>
<DICH_DATA CI_END="0.36401985585882474" CI_START="0.0014857235778067334" EFFECT_SIZE="0.023255813953488372" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="21" LOG_CI_END="-0.43887492664013794" LOG_CI_START="-2.828061984519035" LOG_EFFECT_SIZE="-1.6334684555795866" ORDER="12091" O_E="0.0" SE="1.4034203044647386" STUDY_ID="STD-Marthak-1991" TOTAL_1="25" TOTAL_2="25" VAR="1.9695885509839" WEIGHT="1.7715060136387744"/>
<DICH_DATA CI_END="0.9254854201462331" CI_START="0.25741838419626756" EFFECT_SIZE="0.4880952380952381" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" LOG_CI_END="-0.033630418618169004" LOG_CI_START="-0.5893604400661234" LOG_EFFECT_SIZE="-0.3114954293421462" ORDER="12092" O_E="0.0" SE="0.32643856550650063" STUDY_ID="STD-Oosterlinck-1990" TOTAL_1="84" TOTAL_2="41" VAR="0.10656213704994191" WEIGHT="16.274263663712322"/>
<DICH_DATA CI_END="0.6481190611137947" CI_START="0.011710974197280389" EFFECT_SIZE="0.08712121212121213" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="11" LOG_CI_END="-0.18834520580373956" LOG_CI_START="-1.9314069759007366" LOG_EFFECT_SIZE="-1.0598760908522382" ORDER="12093" O_E="0.0" SE="1.0238831120498935" STUDY_ID="STD-Persson-1985" TOTAL_1="48" TOTAL_2="46" VAR="1.0483366271409749" WEIGHT="3.167165060255772"/>
<DICH_DATA CI_END="0.822753199489386" CI_START="0.35286700211719435" EFFECT_SIZE="0.5388157894736842" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="40" LOG_CI_END="-0.08473042016347825" LOG_CI_START="-0.4523889522052299" LOG_EFFECT_SIZE="-0.26855968618435405" ORDER="12094" O_E="0.0" SE="0.21596444166041012" STUDY_ID="STD-Sandhu-1994" TOTAL_1="76" TOTAL_2="78" VAR="0.04664064006169269" WEIGHT="22.091138144036602"/>
<DICH_DATA CI_END="0.6995892973708534" CI_START="0.19824779168995368" EFFECT_SIZE="0.3724137931034483" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="20" LOG_CI_END="-0.1551568431732558" LOG_CI_START="-0.7027916416507569" LOG_EFFECT_SIZE="-0.4289742424120064" ORDER="12095" O_E="0.0" SE="0.3216833914616564" STUDY_ID="STD-Sommer-1989" TOTAL_1="29" TOTAL_2="27" VAR="0.10348020434227329" WEIGHT="16.49769045526449"/>
<DICH_DATA CI_END="7.796078149940863" CI_START="0.01425218025962887" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.891876183949684" LOG_CI_START="-1.8461186933890088" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="12096" O_E="0.0" SE="1.6083117442419756" STUDY_ID="STD-Torralba-1999" TOTAL_1="24" TOTAL_2="24" VAR="2.5866666666666664" WEIGHT="1.3677800791743338"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.5794585189598065" CI_END="0.5316507468161468" CI_START="0.22515718190686396" CI_STUDY="95" CI_TOTAL="95" DF="9.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.34598408043117135" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="74" I2="0.0" I2_Q="0.0" ID="CMP-001.13" LOG_CI_END="-0.2743735717278696" LOG_CI_START="-0.64751419565741" LOG_EFFECT_SIZE="-0.4609438836926397" METHOD="MH" MODIFIED="2008-10-14 14:09:42 +1100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.5770172330802796" P_Q="0.0" P_Z="1.2833097882431895E-6" Q="0.0" RANDOM="YES" SCALE="500.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="446" TOTAL_2="380" WEIGHT="100.0" Z="4.8423213823118205">
<NAME>Vomiting as adverse event</NAME>
<GROUP_LABEL_1>NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Opioids</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NSAIDs</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Opioids</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.5474961335338205" CI_START="0.1583744635148619" EFFECT_SIZE="0.294464609800363" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="38" LOG_CI_END="-0.26161894350310516" LOG_CI_START="-0.8003148432556513" LOG_EFFECT_SIZE="-0.5309668933793782" ORDER="12097" O_E="0.0" SE="0.31643263810235545" STUDY_ID="STD-Arnau-1991" TOTAL_1="116" TOTAL_2="118" VAR="0.10012961445641626" WEIGHT="47.97972195224134"/>
<DICH_DATA CI_END="4.218029160247535" CI_START="0.09867951944321567" EFFECT_SIZE="0.6451612903225806" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.625109577795791" LOG_CI_START="-1.005772974136374" LOG_EFFECT_SIZE="-0.1903316981702915" ORDER="12098" O_E="0.0" SE="0.9579884840037853" STUDY_ID="STD-Cordell-1994" TOTAL_1="31" TOTAL_2="20" VAR="0.917741935483871" WEIGHT="5.234795180489395"/>
<DICH_DATA CI_END="2.978070410686122" CI_START="0.15526832352276956" EFFECT_SIZE="0.68" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.47393496158639137" LOG_CI_START="-0.8089171361739187" LOG_EFFECT_SIZE="-0.16749108729376364" ORDER="12099" O_E="0.0" SE="0.7535536724447051" STUDY_ID="STD-Lehtonen-1983" TOTAL_1="25" TOTAL_2="17" VAR="0.5678431372549019" WEIGHT="8.460419340504243"/>
<DICH_DATA CI_END="4.328128139816059" CI_START="0.20466426135585108" EFFECT_SIZE="0.9411764705882353" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6363001101371492" LOG_CI_START="-0.6889579875818475" LOG_EFFECT_SIZE="-0.026328938722349152" ORDER="12100" O_E="0.0" SE="0.7784631667335227" STUDY_ID="STD-Lundstam-1982" TOTAL_1="34" TOTAL_2="32" VAR="0.6060049019607843" WEIGHT="7.927643894066827"/>
<DICH_DATA CI_END="0.9672211209764394" CI_START="0.0035774731727979234" EFFECT_SIZE="0.058823529411764705" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="8" LOG_CI_END="-0.014474228458938752" LOG_CI_START="-2.446423614297609" LOG_EFFECT_SIZE="-1.2304489213782739" ORDER="12101" O_E="0.0" SE="1.4285391075852467" STUDY_ID="STD-Marthak-1991" TOTAL_1="25" TOTAL_2="25" VAR="2.040723981900453" WEIGHT="2.3541601428773364"/>
<DICH_DATA CI_END="0.8989654542002397" CI_START="0.08653464993406991" EFFECT_SIZE="0.2789115646258503" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="-0.04625699718610019" LOG_CI_START="-1.0628099588707811" LOG_EFFECT_SIZE="-0.5545334780284406" ORDER="12102" O_E="0.0" SE="0.5971282417118972" STUDY_ID="STD-Oosterlinck-1990" TOTAL_1="84" TOTAL_2="41" VAR="0.3565621370499419" WEIGHT="13.47364333339487"/>
<DICH_DATA CI_END="2.581730479912518" CI_START="0.0072727150796538746" EFFECT_SIZE="0.13702623906705538" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4119109020681534" LOG_CI_START="-2.13830342628226" LOG_EFFECT_SIZE="-0.863196262107053" ORDER="12103" O_E="0.0" SE="1.4980085202375515" STUDY_ID="STD-Persson-1985" TOTAL_1="48" TOTAL_2="46" VAR="2.2440295267042987" WEIGHT="2.140876937506107"/>
<DICH_DATA CI_END="1.1702920222073983" CI_START="0.06046460211093899" EFFECT_SIZE="0.2660098522167488" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.06829424448876045" LOG_CI_START="-1.2184988006692492" LOG_EFFECT_SIZE="-0.5751022780902444" ORDER="12104" O_E="0.0" SE="0.7558686044541181" STUDY_ID="STD-Sommer-1989" TOTAL_1="29" TOTAL_2="27" VAR="0.5713373471994161" WEIGHT="8.408676737750792"/>
<DICH_DATA CI_END="2.6478392990454207" CI_START="0.007707478045462773" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4228916236469527" LOG_CI_START="-2.1130877036754665" LOG_EFFECT_SIZE="-0.8450980400142569" ORDER="12105" O_E="0.0" SE="1.4896468101693163" STUDY_ID="STD-Thompson-1989" TOTAL_1="29" TOTAL_2="29" VAR="2.219047619047619" WEIGHT="2.1649788042249685"/>
<DICH_DATA CI_END="70.29633525231894" CI_START="0.12802943379190027" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.846932684604724" LOG_CI_START="-0.8926901751653996" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="12106" O_E="0.0" SE="1.6092680291808414" STUDY_ID="STD-Uden-1983" TOTAL_1="25" TOTAL_2="25" VAR="2.58974358974359" WEIGHT="1.85508367694411"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="34.929903707523" CI_END="-0.21838952092670372" CI_START="-10.86949792327174" CI_STUDY="95" CI_TOTAL="95" DF="8.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.543943722099222" ESTIMABLE="YES" I2="77.09698810799468" I2_Q="83.27875354984909" ID="CMP-001.14" MODIFIED="2008-10-14 14:09:59 +1100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="2.7536153244578365E-5" P_Q="0.014465644530357591" P_Z="0.041316683319874065" Q="5.980415413295788" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="46.70059046569724" TOTALS="SUB" TOTAL_1="369" TOTAL_2="373" UNITS="" WEIGHT="200.0" Z="2.040337891076027">
<NAME>VAS at 30 minutes by route</NAME>
<GROUP_LABEL_1>NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Opioids</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NSAIDs</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Opioids</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="14.924681198453204" CI_END="4.50985201580288" CI_START="-7.670129327224351" DF="3.0" EFFECT_SIZE="-1.5801386557107353" ESTIMABLE="YES" I2="79.89906812675557" ID="CMP-001.14.01" NO="1" P_CHI2="0.0018821620096454161" P_Z="0.611073430250149" STUDIES="4" TAU2="30.684254141308497" TOTAL_1="209" TOTAL_2="217" WEIGHT="100.0" Z="0.5085418061901301">
<NAME>IM</NAME>
<CONT_DATA CI_END="1.61273522625297" CI_START="-7.61273522625297" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="20.0" MEAN_2="23.0" ORDER="12107" SD_1="18.0" SD_2="18.0" SE="2.3534795856646533" STUDY_ID="STD-Arnau-1991" TOTAL_1="116" TOTAL_2="118" WEIGHT="26.160072039071572"/>
<CONT_DATA CI_END="15.61259228793865" CI_START="2.587407712061353" EFFECT_SIZE="9.100000000000001" ESTIMABLE="YES" MEAN_1="35.2" MEAN_2="26.1" ORDER="12108" SD_1="13.2" SD_2="14.6" SE="3.322812224770019" STUDY_ID="STD-Larkin-1999" TOTAL_1="33" TOTAL_2="37" WEIGHT="23.66727377309728"/>
<CONT_DATA CI_END="-0.12269316152324983" CI_START="-10.87730683847675" EFFECT_SIZE="-5.5" ESTIMABLE="YES" MEAN_1="39.1" MEAN_2="44.6" ORDER="12109" SD_1="9.7" SD_2="9.7" SE="2.7435743110038042" STUDY_ID="STD-Marthak-1991" TOTAL_1="25" TOTAL_2="25" WEIGHT="25.200878311247507"/>
<CONT_DATA CI_END="-0.44782973563310424" CI_START="-11.552170264366897" EFFECT_SIZE="-6.0" ESTIMABLE="YES" MEAN_1="17.0" MEAN_2="23.0" ORDER="12110" SD_1="11.0" SD_2="13.0" SE="2.8327919840169034" STUDY_ID="STD-Oosterlinck-1990" TOTAL_1="35" TOTAL_2="37" WEIGHT="24.971775876583653"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="14.02480709577401" CI_END="-1.1202092691215828" CI_START="-19.890478598804904" DF="4.0" EFFECT_SIZE="-10.505343933963243" ESTIMABLE="YES" I2="71.47910860602646" ID="CMP-001.14.02" NO="2" P_CHI2="0.007216330680573924" P_Z="0.028242225402099964" STUDIES="5" TAU2="80.54903854233997" TOTAL_1="160" TOTAL_2="156" WEIGHT="100.0" Z="2.193905201265609">
<NAME>IV</NAME>
<CONT_DATA CI_END="-18.45659002788445" CI_START="-45.34340997211555" EFFECT_SIZE="-31.900000000000002" ESTIMABLE="YES" MEAN_1="24.7" MEAN_2="56.6" ORDER="12111" SD_1="27.6" SD_2="30.1" SE="6.859008674728441" STUDY_ID="STD-Cordell-1996" TOTAL_1="36" TOTAL_2="35" WEIGHT="17.13000457163124"/>
<CONT_DATA CI_END="11.604361642012151" CI_START="-11.604361642012151" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="26.8" MEAN_2="26.8" ORDER="12112" SD_1="19.9" SD_2="16.8" SE="5.9207014687748725" STUDY_ID="STD-Curry-1995" TOTAL_1="17" TOTAL_2="24" WEIGHT="19.642513635026837"/>
<CONT_DATA CI_END="2.6724096327646993" CI_START="-20.672409632764698" EFFECT_SIZE="-9.0" ESTIMABLE="YES" MEAN_1="24.0" MEAN_2="33.0" ORDER="12113" SD_1="20.0" SD_2="25.0" SE="5.955420469373507" STUDY_ID="STD-Jonsson-1987" TOTAL_1="35" TOTAL_2="26" WEIGHT="19.54394512294678"/>
<CONT_DATA CI_END="1.8321464611863947" CI_START="-13.832146461186394" EFFECT_SIZE="-6.0" ESTIMABLE="YES" MEAN_1="17.0" MEAN_2="23.0" ORDER="12114" SD_1="16.0" SD_2="22.0" SE="3.996066521102105" STUDY_ID="STD-Persson-1985" TOTAL_1="47" TOTAL_2="46" WEIGHT="25.62472648843957"/>
<CONT_DATA CI_END="4.335905693295514" CI_START="-21.135905693295513" EFFECT_SIZE="-8.399999999999999" ESTIMABLE="YES" MEAN_1="13.0" MEAN_2="21.4" ORDER="12115" SD_1="21.9" SD_2="24.0" SE="6.498030470842684" STUDY_ID="STD-Uden-1983" TOTAL_1="25" TOTAL_2="25" WEIGHT="18.05881018195557"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="6.080266267816494" CI_END="1.0070902886061173" CI_START="0.7587399555264209" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8741393714895216" ESTIMABLE="YES" EVENTS_1="197" EVENTS_2="160" I2="1.3201110655523802" I2_Q="0.0" ID="CMP-001.15" LOG_CI_END="0.0030684080765915867" LOG_CI_START="-0.11990704522584379" LOG_EFFECT_SIZE="-0.058419318574626095" METHOD="MH" MODIFIED="2008-10-14 14:10:15 +1100" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.4142591321392559" P_Q="0.0" P_Z="0.06258105561142908" Q="0.0" RANDOM="YES" SCALE="200.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="5.060499309904997E-4" TOTALS="SUB" TOTAL_1="384" TOTAL_2="281" WEIGHT="200.0" Z="1.8621563463734179">
<NAME>Failure of complete pain relief by route</NAME>
<GROUP_LABEL_1>NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Opioids</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NSAIDs</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Opioids</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.0012501041009525" CI_END="1.2088186882986582" CI_START="0.7480049884955015" DF="2.0" EFFECT_SIZE="0.9508955826135618" ESTIMABLE="YES" EVENTS_1="116" EVENTS_2="94" I2="33.36110185328539" ID="CMP-001.15.01" LOG_CI_END="0.08236116556181344" LOG_CI_START="-0.12609550578681528" LOG_EFFECT_SIZE="-0.021867170112500896" NO="1" P_CHI2="0.22299080430759333" P_Z="0.6809246636625728" STUDIES="4" TAU2="0.015218098244509232" TOTAL_1="172" TOTAL_2="132" WEIGHT="100.0" Z="0.411201671666666">
<NAME>IM</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="25" EVENTS_2="25" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="12116" O_E="0.0" SE="0.0" STUDY_ID="STD-Marthak-1991" TOTAL_1="25" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.164408466738485" CI_START="0.6720531506354778" EFFECT_SIZE="0.8846153846153846" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="26" LOG_CI_END="0.06610535465447095" LOG_CI_START="-0.17259637856092114" LOG_EFFECT_SIZE="-0.0532455119532251" ORDER="12117" O_E="0.0" SE="0.1402145796833572" STUDY_ID="STD-Oosterlinck-1990" TOTAL_1="74" TOTAL_2="37" VAR="0.01966012835578053" WEIGHT="47.37685471137635"/>
<DICH_DATA CI_END="1.1604389792095564" CI_START="0.6181778451406165" EFFECT_SIZE="0.8469696969696969" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="30" LOG_CI_END="0.06462230835132819" LOG_CI_START="-0.208886563662219" LOG_EFFECT_SIZE="-0.0721321276554454" ORDER="12118" O_E="0.0" SE="0.16066046531150932" STUDY_ID="STD-Persson-1985" TOTAL_1="44" TOTAL_2="43" VAR="0.02581178511411069" WEIGHT="36.30276187759236"/>
<DICH_DATA CI_END="2.181896214298587" CI_START="0.8486291413077123" EFFECT_SIZE="1.3607427055702919" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="13" LOG_CI_END="0.3388340887686345" LOG_CI_START="-0.07128205895658765" LOG_EFFECT_SIZE="0.13377601490602345" ORDER="12119" O_E="0.0" SE="0.24090425528146792" STUDY_ID="STD-Sommer-1989" TOTAL_1="29" TOTAL_2="27" VAR="0.058034860212718656" WEIGHT="16.32038341103128"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.0907134933560503" CI_END="0.9940389179194767" CI_START="0.6550581272850651" DF="3.0" EFFECT_SIZE="0.8069406868046778" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="66" I2="0.0" ID="CMP-001.15.02" LOG_CI_END="-0.0025966120747117427" LOG_CI_START="-0.18372016071191766" LOG_EFFECT_SIZE="-0.09315838639331465" NO="2" P_CHI2="0.5537938221115453" P_Z="0.04378318383034554" STUDIES="4" TAU2="0.0" TOTAL_1="212" TOTAL_2="149" WEIGHT="100.0" Z="2.0161606103962613">
<NAME>IV</NAME>
<DICH_DATA CI_END="101.58460526662178" CI_START="0.24610028197072092" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.006827897373713" LOG_CI_START="-0.6088878887016753" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="12120" O_E="0.0" SE="1.5364844007426468" STUDY_ID="STD-al_x002d_Sahlawi-1996" TOTAL_1="50" TOTAL_2="50" VAR="2.3607843137254902" WEIGHT="0.48692573893299723"/>
<DICH_DATA CI_END="1.3087348535066419" CI_START="0.5448669895528746" EFFECT_SIZE="0.8444444444444444" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="15" LOG_CI_END="0.11685166845839784" LOG_CI_START="-0.26370950277546495" LOG_EFFECT_SIZE="-0.07342891715853352" ORDER="12121" O_E="0.0" SE="0.22354351579095025" STUDY_ID="STD-Lehtonen-1983" TOTAL_1="93" TOTAL_2="31" VAR="0.04997170345217883" WEIGHT="22.77781751559022"/>
<DICH_DATA CI_END="1.1604389792095564" CI_START="0.6181778451406165" EFFECT_SIZE="0.8469696969696969" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="30" LOG_CI_END="0.06462230835132819" LOG_CI_START="-0.208886563662219" LOG_EFFECT_SIZE="-0.0721321276554454" ORDER="12122" O_E="0.0" SE="0.16066046531150932" STUDY_ID="STD-Persson-1985" TOTAL_1="44" TOTAL_2="43" VAR="0.02581178511411069" WEIGHT="43.68798015446247"/>
<DICH_DATA CI_END="1.0267952805376401" CI_START="0.496889780566098" EFFECT_SIZE="0.7142857142857143" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="21" LOG_CI_END="0.0114838638549075" LOG_CI_START="-0.30373993521138354" LOG_EFFECT_SIZE="-0.146128035678238" ORDER="12123" O_E="0.0" SE="0.1851640199545103" STUDY_ID="STD-Uden-1983" TOTAL_1="25" TOTAL_2="25" VAR="0.03428571428571429" WEIGHT="33.04727659101432"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.182076093961803" CI_END="0.944584063090198" CI_START="0.6185553677766725" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7643804959185845" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="84" I2="0.0" I2_Q="0.0" ID="CMP-001.16" LOG_CI_END="-0.0247593860622757" LOG_CI_START="-0.20862141997397185" LOG_EFFECT_SIZE="-0.11669040301812374" METHOD="MH" MODIFIED="2008-10-14 14:10:35 +1100" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.9022144857401273" P_Q="0.0" P_Z="0.01285241883825063" Q="0.0" RANDOM="YES" SCALE="200.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="407" TOTAL_2="348" WEIGHT="200.0" Z="2.487832668780649">
<NAME>Rescue analgesia required by route</NAME>
<GROUP_LABEL_1>NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Opioids</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NSAIDs</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Opioids</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.053256234029315716" CI_END="1.1884031518124583" CI_START="0.5431478911211264" DF="2.0" EFFECT_SIZE="0.8034168691959589" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="43" I2="0.0" ID="CMP-001.16.01" LOG_CI_END="0.07496379494325844" LOG_CI_START="-0.26508190235806445" LOG_EFFECT_SIZE="-0.095059053707403" NO="1" P_CHI2="0.9737233058304908" P_Z="0.27316301974927737" STUDIES="4" TAU2="0.0" TOTAL_1="203" TOTAL_2="207" WEIGHT="100.0" Z="1.095807552629449">
<NAME>IM</NAME>
<DICH_DATA CI_END="1.4578691487365771" CI_START="0.48437421996458446" EFFECT_SIZE="0.8403298350824587" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="23" LOG_CI_END="0.1637185455650283" LOG_CI_START="-0.31481897953614235" LOG_EFFECT_SIZE="-0.07555021698555703" ORDER="12124" O_E="0.0" SE="0.28109531104338037" STUDY_ID="STD-Arnau-1991" TOTAL_1="116" TOTAL_2="118" VAR="0.07901457389057477" WEIGHT="50.494324833737814"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="12125" O_E="0.0" SE="0.0" STUDY_ID="STD-Hetherington-1986" TOTAL_1="30" TOTAL_2="28" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.4151555488967953" CI_START="0.41987188492528793" EFFECT_SIZE="0.7708333333333334" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="16" LOG_CI_END="0.15080417859865414" LOG_CI_START="-0.3768832052158385" LOG_EFFECT_SIZE="-0.11303951330859219" ORDER="12126" O_E="0.0" SE="0.3099661813473102" STUDY_ID="STD-Larkin-1999" TOTAL_1="33" TOTAL_2="37" VAR="0.09607903357903358" WEIGHT="41.52610004500206"/>
<DICH_DATA CI_END="2.998828618438036" CI_START="0.18757323994492983" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.4769516467553787" LOG_CI_START="-0.7268291199719785" LOG_EFFECT_SIZE="-0.12493873660829993" ORDER="12127" O_E="0.0" SE="0.7071067811865475" STUDY_ID="STD-Torralba-1999" TOTAL_1="24" TOTAL_2="24" VAR="0.49999999999999994" WEIGHT="7.979575121260123"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.1427899205361602" CI_END="0.9630665081628434" CI_START="0.5822232018285733" DF="3.0" EFFECT_SIZE="0.7488121700109012" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="41" I2="0.0" ID="CMP-001.16.02" LOG_CI_END="-0.01634372000864235" LOG_CI_START="-0.23491049174272158" LOG_EFFECT_SIZE="-0.1256271058756819" NO="2" P_CHI2="0.5433047569271725" P_Z="0.02425387915562258" STUDIES="4" TAU2="0.0" TOTAL_1="204" TOTAL_2="141" WEIGHT="100.0" Z="2.2530835867211114">
<NAME>IV</NAME>
<DICH_DATA CI_END="101.58460526662178" CI_START="0.24610028197072092" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.006827897373713" LOG_CI_START="-0.6088878887016753" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="12128" O_E="0.0" SE="1.5364844007426468" STUDY_ID="STD-al_x002d_Sahlawi-1996" TOTAL_1="50" TOTAL_2="50" VAR="2.3607843137254902" WEIGHT="0.698211774898483"/>
<DICH_DATA CI_END="0.9476565651843566" CI_START="0.5490506321046889" EFFECT_SIZE="0.7213261648745519" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="31" LOG_CI_END="-0.023349024337775828" LOG_CI_START="-0.2603876041296071" LOG_EFFECT_SIZE="-0.14186831423369145" ORDER="12129" O_E="0.0" SE="0.13923763512961537" STUDY_ID="STD-Cordell-1996" TOTAL_1="36" TOTAL_2="35" VAR="0.0193871190364879" WEIGHT="85.02178187158728"/>
<DICH_DATA CI_END="1.698490163782303" CI_START="0.40885985639034417" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="8" LOG_CI_END="0.23006303614720783" LOG_CI_START="-0.3884255282424574" LOG_EFFECT_SIZE="-0.07918124604762482" ORDER="12130" O_E="0.0" SE="0.36330324429025945" STUDY_ID="STD-Lehtonen-1983" TOTAL_1="93" TOTAL_2="31" VAR="0.13198924731182796" WEIGHT="12.488346129776437"/>
<DICH_DATA CI_END="6.553055387930549" CI_START="0.15260057191669785" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8164438387284481" LOG_CI_START="-0.8164438387284481" LOG_EFFECT_SIZE="0.0" ORDER="12131" O_E="0.0" SE="0.9591663046625438" STUDY_ID="STD-Uden-1983" TOTAL_1="25" TOTAL_2="25" VAR="0.9199999999999999" WEIGHT="1.7916602237377954"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.939811409248884" CI_END="1.0311723810682716" CI_START="0.7362938259819771" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8713471510848606" ESTIMABLE="YES" EVENTS_1="186" EVENTS_2="147" I2="11.836696878645276" I2_Q="0.0" ID="CMP-001.17" LOG_CI_END="0.013331272353222842" LOG_CI_START="-0.13294884118186193" LOG_EFFECT_SIZE="-0.059808784414319555" METHOD="MH" MODIFIED="2008-10-14 14:10:49 +1100" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="0.33793131658141606" P_Q="0.0" P_Z="0.10899639039571184" Q="0.0" RANDOM="YES" SCALE="200.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.007072542523751993" TOTALS="YES" TOTAL_1="393" TOTAL_2="281" WEIGHT="100.00000000000003" Z="1.6027204324403443">
<NAME>Failure of complete pain relief by opioid type</NAME>
<GROUP_LABEL_1>NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Opioids</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NSAIDs</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Opioids</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.9284224450884535" CI_END="1.1258418723987929" CI_START="0.7139181055904583" DF="3.0" EFFECT_SIZE="0.896526015650054" ESTIMABLE="YES" EVENTS_1="118" EVENTS_2="69" I2="0.0" ID="CMP-001.17.01" LOG_CI_END="0.051477396938828565" LOG_CI_START="-0.146351603812076" LOG_EFFECT_SIZE="-0.047437103436623676" NO="1" P_CHI2="0.5873952373769599" P_Z="0.34724151022784444" STUDIES="5" TAU2="0.0" TOTAL_1="266" TOTAL_2="157" WEIGHT="42.86805283305856" Z="0.9399533325627288">
<NAME>Pethidine</NAME>
<DICH_DATA CI_END="101.58460526662178" CI_START="0.24610028197072092" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.006827897373713" LOG_CI_START="-0.6088878887016753" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="12132" O_E="0.0" SE="1.5364844007426468" STUDY_ID="STD-al_x002d_Sahlawi-1996" TOTAL_1="50" TOTAL_2="50" VAR="2.3607843137254902" WEIGHT="0.3118102137888956"/>
<DICH_DATA CI_END="1.3087348535066419" CI_START="0.5448669895528746" EFFECT_SIZE="0.8444444444444444" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="15" LOG_CI_END="0.11685166845839784" LOG_CI_START="-0.26370950277546495" LOG_EFFECT_SIZE="-0.07342891715853352" ORDER="12133" O_E="0.0" SE="0.22354351579095025" STUDY_ID="STD-Lehtonen-1983" TOTAL_1="93" TOTAL_2="31" VAR="0.04997170345217883" WEIGHT="12.94296979365991"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="25" EVENTS_2="25" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="12134" O_E="0.0" SE="0.0" STUDY_ID="STD-Marthak-1991" TOTAL_1="25" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.164408466738485" CI_START="0.6720531506354778" EFFECT_SIZE="0.8846153846153846" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="26" LOG_CI_END="0.06610535465447095" LOG_CI_START="-0.17259637856092114" LOG_EFFECT_SIZE="-0.0532455119532251" ORDER="12135" O_E="0.0" SE="0.1402145796833572" STUDY_ID="STD-Oosterlinck-1990" TOTAL_1="74" TOTAL_2="37" VAR="0.01966012835578053" WEIGHT="27.61871254450164"/>
<DICH_DATA CI_END="4.434098798328407" CI_START="0.4178128501531218" EFFECT_SIZE="1.3611111111111112" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.646805365614469" LOG_CI_START="-0.37901820709201606" LOG_EFFECT_SIZE="0.13389357926122641" ORDER="12136" O_E="0.0" SE="0.6025738445163696" STUDY_ID="STD-Quilez-1984" TOTAL_1="24" TOTAL_2="14" VAR="0.363095238095238" WEIGHT="1.9945602811081118"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.935674107854374" CI_END="1.1516278705015435" CI_START="0.6278956498177349" DF="3.0" EFFECT_SIZE="0.8503541204091275" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="78" I2="49.45814164510391" ID="CMP-001.17.02" LOG_CI_END="0.06131216667718259" LOG_CI_START="-0.20211252580723088" LOG_EFFECT_SIZE="-0.07040017956502416" NO="2" P_CHI2="0.11478215145861093" P_Z="0.29482308378893163" STUDIES="4" TAU2="0.04598514807591524" TOTAL_1="127" TOTAL_2="124" WEIGHT="57.13194716694146" Z="1.0475997155108323">
<NAME>Non-pethidine opioid</NAME>
<DICH_DATA CI_END="1.1604389792095564" CI_START="0.6181778451406165" EFFECT_SIZE="0.8469696969696969" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="30" LOG_CI_END="0.06462230835132819" LOG_CI_START="-0.208886563662219" LOG_EFFECT_SIZE="-0.0721321276554454" ORDER="12137" O_E="0.0" SE="0.16066046531150932" STUDY_ID="STD-Persson-1985" TOTAL_1="44" TOTAL_2="43" VAR="0.02581178511411069" WEIGHT="22.452092093818035"/>
<DICH_DATA CI_END="2.181896214298587" CI_START="0.8486291413077123" EFFECT_SIZE="1.3607427055702919" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="13" LOG_CI_END="0.3388340887686345" LOG_CI_START="-0.07128205895658765" LOG_EFFECT_SIZE="0.13377601490602345" ORDER="12138" O_E="0.0" SE="0.24090425528146792" STUDY_ID="STD-Sommer-1989" TOTAL_1="29" TOTAL_2="27" VAR="0.058034860212718656" WEIGHT="11.340061521990329"/>
<DICH_DATA CI_END="1.1504232669717585" CI_START="0.28383519494039733" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="14" LOG_CI_END="0.06085765660562079" LOG_CI_START="-0.5469337539782099" LOG_EFFECT_SIZE="-0.24303804868629447" ORDER="12139" O_E="0.0" SE="0.3570196831929468" STUDY_ID="STD-Thompson-1989" TOTAL_1="29" TOTAL_2="29" VAR="0.12746305418719212" WEIGHT="5.487930113803985"/>
<DICH_DATA CI_END="1.0267952805376401" CI_START="0.496889780566098" EFFECT_SIZE="0.7142857142857143" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="21" LOG_CI_END="0.0114838638549075" LOG_CI_START="-0.30373993521138354" LOG_EFFECT_SIZE="-0.146128035678238" ORDER="12140" O_E="0.0" SE="0.1851640199545103" STUDY_ID="STD-Uden-1983" TOTAL_1="25" TOTAL_2="25" VAR="0.03428571428571429" WEIGHT="17.851863437329104"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.5794585189598065" CI_END="0.5316507468161467" CI_START="0.2251571819068639" CI_STUDY="95" CI_TOTAL="95" DF="9.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.34598408043117124" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="74" I2="0.0" I2_Q="0.0" ID="CMP-001.18" LOG_CI_END="-0.2743735717278697" LOG_CI_START="-0.6475141956574101" LOG_EFFECT_SIZE="-0.46094388369263983" METHOD="MH" MODIFIED="2008-10-14 14:11:11 +1100" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="0.5770172330802796" P_Q="0.0" P_Z="1.2833097882431848E-6" Q="0.0" RANDOM="YES" SCALE="500.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="446" TOTAL_2="380" WEIGHT="100.00000000000001" Z="4.842321382311821">
<NAME>Vomiting as adverse event by opioid type</NAME>
<GROUP_LABEL_1>NSAIDS</GROUP_LABEL_1>
<GROUP_LABEL_2>Opioids</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NSAIDs</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours Opioids</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.8620911112513254" CI_END="0.4909909340375194" CI_START="0.18137173451761457" DF="4.0" EFFECT_SIZE="0.2984156117544935" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="59" I2="0.0" ID="CMP-001.18.01" LOG_CI_END="-0.3089265268868657" LOG_CI_START="-0.7414303936789348" LOG_EFFECT_SIZE="-0.5251784602829003" NO="1" P_CHI2="0.5811629772184663" P_Z="1.937186804885782E-6" STUDIES="5" TAU2="0.0" TOTAL_1="279" TOTAL_2="230" WEIGHT="74.43292357324277" Z="4.75986897063071">
<NAME>Pethidine</NAME>
<DICH_DATA CI_END="0.5474961335338205" CI_START="0.1583744635148619" EFFECT_SIZE="0.294464609800363" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="38" LOG_CI_END="-0.26161894350310516" LOG_CI_START="-0.8003148432556513" LOG_EFFECT_SIZE="-0.5309668933793782" ORDER="12141" O_E="0.0" SE="0.31643263810235545" STUDY_ID="STD-Arnau-1991" TOTAL_1="116" TOTAL_2="118" VAR="0.10012961445641626" WEIGHT="47.97972195224135"/>
<DICH_DATA CI_END="2.978070410686122" CI_START="0.15526832352276956" EFFECT_SIZE="0.68" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.47393496158639137" LOG_CI_START="-0.8089171361739187" LOG_EFFECT_SIZE="-0.16749108729376364" ORDER="12142" O_E="0.0" SE="0.7535536724447051" STUDY_ID="STD-Lehtonen-1983" TOTAL_1="25" TOTAL_2="17" VAR="0.5678431372549019" WEIGHT="8.460419340504243"/>
<DICH_DATA CI_END="0.9672211209764394" CI_START="0.0035774731727979234" EFFECT_SIZE="0.058823529411764705" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="8" LOG_CI_END="-0.014474228458938752" LOG_CI_START="-2.446423614297609" LOG_EFFECT_SIZE="-1.2304489213782739" ORDER="12143" O_E="0.0" SE="1.4285391075852467" STUDY_ID="STD-Marthak-1991" TOTAL_1="25" TOTAL_2="25" VAR="2.040723981900453" WEIGHT="2.354160142877337"/>
<DICH_DATA CI_END="0.8989654542002397" CI_START="0.08653464993406991" EFFECT_SIZE="0.2789115646258503" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="-0.04625699718610019" LOG_CI_START="-1.0628099588707811" LOG_EFFECT_SIZE="-0.5545334780284406" ORDER="12144" O_E="0.0" SE="0.5971282417118972" STUDY_ID="STD-Oosterlinck-1990" TOTAL_1="84" TOTAL_2="41" VAR="0.3565621370499419" WEIGHT="13.473643333394872"/>
<DICH_DATA CI_END="2.6478392990454207" CI_START="0.007707478045462773" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4228916236469527" LOG_CI_START="-2.1130877036754665" LOG_EFFECT_SIZE="-0.8450980400142569" ORDER="12145" O_E="0.0" SE="1.4896468101693163" STUDY_ID="STD-Thompson-1989" TOTAL_1="29" TOTAL_2="29" VAR="2.219047619047619" WEIGHT="2.164978804224969"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.4165524676943053" CI_END="1.2446300092029294" CI_START="0.22755252951310576" DF="4.0" EFFECT_SIZE="0.5321829637465358" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="15" I2="0.0" ID="CMP-001.18.02" LOG_CI_END="0.09504026802409078" LOG_CI_START="-0.642918332438503" LOG_EFFECT_SIZE="-0.2739390322072061" NO="2" P_CHI2="0.49067988451270295" P_Z="0.1456349346696825" STUDIES="5" TAU2="0.0" TOTAL_1="167" TOTAL_2="150" WEIGHT="25.567076426757236" Z="1.4551240049220004">
<NAME>Non-pethidine</NAME>
<DICH_DATA CI_END="4.218029160247535" CI_START="0.09867951944321567" EFFECT_SIZE="0.6451612903225806" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.625109577795791" LOG_CI_START="-1.005772974136374" LOG_EFFECT_SIZE="-0.1903316981702915" ORDER="12146" O_E="0.0" SE="0.9579884840037853" STUDY_ID="STD-Cordell-1994" TOTAL_1="31" TOTAL_2="20" VAR="0.917741935483871" WEIGHT="5.234795180489396"/>
<DICH_DATA CI_END="4.328128139816059" CI_START="0.20466426135585108" EFFECT_SIZE="0.9411764705882353" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6363001101371492" LOG_CI_START="-0.6889579875818475" LOG_EFFECT_SIZE="-0.026328938722349152" ORDER="12147" O_E="0.0" SE="0.7784631667335227" STUDY_ID="STD-Lundstam-1982" TOTAL_1="34" TOTAL_2="32" VAR="0.6060049019607843" WEIGHT="7.9276438940668275"/>
<DICH_DATA CI_END="2.581730479912518" CI_START="0.0072727150796538746" EFFECT_SIZE="0.13702623906705538" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4119109020681534" LOG_CI_START="-2.13830342628226" LOG_EFFECT_SIZE="-0.863196262107053" ORDER="12148" O_E="0.0" SE="1.4980085202375515" STUDY_ID="STD-Persson-1985" TOTAL_1="48" TOTAL_2="46" VAR="2.2440295267042987" WEIGHT="2.1408769375061074"/>
<DICH_DATA CI_END="1.1702920222073983" CI_START="0.06046460211093899" EFFECT_SIZE="0.2660098522167488" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.06829424448876045" LOG_CI_START="-1.2184988006692492" LOG_EFFECT_SIZE="-0.5751022780902444" ORDER="12149" O_E="0.0" SE="0.7558686044541181" STUDY_ID="STD-Sommer-1989" TOTAL_1="29" TOTAL_2="27" VAR="0.5713373471994161" WEIGHT="8.408676737750792"/>
<DICH_DATA CI_END="70.29633525231894" CI_START="0.12802943379190027" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.846932684604724" LOG_CI_START="-0.8926901751653996" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="12150" O_E="0.0" SE="1.6092680291808414" STUDY_ID="STD-Uden-1983" TOTAL_1="25" TOTAL_2="25" VAR="2.58974358974359" WEIGHT="1.8550836769441101"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="2.1840056369691534" CI_END="-1.701518843964403" CI_START="-7.50374686480998" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.602632854387191" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.19" MODIFIED="2008-10-14 14:11:32 +1100" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="0.8231429476614358" P_Q="0.6079051689603752" P_Z="0.001874085238033328" Q="0.9954729602987589" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="265" TOTAL_2="264" UNITS="" WEIGHT="100.0" Z="3.1094933174808337">
<NAME>VAS at 30 minutes by NSAID type (excluding ketorolac)</NAME>
<GROUP_LABEL_1>NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Opioids</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NSAIDs</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Opioids</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.004633715536599274" CI_END="-0.12099752914182993" CI_START="-17.33118866520344" DF="1.0" EFFECT_SIZE="-8.726093097172635" ESTIMABLE="YES" I2="0.0" ID="CMP-001.19.01" NO="1" P_CHI2="0.9457287968518721" P_Z="0.04686443320377274" STUDIES="2" TAU2="0.0" TOTAL_1="60" TOTAL_2="51" WEIGHT="11.366275983563643" Z="1.9875233297514396">
<NAME>Indomethacin</NAME>
<CONT_DATA CI_END="2.6724096327646993" CI_START="-20.672409632764698" EFFECT_SIZE="-9.0" ESTIMABLE="YES" MEAN_1="24.0" MEAN_2="33.0" ORDER="12151" SD_1="20.0" SD_2="25.0" SE="5.955420469373507" STUDY_ID="STD-Jonsson-1987" TOTAL_1="35" TOTAL_2="26" WEIGHT="6.1774402313320245"/>
<CONT_DATA CI_END="4.335905693295514" CI_START="-21.135905693295513" EFFECT_SIZE="-8.399999999999999" ESTIMABLE="YES" MEAN_1="13.0" MEAN_2="21.4" ORDER="12152" SD_1="21.9" SD_2="24.0" SE="6.498030470842684" STUDY_ID="STD-Uden-1983" TOTAL_1="25" TOTAL_2="25" WEIGHT="5.1888357522316175"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.4783383095875051" CI_END="-0.5586943550442109" CI_START="-7.560867145814135" DF="1.0" EFFECT_SIZE="-4.059780750429173" ESTIMABLE="YES" I2="0.0" ID="CMP-001.19.02" NO="2" P_CHI2="0.4891759994857984" P_Z="0.023042456107795862" STUDIES="2" TAU2="0.0" TOTAL_1="141" TOTAL_2="143" WEIGHT="68.6631837996001" Z="2.272729992170119">
<NAME>Diclofenac</NAME>
<CONT_DATA CI_END="1.61273522625297" CI_START="-7.61273522625297" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="20.0" MEAN_2="23.0" ORDER="12153" SD_1="18.0" SD_2="18.0" SE="2.3534795856646533" STUDY_ID="STD-Arnau-1991" TOTAL_1="116" TOTAL_2="118" WEIGHT="39.55601561800154"/>
<CONT_DATA CI_END="-0.12269316152324983" CI_START="-10.87730683847675" EFFECT_SIZE="-5.5" ESTIMABLE="YES" MEAN_1="39.1" MEAN_2="44.6" ORDER="12154" SD_1="9.7" SD_2="9.7" SE="2.7435743110038042" STUDY_ID="STD-Marthak-1991" TOTAL_1="25" TOTAL_2="25" WEIGHT="29.107168181598567"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.7055606515462901" CI_END="2.369667607295459" CI_START="-10.614074648000962" DF="1.0" EFFECT_SIZE="-4.122203520352751" ESTIMABLE="YES" I2="0.0" ID="CMP-001.19.03" NO="3" P_CHI2="0.4009219701526665" P_Z="0.21330220614218998" STUDIES="2" TAU2="0.0" TOTAL_1="64" TOTAL_2="70" WEIGHT="19.97054021683625" Z="1.2445364792326838">
<NAME>Other</NAME>
<CONT_DATA CI_END="11.604361642012151" CI_START="-11.604361642012151" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="26.8" MEAN_2="26.8" ORDER="12155" SD_1="19.9" SD_2="16.8" SE="5.9207014687748725" STUDY_ID="STD-Curry-1995" TOTAL_1="17" TOTAL_2="24" WEIGHT="6.2501016859714875"/>
<CONT_DATA CI_END="1.8321464611863947" CI_START="-13.832146461186394" EFFECT_SIZE="-6.0" ESTIMABLE="YES" MEAN_1="17.0" MEAN_2="23.0" ORDER="12156" SD_1="16.0" SD_2="22.0" SE="3.996066521102105" STUDY_ID="STD-Persson-1985" TOTAL_1="47" TOTAL_2="46" WEIGHT="13.720438530864762"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>